



Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID: | bmjopen-2013-003132 |
| Article Type: | Research |
| Date Submitted by the Author: | 26-Apr-2013 |
| Complete List of Authors: | Hozumi, Hironao; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Nakamura, Yutaro; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Johkoh, Takeshi; Kinki Central Hospital of Mutual Aid Association of Public Teachers, Department of Radiology Sumikawa, Hiromitsu; Osaka University Graduate School of Medicine, Diagnostic and Interventional Radiology Colby, Thomas; Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology kono, Masato; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Hashimoto, Dai; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Enomoto, Noriyuki; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Fujisawa, Tomoyuki; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Inui, Naoki; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Suda, Takafumi; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Chida, Kingo; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine |
| Primary Subject Heading: | Respiratory medicine |
| Secondary Subject Heading: | Rheumatology |
| Keywords: | Interstitial lung disease < THORACIC MEDICINE, RHEUMATOLOGY, Adult thoracic medicine < THORACIC MEDICINE |
| | |

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **Title:** Acute exacerbation in rheumatoid arthritis associated interstitial lung disease
7
8
9

10
11
12 **Authors:**

13
14 Hironao Hozumi, M.D., Ph.D.¹

15
16 Yutaro Nakamura, M.D., Ph.D.¹

17
18 Takeshi Johkoh, M.D., Ph.D.²

19
20 Hiromitsu Sumikawa, M.D., Ph.D.³

21
22 Thomas V. Colby, M.D.⁴

23
24 Masato Kono, M.D, Ph.D.¹

25
26 Dai Hashimoto, M.D., Ph.D.¹

27
28 Noriyuki Enomoto, M.D., Ph.D.¹

29
30 Tomoyuki Fujisawa, M.D., Ph.D.¹

31
32 Naoki Inui, M.D., Ph.D.¹

33
34 Takafumi Suda, M.D., Ph.D.¹

35
36 Kingo Chida, M.D., Ph.D.¹

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 **Affiliations:**

53
54
55 ¹Second division, Department of Internal Medicine, Hamamatsu University School of
56
57
58

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

²Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public
School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan

³Diagnostic and Interventional Radiology, Osaka University Graduate School of
Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

⁴Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East
Shea Boulevard Scottsdale, AZ 85259, USA

Corresponding author:

Yutaro Nakamura, M.D., Ph.D.

Second division, Department of Internal Medicine, Hamamatsu University School of
Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

Tel: 81-53-435-2263, Fax: 81-53-435-2354

E-mail address: nakayuta@hama-med.ac.jp

Keywords: Acute exacerbation, interstitial lung disease, risk factor, prognostic factor,
rheumatoid arthritis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word count paper: 2779

Word count abstract: 292

For peer review only

ABSTRACT

Background Acute exacerbation (AE) in idiopathic pulmonary fibrosis is characterised by acute deterioration of respiratory status and the mortality is high.

Recently, AE was reported in patients with other interstitial lung diseases, especially rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives To investigate the risk factors and prognosis associated with AE in patients with RA-ILD.

Design A retrospective cohort study.

Setting A single academic hospital.

Participants 51 consecutive patients diagnosed with RA-ILD between 1995 and 2012.

All patients fulfilled the diagnostic criteria of the American College of Rheumatology for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures Overall survival and cumulative AE incidence were analysed using Kaplan–Meier method. Cox hazards analysis was used to determine significant variables associated with AE occurrence and survival status.

Results A total of 11 patients (22%) developed AE, with an overall 1-year incidence of 2.8%. Univariate analysis revealed that higher age at ILD diagnosis [hazard ratio

1
2
3
4
5
6 (HR), 1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], usual interstitial
7
8
9 pneumonia (UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and
10
11 treatment with methotrexate (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were risk factors
12
13 for AE. Of 11 patients who developed AE during observation period, seven (64%) died
14
15 of initial AE. In survival, AE was a prognostic factor for poor outcome (HR, 2.47; 95%
16
17 CI, 1.39–4.56; $P = 0.003$).
18
19
20
21
22

23 **Conclusions** In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on
24
25 HRCT and treatment with methotrexate are risk factors for AE. Furthermore, AE has a
26
27 serious impact on their survival. We should carefully observe the patients having any of
28
29 these risk factors.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis (IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with RA-ILD?

Key messages;

In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on HRCT, and treatment with methotrexate are risk factors for AE occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE may have a serious impact on the survival of patients with RA-ILD as well as that with IPF. Thus, the patients with any of these risk factors should be carefully observed.

Given its retrospective study design, it is subject to several possible biases. Therefore, prospective studies are necessary to confirm our results.

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterized by acute deterioration in respiratory status, with newly developed bilateral ground-glass opacities and/or consolidations on chest radiographs or computed tomography scans. It should be in the absence of other alternative causes such as infection, left heart failure, pulmonary embolism, and an identifiable cause of acute lung injury. AE reportedly occurs not only in patients with IPF but also in patients with other interstitial lung diseases (ILDs), including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital mortality associated with AE in patients with CVD-ILD was demonstrated to be as high as that in patients with IPF,[1-4] suggesting that AE may be associated with poor prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown etiology that primarily involves joints.[5] ILD is the most common extra-articular manifestations,[6] with a prevalence of 1%–58%.[7-12] We and Park *et al* previously reported that RA-associated ILD (RA-ILD) was the most common CVD-ILD associated with AE.[3, 4] However the risk factors and prognosis associated with AE in patients

1
2
3
4
5
6 with RA-ILD are not clarified.
7

8
9 In the present study, we attempted to elucidate the cumulative incidence of AE, its
10
11 risk factors, and prognostic factors in patients with RA-ILD.
12
13

14 15 16 17 **MATERIALS AND METHODS** 18

19 20 **Subjects** 21

22
23 Institutional review board in Hamamatsu University School of Medicine approved
24
25 this study (approval number 24-191) and waived patient approval or informed consent
26
27 because the study involved a retrospective review of patient records and images. We
28
29 retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995
30
31 and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the
32
33 diagnostic criteria of the American College of Rheumatology for RA.[13] Patients with
34
35 other coexisting CVD were excluded. In addition, because our aim was to investigate
36
37 the features of AE among patients with a chronic course of RA-ILD, patients with no
38
39 evidence of chronic ILD were also excluded.
40
41
42
43
44
45
46
47
48

49
50 ILD was diagnosed on the basis of clinical presentation, pulmonary function tests,
51
52 high resolution computed tomography (HRCT) findings, and lung biopsy findings.
53
54
55 HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities
56
57
58
59
60

1
2
3
4
5
6 and honeycomb patterns were interpreted and defined as ILD by a consensus between
7
8 radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and
9
10 bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to
11
12 definitively diagnose ILD or rule out other diseases. The patients with environmental
13
14 exposures, suspected of drug induced pneumonia (ILD developed within 1 year after
15
16 initiation of new drug), or with other known causes of ILD were excluded after
17
18 considering exposure history and the findings of appropriate tests and histopathological
19
20 examinations.
21
22
23
24
25
26
27
28
29
30
31

32 **Acute exacerbation (AE)**

33
34
35 AE was defined using recently proposed criteria[1] that were slightly modified for
36
37 adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or
38
39 development of dyspnea within 30 days of onset, new bilateral ground-glass
40
41 abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern
42
43 on HRCT, no evidence of pulmonary infection on negative respiratory culture,
44
45 including endotracheal aspirate or bronchoalveolar lavage, and serological test results
46
47 for respiratory pathogens, and exclusion of alternative causes such as left heart failure,
48
49 pulmonary embolism, and an identifiable cause of acute lung injury. Patients with AE
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 were required to meet all five criteria. In our institution, cultures of sputum, blood, urine,
7
8
9 and bronchoalveolar lavage fluid, and serological tests examined for mycobacteria,
10
11
12 fungi, bacteria, and some viruses were routinely performed. Echocardiography and, if
13
14
15 necessary, CT scanning with intravenous contrast were performed to rule out left heart
16
17
18 failure or pulmonary thromboembolism. The patients who developed acute pneumonitis
19
20
21 within 1 year after initiation of drug for RA were excluded because drug-induced
22
23
24 pneumonitis was not completely ruled out. Patients who did or did not develop AE
25
26
27 during the observation period were classified into the AE and non-AE groups,
28
29
30 respectively.
31
32
33
34

35 **Data collection**

36
37
38 All clinical and laboratory data were collected from medical records. The observation
39
40
41 period was calculated from the date of diagnosis of RA-ILD to the last visit. The
42
43
44 AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis
45
46
47 and the first AE occurrence (AE group) or the last visit (non-AE group).
48
49
50
51

52 **Review of radiographic findings**

53
54
55 HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images
56
57
58
59
60

1
2
3
4
5
6 comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were
7
8
9 reconstructed by a high spatial frequency algorithm, and were displayed at window
10
11 settings appropriate for viewing the lung parenchyma (window level, -600 to -800
12
13 Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were
14
15 randomised and reviewed independently by two expert chest radiologists (with 23 and
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

12 years of experience) who were unaware of the related clinical information.

RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a non-UIP pattern according to recent guideline.[14] Briefly, a UIP pattern on HRCT was characterised by subpleural and basal predominance, reticular abnormalities, honeycombing with or without traction bronchiectasis and the absence of features listed as inconsistent with a UIP pattern, including upper or mid-lung predominance, peribronchovascular predominance, extensive ground glass abnormalities, profuse micronodules, discrete cysts, diffuse mosaic attenuation/air-trapping and consolidation in bronchopulmonary segment(s)/lobe(s). If the HRCT pattern did not meet the criteria, it was interpreted as a non-UIP pattern. Disagreements regarding HRCT interpretation were resolved by a consensus between both radiologists.

Review of histopathological findings

1
2
3
4
5
6 SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was
7
8
9 originally made in all cases on the basis of histological features evaluated by a lung
10
11
12 pathologist at our hospital, correlated with the clinical and radiological findings. All
13
14
15 SLB specimens were also reviewed by a second lung pathologist with 36 years of
16
17
18 experience. The histological classification of interstitial pneumonia was based on the
19
20
21 consensus statement criteria for idiopathic interstitial pneumonias,[15] and histological
22
23
24 patterns that could not be classified according to the criteria were categorised as
25
26
27 unclassified interstitial pneumonia.
28
29
30
31

32 **Statistical analysis**

33
34
35 All values are expressed as median (range) or number (%). The Mann-Whitney U test
36
37
38 was used for nonparametric comparisons involving continuous data, whereas Fisher's
39
40
41 exact test was used for comparing categorical data. Interobserver agreement on HRCT
42
43
44 pattern was analyzed using the κ statistic test. Interobserver agreement was classified as
45
46
47 follows: poor ($\kappa = 0-0.20$), fair ($\kappa = 0.21-0.40$), moderate ($\kappa = 0.41-0.60$), good ($\kappa =$
48
49
50 $0.61-0.80$) and excellent ($\kappa = 0.81-1.00$). Survival was evaluated using the
51
52
53 Kaplan–Meier method and the log-rank test. The cumulative AE incidence was obtained
54
55
56 from a Kaplan–Meier survival curve by treating AE as the death variable. The 1-year
57
58
59
60

1
2
3
4
5
6 AE incidence was calculated by dividing the number of patients who developed AE by
7
8
9 the total of AE-free period (year) of all the patients. Cox hazards analysis was used to
10
11
12 determine significant variables associated with survival and AE occurrence. In all
13
14
15 analyses, $P < 0.05$ was considered statistically significant. All data were analysed using
16
17
18 commercially available software (JMP version 9.0.3a, SAS Institute Inc, Cary, NC,
19
20
21 USA).

22 23 24 25 26 **RESULTS**

27 28 29 **Patient characteristics (Table 1)**

30
31
32 The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82)
33
34 years and 62 (range, 31–83) years, respectively. The median observation period and
35
36
37 AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.

38
39
40 During the observation period, 11 patients (22%) developed AE. The median age at
41
42
43 the onset of AE was 72 (range, 60–86) years. There were no statistically significant
44
45
46 differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period,
47
48
49 AE-free period, smoking habits, predicted forced vital capacity (%FVC) and arterial
50
51
52 oxygen pressure (PaO₂) between the AE and non-AE groups.

53
54
55 In the AE group, seven of 11 patients (64%) died of initial AE during the observation
56
57
58

1
2
3
4
5
6 period. In the non-AE group, 5 of 40 patients (13%) died. There was a statistically
7
8
9 significant difference in the mortality rate between the AE and non-AE groups.
10

11 12 13 14 15 **HRCT pattern (Table 1)** 16

17
18 Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT.
19
20
21 HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%)
22
23 patients in the AE group demonstrated a UIP pattern. Interobserver agreement between
24
25 both radiologists was moderate (κ statistic test, $\kappa = 0.44$). The number of patients who
26
27 exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the
28
29 non-AE group.
30
31
32
33
34
35
36
37

38 **Correlation between histopathological findings and HRCT pattern (Table 2)** 39

40
41 Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis
42
43 revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and
44
45 an unclassified interstitial pneumonia in 1. The correlation between histopathological
46
47 and HRCT pattern was evaluated in 21 histopathologically confirmed patients. When
48
49 the pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive
50
51 predictive value and negative predictive value for detecting histopathological UIP was
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 41.7%, 100%, 100% and 56.3%, respectively.
7
8
9

10 11 12 **Treatment for RA (Table 3)** 13

14
15 Of the 51 patients, 37 (73%) had received treatment for RA at their final visit
16
17 (non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) received
18
19 corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10 (20%)
20
21 received MTX and 17 (33%) received other drugs. The number of patients who received
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
MTX was significantly higher in the AE group than in the non-AE group (55% vs. 10%,
 $P = 0.001$).

AE incidence

The cumulative AE incidence in patients with RA-ILD is shown in Figure 1. The AE incidence was significantly higher in patients with a UIP pattern on HRCT (UIP pattern group) than in patients with a non-UIP pattern on HRCT (non-UIP pattern group) (log-rank test, $P = 0.018$). The overall 1-year AE incidence was 2.8%. The 1-year AE incidence was 6.5% in the UIP pattern group and 1.7 % in the non-UIP pattern group.

Univariate analysis (Table 4) revealed that higher age at ILD diagnosis [hazard ratio (HR), 1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], UIP pattern on HRCT

(HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and treatment with MTX (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were significant risk factors for AE occurrence.

Survival

The overall survival of patients with RA-ILD is shown in Figure 2.

The 5-year survival was 90% in all patients, 70% in the UIP pattern group and 97% in the non-UIP pattern group. Survival was significantly poorer in the UIP pattern group than in the non-UIP pattern group (log-rank test, $P = 0.04$). In addition, significantly worse survival was demonstrated in the AE group compared with the non-AE group (Figure 3, log-rank test, $P = 0.001$).

Univariate analysis (Table 5) revealed that higher age at ILD diagnosis (HR, 1.08; 95% CI, 0.99–1.17; $P = 0.057$) and UIP pattern on HRCT (HR, 1.74; 95% CI, 0.97–3.12; $P = 0.06$) showed a trend toward poor outcome, while AE (HR, 2.47; 95% CI, 1.39–4.56; $P = 0.003$) was significantly associated with poor survival.

DISCUSSION

To our knowledge, the present study is the first one focusing on the risk factors and prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence

1
2
3
4
5
6 was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern
7
8
9 on HRCT, MTX treatment and higher age at ILD diagnosis were significant risk factors
10
11
12 for AE. Furthermore, AE was a prognostic factor for poor survival.
13

14
15 The 1-year AE incidence among patients with IPF has been reported to be 5-19%,[16,
16
17 17] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP, 3.3 %
18
19 for CVD-ILD and 5.6 % for CVD-UIP.[4] In the present study, patients with RA-ILD
20
21 had a relatively lower incidence of AE. However, the 1-year AE incidence among
22
23 patients with a UIP pattern on HRCT was 6.5%, comparable to that in patients with IPF.
24
25
26 Furthermore, a UIP pattern on HRCT was a risk factor for AE. In a previous report of
27
28 small number of biopsy-proven cases, AE incidence among patients with RA-UIP was
29
30 11.1%, also similar to that among patients with IPF.[4] The correlation between
31
32 pathological and radiological UIP patterns has been established in IPF, but not in
33
34 RA-ILD.[18] In the present study, determination of a UIP pattern on HRCT exhibited
35
36 high specificity and positive predictive values for the detection of pathological UIP.
37
38 Therefore, a typical UIP pattern on HRCT was assumed to be highly suggestive of
39
40 pathological UIP in patients with RA-ILD as well as IPF.[14, 18] Collectively, these
41
42
43 results suggest that AE occurs less frequently in RA-ILD than in IPF, while AE
44
45
46 incidence in a subgroup with pathological UIP or a UIP pattern on HRCT may be as
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 high as that in patients with IPF.
7

8
9 The present study also identified MTX treatment as a risk factor for AE. MTX is
10
11 widely used to treat RA, while its toxicity affects the pulmonary system. Diagnostic
12
13 criteria for MTX-associated pneumonitis (MTX-pneumonitis) have been proposed
14
15 previously.[19] However, the specificity of the criteria has not been fully examined yet.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MTX-pneumonitis typically occurs with acute/subacute onset early in the course of
MTX treatment,[19-22] in particular, mostly within the first year[23] and often presents
a hypersensitive pneumonitis pattern. Patients with MTX-pneumonitis generally
respond to discontinuation of MTX or corticosteroid treatment and have a favorable
prognosis.[19-22] In the present study, 6 of 11 patients with AE had received MTX, and
5 of the 6 patients had been treated for 3 or more years. The remaining patient had been
treated for 1 year. In all 6 patients, their respiratory conditions progressively
deteriorated despite discontinuation of MTX, and they poorly responded to high-dose
corticosteroid. Consequently, on the basis of inconsistency in terms of MTX treatment
duration and clinical features, we diagnosed these patients with AE of RA-ILD. Similar
to AE in patients with IPF, the etiology of AE in RA-ILD is unknown; however, several
reports have suggested that AE may be a distinct manifestation of the primary disease
process, a distinct condition associated with undiagnosed infection, or a subsequent

1
2
3
4
5
6 acceleration of a fibroproliferative process caused by acute direct stress to the lung.[1]
7
8
9 In the present study, RA joint disease activity in all patients with AE was stable at the
10
11 time of AE occurrence; therefore, RA activity may not be related to AE occurrence, a
12
13 finding similar to that of a previous study.[4] MTX possibly accelerates the
14
15 fibroproliferative process of RA-ILD. It was reported that MTX treatment was a risk
16
17 factor for RA-ILD progression.[10] For RA-ILD, MTX may be associated not only with
18
19 newly developing drug-induced pneumonitis but also with deterioration of pre-existing
20
21 ILD, including AE. Therefore, we think that MTX treatment should be avoided in RA
22
23 patients with ILD.
24
25
26
27
28
29
30
31

32 The present study found that patients with a UIP pattern on HRCT had significantly
33
34 poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic
35
36 factor for poor outcome. AE has a serious impact on the survival of patients with
37
38 IPF,[17] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with these
39
40 reports, the present study revealed that seven (64%) of 11 patients with AE died of
41
42 respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE
43
44 group was significantly poorer than that in the non-AE group. Therefore, AE is
45
46 suggested to be a predictor of poor prognosis in patients with RA-ILD as well as
47
48 patients with IPF.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Other prognostic factors in RA-ILD have been reported, including pathological
7
8
9 UIP,[24-28] UIP pattern on HRCT,[29] and age at RA-ILD onset.[30] In the present
10
11
12 study, pathological UIP could not be identified as prognostic factors because the number
13
14
15 of biopsy-proven cases were small. However, we observed similar results regarding UIP
16
17
18 pattern on HRCT and age at RA-ILD onset.

19
20
21 This study had several limitations. First, given its retrospective study design, it is
22
23
24 subject to several possible biases. For instance, selection and recall bias may exist.
25
26
27 Second, because of the relatively small sample size, it may be difficult to determine the
28
29
30 precise incidence of AE. Therefore, larger studies are necessary to confirm our results.
31
32
33 Third, because the presence of a UIP pattern on HRCT had low sensitivity for the
34
35
36 detection of pathologic UIP, it was likely that some patients with a non-UIP pattern on
37
38
39 HRCT may have had pathological UIP. Finally, RA includes a variety of manifestations.
40
41
42 Therefore, other comorbidities may have affected the results.

43
44
45 In conclusion, higher age at ILD diagnosis, UIP pattern on HRCT and treatment with
46
47
48 MTX are risk factors for AE occurrence in patients with RA-ILD. Furthermore, the
49
50
51 mortality associated with AE is high and AE is prognostic factor for poor outcome. AE
52
53
54 has a serious impact on the survival of patients with RA-ILD. Thus, we should carefully
55
56
57 observe the patients having any of these risk factors.
58
59
60

ACKNOWLEDGMENT

We appreciate the help of Dr. T. Tsuchiya in the statistical advice.

This study was partly supported by the Diffuse Lung Diseases Research Group from the ministry of Health, Labour and Welfare, Japan.

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S., and K.C. revised the paper.

All authors approved the paper.

Competing interest:

All authors do not have any personal or financial support or involvement with organization(s) that have financial interest in the subject matter, or any competing interest.

Funding:

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this study (approval number 24-191) and waived patient approval or informed consent because the study involved a retrospective review of patient records and images.

Copyright:

I [*Yutaro Nakamura*] the Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs, other illustrative material, video, film or any other material howsoever submitted by the Contributor(s) at

1
2
3
4
5
6 any time and related to the Contribution (“the Contribution”) have the right to grant on
7
8
9 behalf of all authors and do grant on behalf of all authors, a licence to the BMJ
10
11
12 Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be
13
14 published in BMJ Open and any other BMJ Group products and to exploit all subsidiary
15
16
17 rights, as set out in the licence
18
19
20
21
22

23 Data sharing:

24
25
26 No unpublished data from the study are available.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.
2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. *Histopathology.* 2011;58:525-30.
3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.
4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.
5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.
6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.* 1998;19:667-85.
7. Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. *Ann Rheum Dis.* 2003;62:897-900.
8. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest

- 1
2
3
4
5
6 radiography, and pulmonary function tests. *Thorax*. 2001;56:622–7.
7
8
9 9. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset
10
11 rheumatoid arthritis. *Am J Respir Crit Care Med*. 1997;156:528–35.
12
13
14 10. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung
15
16 disease in rheumatoid arthritis. *Arch Intern Med*. 2008;168:159–66.
17
18
19
20 11. Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on
21
22 high-resolution computed tomography in patients with early versus longstanding
23
24 rheumatoid arthritis. *J Rheumatol*. 2008;35:1513–21.
25
26
27
28
29 12. Turesson C, O’Fallon WM, Crowson CS, et al. Extra-articular disease
30
31 manifestations in rheumatoid arthritis: incidence trends and risk factors over 46
32
33 years. *Ann Rheum Dis*. 2003;62:722–7.
34
35
36
37
38 13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association
39
40 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*.
41
42 1988;31:315-24.
43
44
45
46 14. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on
47
48 Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:
49
50 idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and
51
52 management. *Am J Respir Crit Care Med*. 2011;183:788-824.
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 15. American Thoracic Society/European Respiratory Society International
7
8
9 Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
10
11
12 *Am J Respir Crit Care Med.* 2002;165:277-304.
13
14
15 16. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary
16
17 fibrosis. *Chest.* 2007;132:1652-8.
18
19
20 17. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary
21
22 fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356-63.
23
24
25 18. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung
26
27 disease: the relevance of histopathologic and radiographic pattern. *Chest.*
28
29
30 2009;136:1397-405.
31
32
33 19. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic,
34
35 and histopathologic features of methotrexate-associated lung injury in patients with
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.

- 1
2
3
4
5
6 21. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in
7
8 patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis*.
9
10 2009;68:1100-4.
11
12
13
14 22. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the
15
16 literature and histopathological findings in nine patients. *Eur Respir J*.
17
18 2000;15:373-81.
19
20
21
22
23 23. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in
24
25 rheumatoid arthritis. *Rheumatology (Oxford)*. 2004;43:143-7.
26
27
28
29 24. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis
30
31 of 54 biopsy-proven cases. *Respir Med*. 2012;106:1164-9.
32
33
34
35 25. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am*
36
37 *Rev Respir Dis*. 1985;131:770-7.
38
39
40
41 26. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of
42
43 rheumatoid arthritis-associated interstitial lung disease. *Chest*. 2005;127:2019-27.
44
45
46
47 27. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern
48
49 as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int*. 2005;26:121-5.
50
51
52
53 28. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia:
54
55 idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care*
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Med. 2007;175:705-11.

29. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in
rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.*
2010;35:1322-8.

30. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study).
Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an
inception cohort. *Rheumatology (Oxford)*. 2010;49:1483-9.

Table 1 Clinical characteristics

| Characteristics | Total N = 51 (100) | Non-AE group [#] N = 40 (78) | AE group [¶] N = 11 (22) | P value ⁺ |
|---|-----------------------|--|--------------------------------------|----------------------|
| Median age, years (range) | | | | |
| at RA diagnosis | 61 (28-82) | 60 (28-81) | 65 (42-82) | 0.15 |
| at ILD diagnosis | 62 (31-83) | 62 (31-83) | 69 (58-83) | 0.15 |
| at AE onset | | | 72 (60-86) | |
| Sex Male, n (%) | 29 (57) | 23 (58) | 6 (55) | 0.86 |
| Observation period, years (range) | 8.5 (1-17) | 9 (1-17) | 6.4 (2-14) | 0.45 |
| AE-free period, years (range) | 7(1-17) | 9 (1-17) | 6 (2-14) | 0.19 |
| Smoking habit, n (%) | | | | |
| Never | 20 (39) | 18 (45) | 2 (18) | |
| Former | 24 (47) | 16 (40) | 8 (73) | 0.15 |
| Current | 7 (14) | 6 (15) | 1 (9) | |
| PaO ₂ , torr (range) | 82.4 (67-109) | 81 (67-102) | 85.8 (74-109) | 0.19 |
| %FVC, % (range) | 91.1 (50.6-130) | 87.5 (51-130) | 95 (60-125) | 0.38 |
| HRCT pattern, n (%) | | | | |
| UIP pattern | 14 (27) | 8 (20) | 6 (55) | |
| non-UIP pattern | 37 (73) | 32 (80) | 5 (45) | 0.02 [§] |
| Death during observation period, n (%) | 12 (24) | 5 (13) | 7 (64) | 0.001 [§] |
| caused by respiratory failure | 8 (16) | 2 (5) | 7 (64) | |
| caused by other diseases | 4 (8) | 3 (8) | 0 (0) | 0.02 [§] |

Data are presented as n (%), median (range).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶]AE group, patients who developed AE during observation period.

⁺Non-AE group vs AE group

[§] $p < 0.05$

In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding and 2 of unknown causes.

Table 2 Correlation between histopathological findings and HRCT pattern in 21 histopathologically confirmed patients.

| | Histopathological pattern | | Total |
|-------------------------|---------------------------|---------------|-------|
| | UIP | Other pattern | |
| UIP pattern on HRCT | 5 | 0 | 5 |
| non-UIP pattern on HRCT | 7 | 9 | 16 |
| Total | 12 | 9 | 21 |

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

When HRCT pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive predictive value and negative predictive value for detecting histopathological UIP was 41.7%, 100%, 100% and 56.3%, respectively.

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

| | Total N = 51 | non-AE group ⁺ N = 40 (78%) | AE group [§] N = 11 (22%) | P value |
|----------------------------------|-----------------|---|---------------------------------------|--------------------|
| Treatment, yes | 37 (73) | 27(68) | 10 (91) | 0.12 |
| Corticosteroid | 29 (57) | 22 (55) | 7 (64) | 0.61 |
| Immunosuppressant except for MTX | 17 (33) | 14 (35) | 3 (27) | 0.63 |
| MTX | 10 (20) | 4 (10) | 6 (55) | 0.001 [*] |
| Other drugs | 17 (33) | 13 (33) | 4 (36) | 0.81 |

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cyclophosphamide (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

⁺ Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

^{*} $p < 0.05$

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 1.03 | 0.97-1.10 | 0.35 |
| Age at ILD diagnosis | 1.11 | 1.02-1.21 | 0.01 ⁺ |
| Sex, male | 0.90 | 0.49-1.69 | 0.73 |
| Smoking habit, yes | 1.60 | 0.81-4.10 | 0.19 |
| UIP pattern on HRCT, yes | 1.95 | 1.07-3.63 | 0.03 ⁺ |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.12 | 0.14 |
| %FVC at ILD diagnosis | 1.02 | 0.99-1.06 | 0.24 |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 0.97 | 0.53-1.92 | 0.94 |
| Immunosuppressant except for MTX | 0.76 | 0.35-1.41 | 0.39 |
| MTX | 3.04 | 1.62-6.02 | 0.001 ⁺ |
| Other drugs | 0.98 | 0.50-1.80 | 0.96 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 0.98 | 0.93-1.04 | 0.48 |
| Age at ILD diagnosis | 1.08 | 0.99-1.17 | 0.057 |
| Sex, male | 1.14 | 0.63-2.22 | 0.67 |
| Smoking habit, yes | 1.70 | 0.87-4.35 | 0.13 |
| UIP pattern on HRCT, yes | 1.74 | 0.97-3.12 | 0.06 |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.11 | 0.15 |
| %FVC at ILD diagnosis | 1.01 | 0.98-1.04 | 0.55 |
| AE during observation period, yes | 2.47 | 1.39-4.56 | 0.003 ⁺ |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 1.23 | 0.67-2.65 | 0.52 |
| Immunosuppressant except for MTX | 0.69 | 0.32-1.27 | 0.25 |
| MTX | 1.44 | 0.67-2.68 | 0.31 |
| Other drugs | 0.76 | 0.36-1.41 | 0.40 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Figure legends

Figure 1. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank $p=0.018$).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 2. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank $p=0.04$).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 3. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly worse survival compared with those who did not (non-AE group) (log-rank $p=0.001$).

AE, acute exacerbation.




FIGURE 1.

Figure 1. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank $p=0.018$).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
85x85mm (300 x 300 DPI)




FIGURE 2.

Figure 2. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank $p=0.04$).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
85x85mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




FIGURE 3.

Figure 3. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly worse survival compared with those who did not (non-AE group) (log-rank $p=0.001$).

AE, acute exacerbation.
85x85mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

| | Item No | Recommendation |
|------------------------------|---------|---|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found |
| Introduction | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses |
| Methods | | |
| Study design | 4 | Present key elements of study design early in the paper |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group |
| Bias | 9 | Describe any efforts to address potential sources of bias |
| Study size | 10 | Explain how the study size was arrived at |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses |
| Results | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) |
| Outcome data | 15* | Report numbers of outcome events or summary measures over time |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |

| | | | |
|----|--------------------------|----|--|
| 1 | Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and |
| 2 | | | sensitivity analyses |
| 3 | Discussion | | |
| 4 | Key results | 18 | Summarise key results with reference to study objectives |
| 5 | Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or |
| 6 | | | imprecision. Discuss both direction and magnitude of any potential bias |
| 7 | Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, |
| 8 | | | multiplicity of analyses, results from similar studies, and other relevant evidence |
| 9 | Generalisability | 21 | Discuss the generalisability (external validity) of the study results |
| 10 | Other information | | |
| 11 | Funding | 22 | Give the source of funding and the role of the funders for the present study and, if |
| 12 | | | applicable, for the original study on which the present article is based |

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.



Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID: | bmjopen-2013-003132.R1 |
| Article Type: | Research |
| Date Submitted by the Author: | 06-Jul-2013 |
| Complete List of Authors: | Hozumi, Hironao; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Nakamura, Yutaro; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Johkoh, Takeshi; Kinki Central Hospital of Mutual Aid Association of Public Teachers, Department of Radiology Sumikawa, Hiromitsu; Osaka University Graduate School of Medicine, Diagnostic and Interventional Radiology Colby, Thomas; Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology kono, Masato; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Hashimoto, Dai; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Enomoto, Noriyuki; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Fujisawa, Tomoyuki; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Inui, Naoki; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Suda, Takafumi; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Chida, Kingo; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine |
| Primary Subject Heading: | Respiratory medicine |
| Secondary Subject Heading: | Rheumatology |
| Keywords: | Interstitial lung disease < THORACIC MEDICINE, RHEUMATOLOGY, Adult thoracic medicine < THORACIC MEDICINE |
| | |

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **Title:** Acute exacerbation in rheumatoid arthritis associated interstitial lung disease
7
8
9

10
11
12 **Authors:**

13
14 Hironao Hozumi, M.D., Ph.D.¹

15
16 Yutaro Nakamura, M.D., Ph.D.¹

17
18 Takeshi Johkoh, M.D., Ph.D.²

19
20 Hiromitsu Sumikawa, M.D., Ph.D.³

21
22 Thomas V. Colby, M.D.⁴

23
24 Masato Kono, M.D, Ph.D.¹

25
26 Dai Hashimoto, M.D., Ph.D.¹

27
28 Noriyuki Enomoto, M.D., Ph.D.¹

29
30 Tomoyuki Fujisawa, M.D., Ph.D.¹

31
32 Naoki Inui, M.D., Ph.D.¹

33
34 Takafumi Suda, M.D., Ph.D.¹

35
36 Kingo Chida, M.D., Ph.D.¹

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 **Affiliations:**

53
54
55 ¹Second division, Department of Internal Medicine, Hamamatsu University School of
56
57
58

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

²Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public
School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan

³Diagnostic and Interventional Radiology, Osaka University Graduate School of
Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

⁴Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East
Shea Boulevard Scottsdale, AZ 85259, USA

Corresponding author:

Yutaro Nakamura, M.D., Ph.D.

Second division, Department of Internal Medicine, Hamamatsu University School of
Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

Tel: 81-53-435-2263, Fax: 81-53-435-2354

E-mail address: nakayuta@hama-med.ac.jp

Keywords: Acute exacerbation, interstitial lung disease, risk factor, prognostic factor,
rheumatoid arthritis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word count paper: 3382

Word count abstract: 280

For peer review only

ABSTRACT

Background Acute exacerbation (AE) in idiopathic pulmonary fibrosis is characterised by acute deterioration of respiratory status and the mortality is high.

Recently, AE was reported in patients with other interstitial lung diseases, especially rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives To investigate the risk factors and prognosis associated with AE in patients with RA-ILD.

Design A retrospective case-control study.

Setting A single academic hospital.

Participants 51 consecutive patients diagnosed with RA-ILD between 1995 and 2012.

All patients fulfilled the diagnostic criteria of the American College of Rheumatology for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures Overall survival and cumulative AE incidence were analysed using Kaplan–Meier method. Cox hazards analysis was used to determine significant variables associated with AE occurrence and survival status.

Results A total of 11 patients (22%) developed AE, with an overall 1-year incidence of 2.8%. Univariate analysis revealed that higher age at ILD diagnosis [hazard ratio

1
2
3
4
5
6 (HR), 1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], usual interstitial
7
8
9 pneumonia (UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and
10
11
12 treatment with methotrexate (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were risk factors
13
14
15 for AE. Of 11 patients who developed AE during observation period, seven (64%) died
16
17
18 of initial AE. In survival, AE was a prognostic factor for poor outcome (HR, 2.47; 95%
19
20
21 CI, 1.39–4.56; $P = 0.003$).

22
23 **Conclusions** In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on
24
25
26 HRCT and treatment with methotrexate are risk factors for AE. Furthermore, AE has a
27
28
29 serious impact on their survival.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis (IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with RA-ILD?

Key messages;

In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on HRCT, and treatment with methotrexate are risk factors for AE occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE has a serious impact on the survival of patients with RA-ILD.

Given its retrospective study design, it is subject to several possible biases. Therefore, prospective studies are necessary to confirm our results.

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterised by acute deterioration in respiratory status, with newly developed bilateral ground-glass opacities and/or consolidations on chest radiographs or computed tomography scans. It should be in the absence of other alternative causes such as infection, left heart failure, pulmonary embolism, and an identifiable cause of acute lung injury. AE reportedly occurs not only in patients with IPF but also in patients with other interstitial lung diseases (ILDs), including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital mortality associated with AE in patients with CVD-ILD was demonstrated to be as high as that in patients with IPF,[1-4] suggesting that AE may be associated with poor prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown etiology that primarily involves joints.[5] ILD is one of common extra-articular manifestations.[6, 7] The reported prevalence is variable (1–58%) and depends on the detection and diagnostic method, or the selected population.[8-13] We and Park *et al* previously reported that RA-associated ILD (RA-ILD) was the most common

1
2
3
4
5
6 CVD-ILD associated with AE.[3, 4] However the risk factors and prognosis associated
7
8
9 with AE in patients with RA-ILD are not clarified.

10
11 In the present study, we attempted to elucidate the cumulative incidence of AE, its
12
13 risk factors, and prognostic factors in patients with RA-ILD.
14
15
16
17
18
19

20 MATERIALS AND METHODS

21 Subjects

22
23
24
25 Institutional review board in Hamamatsu University School of Medicine approved
26
27 this study (approval number 24-191) and waived patient approval or informed consent
28
29 because the study involved a retrospective review of patient records and images. We
30
31 retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995
32
33 and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the
34
35 diagnostic criteria of the American College of Rheumatology for RA.[14] Patients with
36
37 other coexisting CVD were excluded. In addition, because our aim was to investigate
38
39 the features of AE among patients with a chronic course of RA-ILD, patients with no
40
41 evidence of chronic ILD were also excluded.
42
43
44
45
46
47
48
49
50
51

52
53 ILD was diagnosed on the basis of clinical presentation, pulmonary function tests,
54
55 high resolution computed tomography (HRCT) findings, and lung biopsy findings.
56
57
58
59
60

1
2
3
4
5
6 HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities
7
8
9 and honeycomb patterns were interpreted and defined as ILD by a consensus between
10
11 radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and
12
13 bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to
14
15 definitively diagnose ILD or rule out other diseases. The patients with environmental
16
17 exposures, suspected of drug induced pneumonia (ILD developed within 1 year after
18
19 initiation of new drug), or with other known causes of ILD were excluded after
20
21 considering exposure history and the findings of appropriate tests and histopathological
22
23 examinations.
24
25
26
27
28
29
30
31
32
33
34

35 **Acute exacerbation (AE)**

36
37
38 AE was defined using recently proposed criteria[1] that were slightly modified for
39
40 adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or
41
42 development of dyspnea within 30 days of onset, new bilateral ground-glass
43
44 abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern
45
46
47 on HRCT, no evidence of pulmonary infection on negative respiratory culture,
48
49 including endotracheal aspirate or bronchoalveolar lavage, and serological test results
50
51
52
53
54
55 for respiratory pathogens, and exclusion of alternative causes such as left heart failure,
56
57
58
59
60

1
2
3
4
5
6 pulmonary embolism, and an identifiable cause of acute lung injury. Patients with AE
7
8
9 were required to meet all five criteria. In our institution, cultures of sputum, blood, urine,
10
11 and bronchoalveolar lavage fluid, and serological tests examined for mycobacteria,
12
13 fungi, bacteria, and some viruses were routinely performed. Echocardiography and, if
14
15 necessary, CT scanning with intravenous contrast were performed to rule out left heart
16
17 failure or pulmonary thromboembolism. The patients who developed acute pneumonitis
18
19 within 1 year after initiation of drug for RA were excluded because drug-induced
20
21 pneumonitis was not completely ruled out. Patients who did or did not develop AE
22
23 during the observation period were classified into the AE and non-AE groups,
24
25 respectively.
26
27
28
29
30
31
32
33
34
35
36
37

38 **Data collection**

39
40 All clinical and laboratory data were collected from medical records. The observation
41
42 period was calculated from the date of diagnosis of RA-ILD to the last visit. The
43
44 AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis
45
46 and the first AE occurrence (AE group) or the last visit (non-AE group).
47
48
49
50
51
52
53
54

55 **Review of radiographic findings**

56
57
58
59
60

1
2
3
4
5
6 HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images
7
8
9 comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were
10
11
12 reconstructed by a high spatial frequency algorithm, and were displayed at window
13
14
15 settings appropriate for viewing the lung parenchyma (window level, -600 to -800
16
17 Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were
18
19
20 randomised and reviewed independently by two expert chest radiologists (with 23 and
21
22
23 12 years of experience) who were unaware of the related clinical information.
24
25
26 Interobserver agreement was classified as follows: poor ($\kappa = 0-0.20$), fair ($\kappa =$
27
28
29 $0.21-0.40$), moderate ($\kappa = 0.41-0.60$), good ($\kappa = 0.61-0.80$) and excellent ($\kappa =$
30
31
32 $0.81-1.00$).

33
34
35 RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a
36
37
38 non-UIP pattern according to recent guideline with slight modification.[15] Briefly, a
39
40
41 UIP pattern on HRCT was characterised by subpleural and basal predominance,
42
43
44 reticular abnormalities, honeycombing with or without traction bronchiectasis and the
45
46
47 absence of features listed as inconsistent with a UIP pattern, including upper or
48
49
50 mid-lung predominance, peribronchovascular predominance, extensive ground glass
51
52
53 abnormalities, profuse micronodules, discrete cysts, diffuse mosaic
54
55
56 attenuation/air-trapping and consolidation in bronchopulmonary segment(s)/lobe(s). If
57
58
59
60

1
2
3
4
5
6 the HRCT pattern did not meet the criteria, it was interpreted as a non-UIP pattern.
7

8
9 Disagreements regarding HRCT interpretation were resolved by a consensus between
10
11 both radiologists.
12
13

14 15 16 17 **Review of histopathological findings** 18

19
20 SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was
21
22 originally made in all cases on the basis of histological features evaluated by a lung
23
24 pathologist at our hospital, correlated with the clinical and radiological findings. All
25
26 SLB specimens were also reviewed by a second lung pathologist with 36 years of
27
28 experience. The histological classification of interstitial pneumonia was based on the
29
30 consensus statement criteria for idiopathic interstitial pneumonias,[16] and histological
31
32 patterns that could not be classified according to the criteria were categorised as
33
34 unclassified interstitial pneumonia.
35
36
37
38
39
40
41
42
43
44
45
46

47 **Statistical analysis** 48

49
50 All values are expressed as median (range) or number (%). The Mann-Whitney U test
51
52 was used for nonparametric comparisons involving continuous data, whereas Fisher's
53
54 exact test was used for comparing categorical data. Interobserver agreement on HRCT
55
56
57
58
59
60

1
2
3
4
5
6 pattern was analyzed using the κ statistic test. Survival was evaluated using the
7
8 Kaplan–Meier method and the log-rank test according to observation period. The
9
10 cumulative AE incidence was obtained from a Kaplan–Meier survival curve by treating
11
12 AE as the death variable according to AE free period. The 1-year AE incidence was
13
14 based on person year method and calculated by dividing the number of patients who
15
16 developed AE by the total of AE-free period (year) of all the patients. Cox hazards
17
18 analysis was used to determine significant variables associated with survival and AE
19
20 occurrence. In all analyses, $P < 0.05$ was considered statistically significant. All data
21
22 were analysed using commercially available software (JMP version 9.0.3a, SAS
23
24 Institute Inc, Cary, NC, USA).
25
26
27
28
29
30
31
32
33
34
35
36
37

38 RESULTS

39 Patient characteristics (Table 1)

40
41
42 A total of 82 patients with RA-ILD were identified from medical records at
43
44 Hamamatsu University Hospital. From these, 11 patients with other coexisting CVDs, 8
45
46 with no evidence of chronic ILD and an initial acute/subacute course of ILD, and 3
47
48 suspected of drug-induced pneumonitis were excluded. In addition, 9 patients for whom
49
50 no initial HRCT images were available for review were also excluded. The remaining
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 51 patients with RA-ILD were included in this study.(Figure 1)
7

8
9 The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82)
10
11 years and 62 (range, 31–83) years, respectively. The median observation period and
12
13 AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.
14
15

16
17 During the observation period, 11 patients (22%) developed AE. The median age at
18
19 the onset of AE was 72 (range, 60–86) years. There were no statistically significant
20
21 differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period,
22
23 AE-free period, smoking habits, predicted forced vital capacity (%FVC) at diagnosis of
24
25 RA-ILD, and arterial oxygen pressure (PaO₂) at diagnosis of RA-ILD between the AE
26
27 and non-AE groups. Also there were no statistically significant differences in articular
28
29 disease activities (RF and DAS28-CRP) at the last visit (non-AE group) or the first AE
30
31 occurrence (AE group).
32
33
34
35
36
37
38
39

40
41 In the AE group, seven of 11 patients (64%) died of initial AE during the observation
42
43 period. In the non-AE group, 2 of 40 patients (5%) died of respiratory failure. There was
44
45 a statistically significant difference in the mortality rate between the AE and non-AE
46
47 groups.
48
49

50
51 Extra-articular manifestations except for ILD had been observed in 8 (16%) of 51
52
53 patients (pericarditis in 2 patients, pleuritis in 1, neuropathy in 2, cutaneous vasculitis in
54
55
56
57
58
59
60

1
2
3
4
5
6 2, glomerulonephritis in 1, rheumatoid nodule in 2). There was no significant difference
7
8
9 in the incidence between AE group and non-AE group (27% vs. 13%, $P=0.26$).
10

11 12 13 14 **HRCT pattern (Table 1)** 15

16
17 Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT.
18
19
20 HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%)
21
22 patients in the AE group demonstrated a UIP pattern. Interobserver agreement between
23
24 both radiologists was moderate (κ statistic test, $\kappa = 0.44$). The number of patients who
25
26 exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the
27
28 non-AE group.
29
30
31
32
33

34
35 When HRCT pattern was identified as a UIP pattern, the positive predictive value and
36
37 negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.
38
39
40
41
42

43 44 **Diagnostic accuracy of HRCT pattern for histopathological pattern (Table 2)** 45

46
47 Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis
48
49 revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and
50
51 an unclassified interstitial pneumonia in 1. The diagnostic accuracy of HRCT pattern for
52
53 histopathological pattern was evaluated in 21 histopathologically confirmed patients.
54
55
56
57
58
59
60

1
2
3
4
5
6 When the pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity,
7
8 positive predictive value and negative predictive value for detecting histopathological
9
10
11
12 UIP was 41.7%, 100%, 100% and 56.3%, respectively.
13

14 15 16 17 18 **Treatment for RA (Table 3)** 19

20
21 Of the 51 patients, 37 (73%) had received treatment for RA at their final visit
22
23 (non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) had
24
25 received corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10
26
27 (20%) received MTX and 17 (33%) received other drugs. There were 6 (55%) patients
28
29 who had received MTX in AE group while 4 (10%) patients in non-AE group and
30
31 statistically significant difference was observed between the groups ($P = 0.001$).
32
33
34
35
36
37

38 No patients had received MTX before in AE group while 2 in non-AE group. Thus,
39
40 there were 6 (55%) patients who had experienced MTX treatment during observation
41
42 period in AE group while 6 (15%) patients in non-AE group. Median cumulative MTX
43
44 dose were 1952mg (384-3872) in 6 patients who had experienced MTX among AE
45
46
47 group and 802mg (32-2496) in 6 patients among non-AE group. No statistically
48
49
50 significant difference was observed between two groups in cumulative MTX dose
51
52
53
54
55
56
57
58
59
60
($P=0.20$).

1
2
3
4
5
6 Articular disease activities (RF and DAS28-CRP) were compared between patients
7
8
9 who had received MTX at the last visit or at the first AE occurrence, and those who had
10
11
12 not. Median RF (range) were 112 IU/mL (16-334) and 284 IU/mL (6-2666) ($P=0.25$),
13
14
15 Median DAS28-CRP (range) were 1.94 (1.02-3.87) and 1.97 (1.02-5.13) ($P=0.78$),
16
17
18 respectively. There were no statistically significant differences in articular disease
19
20
21 activities.

22 23 24 25 26 **AE incidence**

27
28
29 The cumulative AE incidence in patients with RA-ILD is shown in Figure 2. The
30
31
32 5-year AE incidence was 11% [95% confidence interval (CI), 2–21%] in all patients,
33
34
35 33% (95% CI, 7–60%) in patients with a UIP pattern on HRCT (UIP pattern group) and
36
37
38 3% (95% CI, 0–9%) in patients with a non-UIP pattern on HRCT (non-UIP pattern
39
40
41 group). The AE incidence was significantly higher in UIP pattern group than in
42
43
44 non-UIP pattern group (log-rank test, $P = 0.018$). The overall 1-year AE incidence was
45
46
47 2.8%. The 1-year AE incidence was 6.5% in the UIP pattern group and 1.7 % in the
48
49
50 non-UIP pattern group.

51
52
53 Univariate analysis (Table 4) revealed that higher age at ILD diagnosis [hazard ratio
54
55
56 (HR), 1.11; 95% CI, 1.02–1.21; $P = 0.01$], UIP pattern on HRCT (HR, 1.95; 95% CI,

1
2
3
4
5
6 1.07–3.63; $P = 0.03$) and treatment with MTX (HR, 3.04; 95% CI, 1.62–6.02; $P =$
7
8
9 0.001) were significant risk factors for AE occurrence.

10 11 12 13 14 15 **Survival**

16
17 The overall survival of patients with RA-ILD is shown in Figure 3.

18
19
20 The 5-year survival was 90% (95% CI, 81–98%) in all patients, 70% (95% CI, 44–94%)
21
22 in the UIP pattern group and 97% (95% CI, 92–100%) in the non-UIP pattern group.

23
24
25 Survival was significantly poorer in the UIP pattern group than in the non-UIP pattern
26
27 group (log-rank test, $P = 0.04$). In addition, significantly worse survival was
28
29 demonstrated in the AE group compared with the non-AE group (Figure 4, log-rank test,
30
31
32
33
34
35
36
37 $P = 0.001$).

38
39 Univariate analysis (Table 5) revealed that higher age at ILD diagnosis (HR, 1.08;
40
41 95% CI, 0.99–1.17; $P = 0.057$) and UIP pattern on HRCT (HR, 1.74; 95% CI,
42
43 0.97–3.12; $P = 0.06$) showed a trend toward poor outcome, while AE (HR, 2.47; 95%
44
45 CI, 1.39–4.56; $P = 0.003$) was significantly associated with poor survival.
46
47
48
49
50
51

52 **DISCUSSION**

53
54
55 To our knowledge, the present study is the first one focusing on the risk factors and
56
57
58
59
60

1
2
3
4
5
6 prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence
7
8
9 was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern
10
11
12 on HRCT, MTX treatment and higher age at ILD diagnosis were significant risk factors
13
14
15 for AE. Furthermore, AE was a prognostic factor for poor survival.
16

17
18 The 1-year AE incidence among patients with IPF has been reported to be 5-19%,[17,
19
20 18] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP, 3.3 %
21
22 for CVD-ILD and 5.6 % for CVD-UIP.[4] In the present study, the 1-year AE incidence
23
24 among patients with a UIP pattern on HRCT was 6.5% and cumulative incidence was
25
26 significantly higher in UIP pattern group than in non-UIP pattern group. Furthermore, a
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
typical UIP pattern on HRCT was assumed to be highly suggestive of pathological UIP
pattern in patients with RA-ILD as well as IPF.[15, 19] Collectively, these results
suggest that AE incidence in a subgroup with pathological UIP pattern or a UIP pattern

1
2
3
4
5
6 on HRCT may be higher than that in other patterns..
7

8
9 The present study also identified MTX treatment as a risk factor for AE. MTX is
10
11 widely used to treat RA, while its toxicity affects the pulmonary system. Diagnostic
12
13 criteria for MTX-associated pneumonitis (MTX-pneumonitis) have been proposed
14
15 previously.[20] However, the specificity of the criteria has not been fully examined yet.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
MTX-pneumonitis typically occurs with acute/subacute onset early in the course of
MTX treatment,[20-23] in particular, mostly within the first year[24] and often presents
a hypersensitive pneumonitis pattern. Patients with MTX-pneumonitis generally
respond to discontinuation of MTX or corticosteroid treatment and have a favorable
prognosis.[20-23] In the present study, 6 of 11 patients with AE had received MTX, and
5 of the 6 patients had been treated for 3 or more years. The remaining patient had been
treated for 1 year. In all 6 patients, their respiratory conditions progressively
deteriorated despite discontinuation of MTX, and they poorly responded to high-dose
corticosteroid. Consequently, on the basis of inconsistency in terms of MTX treatment
duration and clinical features, we diagnosed these patients with AE of RA-ILD.

Similar to AE in patients with IPF, the etiology of AE in RA-ILD is unknown;
however, several reports have suggested that AE may be a distinct manifestation of the
primary disease process, a distinct condition associated with undiagnosed infection, or a

1
2
3
4
5
6 subsequent acceleration of a fibroproliferative process caused by acute direct stress to
7
8
9 the lung.[1] In the present study, DAS28-CRP in all patients with AE showed low
10
11
12 disease activity or remission at the time of AE occurrence, and no significant difference
13
14
15 in articular disease activities was observed between AE group and non-AE group or
16
17
18 regardless of MTX treatment; therefore, RA activity may not be related to AE
19
20
21 occurrence, a finding similar to that of a previous study.[4] MTX possibly accelerates
22
23
24 the fibroproliferative process of RA-ILD. It was reported that MTX treatment was a risk
25
26
27 factor for RA-ILD progression.[12] For RA-ILD, MTX may be associated not only with
28
29
30 newly developing drug-induced pneumonitis but also with deterioration of pre-existing
31
32
33 ILD, including AE.

34
35 The present study found that patients with a UIP pattern on HRCT had significantly
36
37
38 poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic
39
40
41 factor for poor outcome. AE has a serious impact on the survival of patients with
42
43
44 IPF,[18] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with these
45
46
47 reports, the present study revealed that seven (64%) of 11 patients with AE died of
48
49
50 respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE
51
52
53 group was significantly poorer than that in the non-AE group. Therefore, AE is
54
55
56 suggested to be a predictor of poor prognosis in patients with RA-ILD as well as
57
58
59
60

1
2
3
4
5
6 patients with IPF.
7

8
9 Other prognostic factors in RA-ILD have been reported, including pathological
10
11 UIP,[25-29] UIP pattern on HRCT,[30] and age at RA-ILD onset.[31] In the present
12
13 study, pathological UIP could not be identified as prognostic factors because the number
14
15 of biopsy-proven cases were small. However, we observed similar results regarding UIP
16
17 pattern on HRCT and age at RA-ILD onset.
18
19
20
21

22
23 In our study, the average time between age at onset of RA and that of RA-ILD was
24
25 relatively shorter than some previous reports.[7, 8] However, Gabbay et al [11] reported
26
27 that nearly 60 % of the patients have interstitial lung disease in recent onset RA. In
28
29 another point of view, since the current authors' institution is regional referral center for
30
31 interstitial lung disease, referral bias might have increased the proportion of patients
32
33 with early-stage ILD, leading above results.
34
35
36
37
38
39

40 This study had several limitations. First, given its retrospective study design, it is
41
42 subject to several possible biases. For instance, selection and recall bias may exist.
43
44 Second, because of the relatively small sample size, it may be difficult to determine the
45
46 precise incidence of AE and the number of event (AE occurrence or death) was too
47
48 small to perform multivariate analysis. Therefore, larger studies are necessary to
49
50 confirm our results. Third, because the presence of a UIP pattern on HRCT had low
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 sensitivity and negative predictive value for the detection of pathologic UIP, it was
7
8 likely that some patients with a non-UIP pattern on HRCT may have had pathological
9
10 UIP. HRCT criteria used in our study do not aim to detect pathological UIP but to
11
12 clinically diagnose IPF and to exclude alternative diagnosis.[15] The frequency of
13
14 honeycombing on HRCT differs between RA-ILD and IPF, and some ILDs by other
15
16 causes including RA-ILD have some of findings inconsistent with UIP. Therefore,
17
18 HRCT pattern in RA-ILD may be more frequently interpreted as non-UIP pattern than
19
20 that in IPF. In our study, 2 of 5 patients with histopathological UIP in the absence of a
21
22 UIP pattern on HRCT develop AE. Thus, SLB may have to be considered for these
23
24 patients to make pathological diagnosis and to predict AE. Finally, RA includes a
25
26 variety of manifestations. Therefore, other comorbidities may have affected the results.
27
28
29
30
31
32
33
34
35
36
37

38 In conclusion, higher age at ILD diagnosis, UIP pattern on HRCT and treatment with
39
40 MTX are risk factors for AE occurrence in patients with RA-ILD. Furthermore, the
41
42 mortality associated with AE is high and AE is prognostic factor for poor outcome.
43
44 Larger prospective studies investigating acute exacerbations in RA-ILD are indicated.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENT

We appreciate the help of Dr. T. Tsuchiya in the statistical advice.

This study was partly supported by the Diffuse Lung Diseases Research Group from the ministry of Health, Labour and Welfare, Japan.

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S., and K.C. revised the paper.

All authors approved the paper.

Competing interest:

All authors do not have any personal or financial support or involvement with organization(s) that have financial interest in the subject matter, or any competing interest.

Funding:

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this study (approval number 24-191) and waived patient approval or informed consent because the study involved a retrospective review of patient records and images.

Copyright:

I [*Yutaro Nakamura*] the Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs, other illustrative material, video, film or any other material howsoever submitted by the Contributor(s) at

1
2
3
4
5
6 any time and related to the Contribution (“the Contribution”) have the right to grant on
7
8
9 behalf of all authors and do grant on behalf of all authors, a licence to the BMJ
10
11
12 Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be
13
14
15 published in BMJ Open and any other BMJ Group products and to exploit all subsidiary
16
17
18 rights, as set out in the licence
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.
2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. *Histopathology.* 2011;58:525-30.
3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.
4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.
5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.
6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.* 1998;19:667-85.
7. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis.* 2003;62:722-7.
8. Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and

- 1
2
3
4
5
6 their impact on outcome. *Rheumatology (Oxford)*. 2013;52:99-110.
7
8
9 9. Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain:
10
11 occurrence of extra-articular manifestations and estimates of disease severity. *Ann*
12
13 *Rheum Dis*. 2003;62:897–900.
14
15
16
17 10. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with
18
19 rheumatoid arthritis as assessed by high resolution computed tomography, chest
20
21 radiography, and pulmonary function tests. *Thorax*. 2001;56:622–7.
22
23
24
25
26 11. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset
27
28 rheumatoid arthritis. *Am J Respir Crit Care Med*. 1997;156:528–35.
29
30
31
32 12. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung
33
34 disease in rheumatoid arthritis. *Arch Intern Med*. 2008;168:159–66.
35
36
37
38 13. Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on
39
40 high-resolution computed tomography in patients with early versus longstanding
41
42 rheumatoid arthritis. *J Rheumatol*. 2008;35:1513–21.
43
44
45
46 14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association
47
48 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*.
49
50 1988;31:315-24.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 15. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on
7
8 Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:
9
10 idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and
11
12 management. *Am J Respir Crit Care Med.* 2011;183:788-824.
13
14
15
16
17 16. American Thoracic Society/European Respiratory Society International
18
19 Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
20
21 *Am J Respir Crit Care Med.* 2002;165:277-304.
22
23
24
25
26 17. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary
27
28 fibrosis. *Chest.* 2007;132:1652-8.
29
30
31
32 18. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary
33
34 fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356-63.
35
36
37
38 19. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung
39
40 disease: the relevance of histopathologic and radiographic pattern. *Chest.*
41
42 2009;136:1397-405.
43
44
45
46 20. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic,
47
48 and histopathologic features of methotrexate-associated lung injury in patients with
49
50 rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum.*
51
52 1997;40:1829-37.
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 21. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced
7
8 lung injury in patients with rheumatoid arthritis. A multicenter, case-control study.
9
10 Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.
11
12
13
14 22. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in
15
16 patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.*
17
18 2009;68:1100-4.
19
20
21
22
23 23. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the
24
25 literature and histopathological findings in nine patients. *Eur Respir J.*
26
27 2000;15:373-81.
28
29
30
31
32 24. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in
33
34 rheumatoid arthritis. *Rheumatology (Oxford).* 2004;43:143-7.
35
36
37
38 25. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis
39
40 of 54 biopsy-proven cases. *Respir Med.* 2012;106:1164-9.
41
42
43
44 26. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am*
45
46 *Rev Respir Dis.* 1985;131:770-7.
47
48
49 27. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of
50
51 rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2005;127:2019-27.
52
53
54
55 28. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern
56
57
58
59
60

- 1
2
3
4
5
6 as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int.* 2005;26:121-5.
7
8
9 29. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia:
10
11 idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care*
12
13 *Med.* 2007;175:705-11.
14
15
16
17 30. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in
18
19 rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.*
20
21 2010;35:1322-8.
22
23
24
25
26 31. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study).
27
28
29 Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an
30
31 inception cohort. *Rheumatology (Oxford).* 2010;49:1483-9.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Clinical characteristics

| Characteristics | Total N = 51 (100) | Non-AE group [#] N = 40 (78) | AE group [¶] N = 11 (22) | P value ⁺ |
|---|-----------------------|--|--------------------------------------|----------------------|
| Median age, years (range) | | | | |
| at RA diagnosis | 61 (28-82) | 60 (28-81) | 65 (42-82) | 0.15 |
| at ILD diagnosis | 62 (31-83) | 62 (31-83) | 69 (58-83) | 0.15 |
| at AE onset | | | 72 (60-86) | |
| Sex Male, n (%) | 29 (57) | 23 (58) | 6 (55) | 0.86 |
| Observation period, years (range) | 8.5 (1-17) | 9 (1-17) | 6.4 (2-14) | 0.45 |
| AE-free period, years (range) | 7(1-17) | 9 (1-17) | 6 (2-14) | 0.19 |
| Smoking habit, n (%) | | | | |
| Never | 20 (39) | 18 (45) | 2 (18) | |
| Former | 24 (47) | 16 (40) | 8 (73) | 0.15 |
| Current | 7 (14) | 6 (15) | 1 (9) | |
| RF, IU/mL (range)* | 197 (6-2666) | 189 (6-2666) | 205 (39-2530) | 0.47 |
| DAS28-CRP, score (range)* | 1.95(1.02-5.13) | 2.53(1.02-5.13) | 1.82(1.47-2.3) | 0.62 |
| PaO ₂ , torr (range) | 82.4 (67-109) | 81 (67-102) | 85.8 (74-109) | 0.19 |
| %FVC, % (range) | 91.1 (50.6-130) | 87.5 (51-130) | 95 (60-125) | 0.38 |
| HRCT pattern, n (%) | | | | |
| UIP pattern | 14 (27) | 8 (20) | 6 (55) | 0.02 [§] |
| non-UIP pattern | 37 (73) | 32 (80) | 5 (45) | |
| Death during observation period, n (%) | | | | |
| caused by respiratory failure | 8 (16) | 2 (5) | 7 (64) | 0.02 [§] |
| caused by other diseases | 4 (8) | 3 (8) | 0 (0) | |

Data are presented as n (%), median (range). AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; RF, rheumatoid factor; DAS28-CRP, disease activity score 28 CRP; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶]AE group, patients who developed AE during observation period.

⁺Non-AE group vs AE group

[§] $p < 0.05$

* at the first AE occurrence (AE group) or the last visit (non-AE group).

When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding and 2 of unknown causes.

For peer review only

Table 2 Diagnostic accuracy of HRCT pattern for histopathological pattern in 21 histopathologically confirmed patients.

| | Histopathological pattern | | Total |
|-------------------------|---------------------------|---------------|-------|
| | UIP | Other pattern | |
| UIP pattern on HRCT | 5 | 0 | 5 |
| non-UIP pattern on HRCT | 7 | 9 | 16 |
| Total | 12 | 9 | 21 |

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

When HRCT pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive predictive value and negative predictive value for detecting histopathological UIP was 41.7%, 100%, 100% and 56.3%, respectively.

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

| | Total N = 51 | non-AE group ⁺ N = 40 (78%) | AE group [§] N = 11 (22%) | P value |
|----------------------------------|-----------------|---|---------------------------------------|--------------------|
| Treatment, yes | 37 (73) | 27(68) | 10 (91) | 0.12 |
| Corticosteroid | 29 (57) | 22 (55) | 7 (64) | 0.61 |
| Immunosuppressant except for MTX | 17 (33) | 14 (35) | 3 (27) | 0.63 |
| MTX | 10 (20) | 4 (10) | 6 (55) | 0.001 [*] |
| Other drugs | 17 (33) | 13 (33) | 4 (36) | 0.81 |

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cyclophosphamide (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

⁺ Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

^{*} $p < 0.05$

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 1.03 | 0.97-1.10 | 0.35 |
| Age at ILD diagnosis | 1.11 | 1.02-1.21 | 0.01 ⁺ |
| Sex, male | 0.90 | 0.49-1.69 | 0.73 |
| Smoking habit, yes | 1.60 | 0.81-4.10 | 0.19 |
| UIP pattern on HRCT, yes | 1.95 | 1.07-3.63 | 0.03 ⁺ |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.12 | 0.14 |
| %FVC at ILD diagnosis | 1.02 | 0.99-1.06 | 0.24 |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 0.97 | 0.53-1.92 | 0.94 |
| Immunosuppressant except for MTX | 0.76 | 0.35-1.41 | 0.39 |
| MTX | 3.04 | 1.62-6.02 | 0.001 ⁺ |
| Other drugs | 0.98 | 0.50-1.80 | 0.96 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 0.98 | 0.93-1.04 | 0.48 |
| Age at ILD diagnosis | 1.08 | 0.99-1.17 | 0.057 |
| Sex, male | 1.14 | 0.63-2.22 | 0.67 |
| Smoking habit, yes | 1.70 | 0.87-4.35 | 0.13 |
| UIP pattern on HRCT, yes | 1.74 | 0.97-3.12 | 0.06 |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.11 | 0.15 |
| %FVC at ILD diagnosis | 1.01 | 0.98-1.04 | 0.55 |
| AE during observation period, yes | 2.47 | 1.39-4.56 | 0.003 ⁺ |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 1.23 | 0.67-2.65 | 0.52 |
| Immunosuppressant except for MTX | 0.69 | 0.32-1.27 | 0.25 |
| MTX | 1.44 | 0.67-2.68 | 0.31 |
| Other drugs | 0.76 | 0.36-1.41 | 0.40 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Figure legends

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were excluded, and 51 patients with chronic course of RA-ILD were included. During observation period, 11 patients developed AE.

RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank $p=0.018$).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank $p=0.04$).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

1
2
3
4
5
6 Figure 4. Survival of AE group and non-AE group.
7

8
9 Patients who developed AE during observation periods (AE group) had a significantly
10
11 worse survival compared with those who did not (non-AE group) (log-rank $p=0.001$).
12
13

14 AE, acute exacerbation.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




FIGURE 1.

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were excluded, and 51 patients with chronic course of RA-ILD were included. During observation period, 11 patients developed AE.

RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.

80x160mm (300 x 300 DPI)

1
2
3
4
5
6 **Title:** Acute exacerbation in rheumatoid arthritis associated interstitial lung disease
7
8
9

10
11
12 **Authors:**

13
14 Hironao Hozumi, M.D., Ph.D.¹

15
16 Yutaro Nakamura, M.D., Ph.D.¹

17
18 Takeshi Johkoh, M.D., Ph.D.²

19
20 Hiromitsu Sumikawa, M.D., Ph.D.³

21
22 Thomas V. Colby, M.D.⁴

23
24 Masato Kono, M.D, Ph.D.¹

25
26 Dai Hashimoto, M.D., Ph.D.¹

27
28 Noriyuki Enomoto, M.D., Ph.D.¹

29
30 Tomoyuki Fujisawa, M.D., Ph.D.¹

31
32 Naoki Inui, M.D., Ph.D.¹

33
34 Takafumi Suda, M.D., Ph.D.¹

35
36 Kingo Chida, M.D., Ph.D.¹

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 **Affiliations:**

53
54
55 ¹Second division, Department of Internal Medicine, Hamamatsu University School of
56
57
58

1
2
3
4
5
6 Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan
7

8
9 ²Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public
10
11 School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan
12
13

14 ³Diagnostic and Interventional Radiology, Osaka University Graduate School of
15
16 Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
17
18

19
20 ⁴Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East
21
22 Shea Boulevard Scottsdale, AZ 85259, USA
23
24
25
26
27

28
29 **Corresponding author:**
30

31
32 Yutaro Nakamura, M.D., Ph.D.
33

34
35 Second division, Department of Internal Medicine, Hamamatsu University School of
36
37 Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan
38
39

40
41 Tel: 81-53-435-2263, Fax: 81-53-435-2354
42

43
44 E-mail address: nakayuta@hama-med.ac.jp
45
46
47
48

49 **Keywords:** Acute exacerbation, interstitial lung disease, risk factor, prognostic factor,
50
51
52
53
54
55
56
57
58
59
60
rheumatoid arthritis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word count paper: ~~2779~~3382

Word count abstract: ~~292~~280

For peer review only

ABSTRACT

Background Acute exacerbation (AE) in idiopathic pulmonary fibrosis is characterised by acute deterioration of respiratory status and the mortality is high.

Recently, AE was reported in patients with other interstitial lung diseases, especially rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives To investigate the risk factors and prognosis associated with AE in patients with RA-ILD.

Design A retrospective ~~cohort~~case-control study.

Setting A single academic hospital.

Participants 51 consecutive patients diagnosed with RA-ILD between 1995 and 2012.

All patients fulfilled the diagnostic criteria of the American College of Rheumatology for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures Overall survival and cumulative AE incidence were analysed using Kaplan–Meier method. Cox hazards analysis was used to determine significant variables associated with AE occurrence and survival status.

Results A total of 11 patients (22%) developed AE, with an overall 1-year incidence of 2.8%. Univariate analysis revealed that higher age at ILD diagnosis [hazard ratio

1
2
3
4
5
6 (HR), 1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], usual interstitial
7
8
9 pneumonia (UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and
10
11
12 treatment with methotrexate (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were risk factors
13
14
15 for AE. Of 11 patients who developed AE during observation period, seven (64%) died
16
17
18 of initial AE. In survival, AE was a prognostic factor for poor outcome (HR, 2.47; 95%
19
20
21 CI, 1.39–4.56; $P = 0.003$).

22
23 **Conclusions** In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on
24
25
26 HRCT and treatment with methotrexate are risk factors for AE. Furthermore, AE has a
27
28
29 serious impact on their survival. ~~We should carefully observe the patients having any of~~
30
31
32 ~~these risk factors.~~
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis (IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with RA-ILD?

Key messages;

In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on HRCT, and treatment with methotrexate are risk factors for AE occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE ~~may have~~has a serious impact on the survival of patients with RA-ILD ~~as well as that with IPF. Thus, the patients with any of these risk factors should be carefully~~ observed.

Given its retrospective study design, it is subject to several possible biases. Therefore, prospective studies are necessary to confirm our results.

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterised by acute deterioration in respiratory status, with newly developed bilateral ground-glass opacities and/or consolidations on chest radiographs or computed tomography scans. It should be in the absence of other alternative causes such as infection, left heart failure, pulmonary embolism, and an identifiable cause of acute lung injury. AE reportedly occurs not only in patients with IPF but also in patients with other interstitial lung diseases (ILDs), including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital mortality associated with AE in patients with CVD-ILD was demonstrated to be as high as that in patients with IPF,[1-4] suggesting that AE may be associated with poor prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown etiology that primarily involves joints.[5] ILD is the most one of common extra-articular manifestations, f. [6] with a, 7] The reported prevalence of is variable (1%—58%.[7-12%]) and depends on the detection and diagnostic method, or the selected population.[8-13] We and Park *et al* previously reported that RA-associated

1
2
3
4
5
6 ILD (RA-ILD) was the most common CVD-ILD associated with AE.[3, 4] However the
7
8
9 risk factors and prognosis associated with AE in patients with RA-ILD are not clarified.

10
11 In the present study, we attempted to elucidate the cumulative incidence of AE, its
12
13 risk factors, and prognostic factors in patients with RA-ILD.
14
15
16
17
18
19

20 MATERIALS AND METHODS

21 Subjects

22
23
24
25 Institutional review board in Hamamatsu University School of Medicine approved
26
27 this study (approval number 24-191) and waived patient approval or informed consent
28
29 because the study involved a retrospective review of patient records and images. We
30
31 retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995
32
33 and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the
34
35
36
37
38
39
40
41 diagnostic criteria of the American College of Rheumatology for RA.^[13,14] Patients
42
43 with other coexisting CVD were excluded. In addition, because our aim was to
44
45
46
47 investigate the features of AE among patients with a chronic course of RA-ILD, patients
48
49 with no evidence of chronic ILD were also excluded.
50
51

52
53 ILD was diagnosed on the basis of clinical presentation, pulmonary function tests,
54
55 high resolution computed tomography (HRCT) findings, and lung biopsy findings.
56
57
58
59
60

1
2
3
4
5
6 HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities
7
8
9 and honeycomb patterns were interpreted and defined as ILD by a consensus between
10
11 radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and
12
13 bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to
14
15 definitively diagnose ILD or rule out other diseases. The patients with environmental
16
17 exposures, suspected of drug induced pneumonia (ILD developed within 1 year after
18
19 initiation of new drug), or with other known causes of ILD were excluded after
20
21 considering exposure history and the findings of appropriate tests and histopathological
22
23 examinations.
24
25
26
27
28
29
30
31
32
33
34

35 **Acute exacerbation (AE)**

36
37
38 AE was defined using recently proposed criteria[1] that were slightly modified for
39
40 adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or
41
42 development of dyspnea within 30 days of onset, new bilateral ground-glass
43
44 abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern
45
46
47 on HRCT, no evidence of pulmonary infection on negative respiratory culture,
48
49 including endotracheal aspirate or bronchoalveolar lavage, and serological test results
50
51
52
53
54
55 for respiratory pathogens, and exclusion of alternative causes such as left heart failure,
56
57
58
59
60

1
2
3
4
5
6 pulmonary embolism, and an identifiable cause of acute lung injury. Patients with AE
7
8
9 were required to meet all five criteria. In our institution, cultures of sputum, blood, urine,
10
11 and bronchoalveolar lavage fluid, and serological tests examined for mycobacteria,
12
13 fungi, bacteria, and some viruses were routinely performed. Echocardiography and, if
14
15 necessary, CT scanning with intravenous contrast were performed to rule out left heart
16
17 failure or pulmonary thromboembolism. The patients who developed acute pneumonitis
18
19 within 1 year after initiation of drug for RA were excluded because drug-induced
20
21 pneumonitis was not completely ruled out. Patients who did or did not develop AE
22
23 during the observation period were classified into the AE and non-AE groups,
24
25 respectively.
26
27
28
29
30
31
32
33
34
35
36
37

38 **Data collection**

39
40 All clinical and laboratory data were collected from medical records. The observation
41
42 period was calculated from the date of diagnosis of RA-ILD to the last visit. The
43
44 AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis
45
46 and the first AE occurrence (AE group) or the last visit (non-AE group).
47
48
49
50
51
52
53
54

55 **Review of radiographic findings**

56
57
58
59
60

1
2
3
4
5
6 HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images
7
8
9 comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were
10
11
12 reconstructed by a high spatial frequency algorithm, and were displayed at window
13
14
15 settings appropriate for viewing the lung parenchyma (window level, -600 to -800
16
17 Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were
18
19
20 randomised and reviewed independently by two expert chest radiologists (with 23 and
21
22
23 12 years of experience) who were unaware of the related clinical information.
24

25
26 Interobserver agreement was classified as follows: poor ($\kappa = 0-0.20$), fair ($\kappa =$
27
28 $0.21-0.40$), moderate ($\kappa = 0.41-0.60$), good ($\kappa = 0.61-0.80$) and excellent ($\kappa =$
29
30 $0.81-1.00$).
31
32
33
34

35 RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a
36
37 non-UIP pattern according to recent guideline.^{[14 with slight modification.[15]} Briefly,
38
39
40 a UIP pattern on HRCT was characterised by subpleural and basal predominance,
41
42
43 reticular abnormalities, honeycombing with or without traction bronchiectasis and the
44
45
46 absence of features listed as inconsistent with a UIP pattern, including upper or
47
48
49 mid-lung predominance, peribronchovascular predominance, extensive ground glass
50
51
52 abnormalities, profuse micronodules, discrete cysts, diffuse mosaic
53
54
55 attenuation/air-trapping and consolidation in bronchopulmonary segment(s)/lobe(s). If
56
57
58
59
60

1
2
3
4
5
6 the HRCT pattern did not meet the criteria, it was interpreted as a non-UIP pattern.
7

8
9 Disagreements regarding HRCT interpretation were resolved by a consensus between
10
11 both radiologists.
12

13 14 15 16 17 18 **Review of histopathological findings** 19

20
21 SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was
22
23 originally made in all cases on the basis of histological features evaluated by a lung
24
25 pathologist at our hospital, correlated with the clinical and radiological findings. All
26
27 SLB specimens were also reviewed by a second lung pathologist with 36 years of
28
29 experience. The histological classification of interstitial pneumonia was based on the
30
31 consensus statement criteria for idiopathic interstitial pneumonias,^[15,16] and
32
33
34
35
36
37
38 histological patterns that could not be classified according to the criteria were
39
40
41 categorised as unclassified interstitial pneumonia.
42
43
44
45

46 47 **Statistical analysis** 48

49
50 All values are expressed as median (range) or number (%). The Mann-Whitney U test
51
52 was used for nonparametric comparisons involving continuous data, whereas Fisher's
53
54 exact test was used for comparing categorical data. Interobserver agreement on HRCT
55
56
57
58
59
60

1
2
3
4
5
6 pattern was analyzed using the κ statistic test. ~~Interobserver agreement was classified as~~
7
8
9 ~~follows: poor ($\kappa = 0-0.20$), fair ($\kappa = 0.21-0.40$), moderate ($\kappa = 0.41-0.60$), good ($\kappa =$~~
10
11 ~~$0.61-0.80$) and excellent ($\kappa = 0.81-1.00$).~~ Survival was evaluated using the
12
13 Kaplan–Meier method and the log-rank test according to observation period. The
14
15 cumulative AE incidence was obtained from a Kaplan–Meier survival curve by treating
16
17 AE as the death variable. according to AE free period. The 1-year AE incidence was
18
19 based on person year method and calculated by dividing the number of patients who
20
21 developed AE by the total of AE-free period (year) of all the patients. Cox hazards
22
23 analysis was used to determine significant variables associated with survival and AE
24
25 occurrence. In all analyses, $P < 0.05$ was considered statistically significant. All data
26
27 were analysed using commercially available software (JMP version 9.0.3a, SAS
28
29 Institute Inc, Cary, NC, USA).

43 RESULTS

46 Patient characteristics (Table 1)

49 A total of 82 patients with RA-ILD were identified from medical records at
50
51 Hamamatsu University Hospital. From these, 11 patients with other coexisting CVDs, 8
52
53 with no evidence of chronic ILD and an initial acute/subacute course of ILD, and 3
54
55
56
57
58
59
60

1
2
3
4
5
6 suspected of drug-induced pneumonitis were excluded. In addition, 9 patients for whom
7
8
9 no initial HRCT images were available for review were also excluded. The remaining
10
11
12 51 patients with RA-ILD were included in this study.(Figure 1)
13

14
15 The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82)
16
17 years and 62 (range, 31–83) years, respectively. The median observation period and
18
19 AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.
20
21
22

23
24 During the observation period, 11 patients (22%) developed AE. The median age at
25
26 the onset of AE was 72 (range, 60–86) years. There were no statistically significant
27
28 differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period,
29
30 AE-free period, smoking habits, predicted forced vital capacity (%FVC) at diagnosis of
31
32 RA-ILD, and arterial oxygen pressure (PaO₂) at diagnosis of RA-ILD between the AE
33
34 and non-AE groups. Also there were no statistically significant differences in articular
35
36 disease activities (RF and DAS28-CRP) at the last visit (non-AE group) or the first AE
37
38 occurrence (AE group).
39
40
41
42
43
44
45

46
47 In the AE group, seven of 11 patients (64%) died of initial AE during the observation
48
49 period. In the non-AE group, 52 of 40 patients (135%) died of respiratory failure. There
50
51
52 was a statistically significant difference in the mortality rate between the AE and
53
54
55 non-AE groups.
56
57
58
59
60

1
2
3
4
5
6 Extra-articular manifestations except for ILD had been observed in 8 (16%) of 51
7
8
9 patients (pericarditis in 2 patients, pleuritis in 1, neuropathy in 2, cutaneous vasculitis in
10
11 2, glomerulonephritis in 1, rheumatoid nodule in 2). There was no significant difference
12 in the incidence between AE group and non-AE group (27% vs. 13%, $P=0.26$).
13
14
15
16
17
18
19

20 21 **HRCT pattern (Table 1)**

22
23 Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT.
24
25 HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%)
26
27 patients in the AE group demonstrated a UIP pattern. Interobserver agreement between
28
29 both radiologists was moderate (κ statistic test, $\kappa = 0.44$). The number of patients who
30
31 exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the
32
33 non-AE group.
34
35
36
37
38
39
40
41
42

43 **Correlation between** When HRCT pattern was identified as a UIP pattern, the
44 positive predictive value and negative predictive value for AE occurrence was 42.9%
45
46 and 86.5%, respectively.
47
48
49
50
51
52
53
54

55 **Diagnostic accuracy of HRCT pattern for** ~~histopathological findings and HRCT~~
56
57
58
59
60

pattern (Table 2)

Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and an unclassified interstitial pneumonia in 1. The ~~correlation between~~ diagnostic accuracy of HRCT pattern for histopathological ~~and HRCT~~ pattern was evaluated in 21 histopathologically confirmed patients. When the pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive predictive value and negative predictive value for detecting histopathological UIP was 41.7%, 100%, 100% and 56.3%, respectively.

Treatment for RA (Table 3)

Of the 51 patients, 37 (73%) had received treatment for RA at their final visit (non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) had received corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10 (20%) received MTX and 17 (33%) received other drugs. ~~The number of~~ There were 6 (55%) patients who had received MTX was significantly higher in the AE group than while 4 (10%) patients in the non-AE group (55% vs. 10%, and statistically significant difference was observed between the groups ($P = 0.001$).

1
2
3
4
5
6 No patients had received MTX before in AE group while 2 in non-AE group. Thus,
7
8
9 there were 6 (55%) patients who had experienced MTX treatment during observation
10
11 period in AE group while 6 (15%) patients in non-AE group. Median cumulative MTX
12
13 dose were 1952mg (384-3872) in 6 patients who had experienced MTX among AE
14
15 group and 802mg (32-2496) in 6 patients among non-AE group. No statistically
16
17 significant difference was observed between two groups in cumulative MTX dose
18
19 (P=0.20).

20
21
22
23
24
25
26 Articular disease activities (RF and DAS28-CRP) were compared between patients
27
28 who had received MTX at the last visit or at the first AE occurrence, and those who had
29
30 not. Median RF (range) were 112 IU/mL (16-334) and 284 IU/mL (6-2666) (P=0.25),
31
32 Median DAS28-CRP (range) were 1.94 (1.02-3.87) and 1.97 (1.02-5.13) (P=0.78),
33
34 respectively. There were no statistically significant differences in articular disease
35
36 activities.

47 **AE incidence**

48
49 The cumulative AE incidence in patients with RA-ILD is shown in Figure 12. The
50
51 5-year AE incidence was significantly higher 11% [95% confidence interval (CI),
52
53 2–21%] in all patients, 33% (95% CI, 7–60%) in patients with a UIP pattern on HRCT
54
55
56
57
58
59
60

1
2
3
4
5
6 (UIP pattern group) ~~than~~ and 3% (95% CI, 0–9%) in patients with a non-UIP pattern on
7
8
9 HRCT (non-UIP pattern group)). The AE incidence was significantly higher in UIP
10
11 pattern group than in non-UIP pattern group (log-rank test, $P = 0.018$). The overall
12
13
14 1-year AE incidence was 2.8%. The 1-year AE incidence was 6.5% in the UIP pattern
15
16
17 group and 1.7 % in the non-UIP pattern group.

18
19
20 Univariate analysis (Table 4) revealed that higher age at ILD diagnosis [hazard ratio
21
22 (HR), 1.11; 95% ~~confidence interval (CI), CI~~, 1.02–1.21; $P = 0.01$], UIP pattern on
23
24 HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and treatment with MTX (HR, 3.04;
25
26 95% CI, 1.62–6.02; $P = 0.001$) were significant risk factors for AE occurrence.
27
28
29
30
31
32
33
34

35 Survival

36
37 The overall survival of patients with RA-ILD is shown in Figure 23.
38
39 The 5-year survival was 90% (95% CI, 81–98%) in all patients, 70% (95% CI, 44–94%)
40
41 in the UIP pattern group and 97% (95% CI, 92–100%) in the non-UIP pattern group.
42
43
44 Survival was significantly poorer in the UIP pattern group than in the non-UIP pattern
45
46
47 group (log-rank test, $P = 0.04$). In addition, significantly worse survival was
48
49
50 demonstrated in the AE group compared with the non-AE group (Figure 34, log-rank
51
52
53 test, $P = 0.001$).
54
55
56
57
58
59
60

1
2
3
4
5
6 Univariate analysis (Table 5) revealed that higher age at ILD diagnosis (HR, 1.08;
7
8
9 95% CI, 0.99–1.17; $P = 0.057$) and UIP pattern on HRCT (HR, 1.74; 95% CI,
10
11
12 0.97–3.12; $P = 0.06$) showed a trend toward poor outcome, while AE (HR, 2.47; 95%
13
14 CI, 1.39–4.56; $P = 0.003$) was significantly associated with poor survival.
15
16
17
18
19

20 DISCUSSION

21
22
23 To our knowledge, the present study is the first one focusing on the risk factors and
24
25 prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence
26
27 was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern
28
29 on HRCT, MTX treatment and higher age at ILD diagnosis were significant risk factors
30
31
32 for AE. Furthermore, AE was a prognostic factor for poor survival.
33
34
35
36
37

38 The 1-year AE incidence among patients with IPF has been reported to be 5-19%^{[16,}
39
40 17, 18] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP,
41
42 3.3 % for CVD-ILD and 5.6 % for CVD-UIP.^[4] In the present study, ~~patients with~~
43
44 ~~RA-ILD had a relatively lower incidence of AE. However,~~ the 1-year AE incidence
45
46
47 among patients with a UIP pattern on HRCT was 6.5%, ~~comparable to that% and~~
48
49 ~~cumulative incidence was significantly higher~~ in ~~patients with IPF/UIP pattern group~~
50
51 ~~than in non-UIP pattern group~~. Furthermore, a UIP pattern on HRCT was a risk factor
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 for AE. In a previous report of small number of biopsy-proven cases, AE incidence
7
8
9 among patients with RA-UIP was reported to be 11.1%, ~~also~~ similar to that among
10
11 patients with IPF.[4] The correlation between pathological and radiological UIP patterns
12
13
14 has been established in IPF, but not in RA-ILD.[~~18~~19] In the present study,
15
16
17 determination of a UIP pattern on HRCT exhibited high specificity and positive
18
19
20 predictive values for the detection of pathological UIP pattern. Therefore, a typical UIP
21
22
23 pattern on HRCT was assumed to be highly suggestive of pathological UIP pattern in
24
25
26 patients with RA-ILD as well as IPF.[~~14, 18~~15, 19] Collectively, these results suggest
27
28
29 that AE ~~occurs less frequently in RA-ILD than in IPF, while AE~~ incidence in a subgroup
30
31
32 with pathological UIP pattern or a UIP pattern on HRCT may be as high as higher than
33
34
35 that in patients with IPF other patterns.
36
37

38 The present study also identified MTX treatment as a risk factor for AE. MTX is
39
40 widely used to treat RA, while its toxicity affects the pulmonary system. Diagnostic
41
42 criteria for MTX-associated pneumonitis (MTX-pneumonitis) have been proposed
43
44
45 previously.[~~19~~20] However, the specificity of the criteria has not been fully examined
46
47
48 yet. MTX-pneumonitis typically occurs with acute/subacute onset early in the course of
49
50
51 MTX treatment,[~~19-22~~20-23] in particular, mostly within the first year[~~23~~24] and often
52
53
54 presents a hypersensitive pneumonitis pattern. Patients with MTX-pneumonitis
55
56
57
58
59
60

1
2
3
4
5
6 generally respond to discontinuation of MTX or corticosteroid treatment and have a
7
8
9 favorable prognosis.^[19-22,20-23] In the present study, 6 of 11 patients with AE had
10
11 received MTX, and 5 of the 6 patients had been treated for 3 or more years. The
12
13 remaining patient had been treated for 1 year. In all 6 patients, their respiratory
14
15 conditions progressively deteriorated despite discontinuation of MTX, and they poorly
16
17 responded to high-dose corticosteroid. Consequently, on the basis of inconsistency in
18
19 terms of MTX treatment duration and clinical features, we diagnosed these patients with
20
21
22
23
24
25
26 AE of RA-ILD.
27
28

29 Similar to AE in patients with IPF, the etiology of AE in RA-ILD is unknown;
30
31 however, several reports have suggested that AE may be a distinct manifestation of the
32
33 primary disease process, a distinct condition associated with undiagnosed infection, or a
34
35 subsequent acceleration of a fibroproliferative process caused by acute direct stress to
36
37 the lung.^[1] In the present study, ~~RA joint disease activity-DAS28-CRP~~ in all patients
38
39 with AE ~~was stable~~showed low disease activity or remission at the time of AE
40
41
42
43
44
45
46
47 occurrence, and no significant difference in articular disease activities was observed
48
49
50 between AE group and non-AE group or regardless of MTX treatment; therefore, RA
51
52 activity may not be related to AE occurrence, a finding similar to that of a previous
53
54
55 study.^[4] MTX possibly accelerates the fibroproliferative process of RA-ILD. It was
56
57
58
59
60

1
2
3
4
5
6 reported that MTX treatment was a risk factor for RA-ILD progression.[4012] For
7
8
9 RA-ILD, MTX may be associated not only with newly developing drug-induced
10
11
12 pneumonitis but also with deterioration of pre-existing ILD, including AE. ~~Therefore,~~
13
14 ~~we think that MTX treatment should be avoided in RA patients with ILD.~~
15
16

17
18 The present study found that patients with a UIP pattern on HRCT had significantly
19
20 poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic
21
22 factor for poor outcome. AE has a serious impact on the survival of patients with
23
24 IPF,[1718] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with
25
26
27
28 these reports, the present study revealed that seven (64%) of 11 patients with AE died of
29
30
31
32 respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE
33
34
35 group was significantly poorer than that in the non-AE group. Therefore, AE is
36
37
38 suggested to be a predictor of poor prognosis in patients with RA-ILD as well as
39
40
41 patients with IPF.
42

43
44 Other prognostic factors in RA-ILD have been reported, including pathological
45
46
47 UIP,[24-28,25-29] UIP pattern on HRCT,[2930] and age at RA-ILD onset.[3031] In the
48
49
50 present study, pathological UIP could not be identified as prognostic factors because the
51
52
53 number of biopsy-proven cases were small. However, we observed similar results
54
55
56 regarding UIP pattern on HRCT and age at RA-ILD onset.
57
58
59
60

1
2
3
4
5
6 In our study, the average time between age at onset of RA and that of RA-ILD was
7
8
9 relatively shorter than some previous reports.[7, 8] However, Gabbay et al [11] reported
10
11 that nearly 60 % of the patients have interstitial lung disease in recent onset RA. In
12
13 another point of view, since the current authors' institution is regional referral center for
14
15 interstitial lung disease, referral bias might have increased the proportion of patients
16
17 with early-stage ILD, leading above results.

18
19
20
21
22
23
24 This study had several limitations. First, given its retrospective study design, it is
25
26 subject to several possible biases. For instance, selection and recall bias may exist.
27
28
29
30 Second, because of the relatively small sample size, it may be difficult to determine the
31
32 precise incidence of AE- and the number of event (AE occurrence or death) was too
33
34 small to perform multivariate analysis. Therefore, larger studies are necessary to
35
36 confirm our results. Third, because the presence of a UIP pattern on HRCT had low
37
38 sensitivity and negative predictive value for the detection of pathologic UIP, it was
39
40 likely that some patients with a non-UIP pattern on HRCT may have had pathological
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
UIP. HRCT criteria used in our study do not aim to detect pathological UIP but to
clinically diagnose IPF and to exclude alternative diagnosis.[15] The frequency of
honeycombing on HRCT differs between RA-ILD and IPF, and some ILDs by other
causes including RA-ILD have some of findings inconsistent with UIP. Therefore,

1
2
3
4
5
6 HRCT pattern in RA-ILD may be more frequently interpreted as non-UIP pattern than
7
8 that in IPF. In our study, 2 of 5 patients with histopathological UIP in the absence of a
9
10 UIP pattern on HRCT develop AE. Thus, SLB may have to be considered for these
11
12 patients to make pathological diagnosis and to predict AE. Finally, RA includes a
13
14 variety of manifestations. Therefore, other comorbidities may have affected the results.
15
16
17
18
19

20
21 In conclusion, higher age at ILD diagnosis, UIP pattern on HRCT and treatment with
22
23 MTX are risk factors for AE occurrence in patients with RA-ILD. Furthermore, the
24
25 mortality associated with AE is high and AE is prognostic factor for poor outcome. ~~AE-~~
26
27 ~~has a serious impact on the survival of patients with RA-ILD. Thus, we should carefully~~
28
29 ~~observe the patients having any of these risk factors.~~ Larger prospective studies
30
31 investigating acute exacerbations in RA-ILD are indicated.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENT

We appreciate the help of Dr. T. Tsuchiya in the statistical advice.

This study was partly supported by the Diffuse Lung Diseases Research Group from the ministry of Health, Labour and Welfare, Japan.

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S., and K.C. revised the paper.

All authors approved the paper.

Competing interest:

All authors do not have any personal or financial support or involvement with organization(s) that have financial interest in the subject matter, or any competing interest.

Funding:

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this study (approval number 24-191) and waived patient approval or informed consent because the study involved a retrospective review of patient records and images.

Copyright:

I [*Yutaro Nakamura*] the Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs, other illustrative material, video, film or any other material howsoever submitted by the Contributor(s) at

1
2
3
4
5
6 any time and related to the Contribution (“the Contribution”) have the right to grant on
7
8
9 behalf of all authors and do grant on behalf of all authors, a licence to the BMJ
10
11
12 Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be
13
14 published in BMJ Open and any other BMJ Group products and to exploit all subsidiary
15
16
17 rights, as set out in the licence
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.
2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. *Histopathology.* 2011;58:525-30.
3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.
4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.
5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.
6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.* 1998;19:667-85.
7. [Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis.* 2003;62:722-7.](#)
8. [Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and](#)

1
2
3
4
5
6 [their impact on outcome. Rheumatology \(Oxford\). 2013;52:99-110.](#)
7
8

9 ~~8-9.~~ Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain:
10 occurrence of extra-articular manifestations and estimates of disease severity. *Ann*
11 *Rheum Dis.* 2003;62:897–900.
12
13
14
15

16
17 ~~9-10.~~ Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with
18 rheumatoid arthritis as assessed by high resolution computed tomography, chest
19 radiography, and pulmonary function tests. *Thorax.* 2001;56:622–7.
20
21
22
23
24

25
26 ~~10-11.~~ Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset
27 rheumatoid arthritis. *Am J Respir Crit Care Med.* 1997;156:528–35.
28
29
30

31
32 ~~11-12.~~ Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial
33 lung disease in rheumatoid arthritis. *Arch Intern Med.* 2008;168:159–66.
34
35
36

37
38 ~~12.~~ Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on
39 high-resolution computed tomography in patients with early versus longstanding
40 rheumatoid arthritis. *J Rheumatol.* 2008;35:1513–21.
41
42
43
44

45
46 ~~13. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease~~
47 ~~manifestations in rheumatoid arthritis: incidence trends and risk factors over 46-~~
48 ~~years. *Ann Rheum Dis.* 2003;62:722–7.~~
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association
7
8 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.*
9
10 1988;31:315-24.
11
12
13
14 15. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on
16
17 Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:
18
19 idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and
20
21 management. *Am J Respir Crit Care Med.* 2011;183:788-824.
22
23
24
25
26 16. American Thoracic Society/European Respiratory Society International
27
28 Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
29
30 *Am J Respir Crit Care Med.* 2002;165:277-304.
31
32
33
34
35 17. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary
36
37 fibrosis. *Chest.* 2007;132:1652-8.
38
39
40
41 18. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary
42
43 fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356-63.
44
45
46
47 19. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung
48
49 disease: the relevance of histopathologic and radiographic pattern. *Chest.*
50
51 2009;136:1397-405.
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 20. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic,
7
8 and histopathologic features of methotrexate-associated lung injury in patients with
9
10 and histopathologic features of methotrexate-associated lung injury in patients with
11
12 rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum.*
13
14 1997;40:1829-37.
15
16
17 21. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced
18
19 lung injury in patients with rheumatoid arthritis. A multicenter, case-control study.
20
21 Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.
22
23
24
25
26 22. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in
27
28 patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.*
29
30 2009;68:1100-4.
31
32
33
34
35 23. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the
36
37 literature and histopathological findings in nine patients. *Eur Respir J.*
38
39 2000;15:373-81.
40
41
42
43
44 24. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in
45
46 rheumatoid arthritis. *Rheumatology (Oxford).* 2004;43:143-7.
47
48
49
50 25. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis
51
52 of 54 biopsy-proven cases. *Respir Med.* 2012;106:1164-9.
53
54
55
56 26. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am*
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Rev Respir Dis.* 1985;131:770-7.
27. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2005;127:2019-27.
28. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int.* 2005;26:121-5.
29. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care Med.* 2007;175:705-11.
30. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.* 2010;35:1322-8.
31. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. *Rheumatology (Oxford).* 2010;49:1483-9.

Table 1 Clinical characteristics

| Characteristics | Total N = 51 (100) | Non-AE group [#] N = 40 (78) | AE group [¶] N = 11 (22) | P value ⁺ |
|---|------------------------|--|--------------------------------------|------------------------------|
| Median age, years (range) | | | | |
| at RA diagnosis | 61 (28-82) | 60 (28-81) | 65 (42-82) | 0.15 |
| at ILD diagnosis | 62 (31-83) | 62 (31-83) | 69 (58-83) | 0.15 |
| at AE onset | | | 72 (60-86) | |
| Sex Male, n (%) | 29 (57) | 23 (58) | 6 (55) | 0.86 |
| Observation period, years (range) | 8.5 (1-17) | 9 (1-17) | 6.4 (2-14) | 0.45 |
| AE-free period, years (range) | 7(1-17) | 9 (1-17) | 6 (2-14) | 0.19 |
| Smoking habit, n (%) | | | | |
| Never | 20 (39) | 18 (45) | 2 (18) | |
| Former | 24 (47) | 16 (40) | 8 (73) | 0.15 |
| Current | 7 (14) | 6 (15) | 1 (9) | |
| <u>RF, IU/mL (range)*</u> | <u>197 (6-2666)</u> | <u>189 (6-2666)</u> | <u>205 (39-2530)</u> | <u>0.47</u> |
| <u>DAS28-CRP, score (range)*</u> | <u>1.95(1.02-5.13)</u> | <u>2.53(1.02-5.13)</u> | <u>1.82(1.47-2.3)</u> | <u>0.62</u> |
| PaO ₂ , torr (range) | 82.4 (67-109) | 81 (67-102) | 85.8 (74-109) | 0.19 |
| %FVC, % (range) | 91.1 (50.6-130) | 87.5 (51-130) | 95 (60-125) | 0.38 |
| HRCT pattern, n (%) | | | | |
| UIP pattern | 14 (27) | 8 (20) | 6 (55) | |
| non-UIP pattern | 37 (73) | 32 (80) | 5 (45) | 0.02 [§] |
| Death during observation period, n (%) | 12 (24) | 5 (13) | 7 (64) | 0.001[§] |
| caused by respiratory failure | 8 (16) | 2 (5) | 7 (64) | |
| caused by other diseases | 4 (8) | 3 (8) | 0 (0) | 0.02 [§] |

Data are presented as n (%), median (range).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; RF, rheumatoid factor; DAS28-CRP, disease activity score 28 CRP; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶]AE group, patients who developed AE during observation period.

⁺Non-AE group vs AE group

[§]*p* < 0.05

* at the first AE occurrence (AE group) or the last visit (non-AE group).

1
2
3
4
5 When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative
6 predictive value for AE occurrence was 42.9% and 86.5%, respectively.
7

8 In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of
9 respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding
10 and 2 of unknown causes.
11
12

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 2 ~~Correlation between~~ Diagnostic accuracy of HRCT pattern for histopathological findings and HRCT pattern in 21 histopathologically confirmed patients.

| | Histopathological pattern | | Total |
|-------------------------|---------------------------|---------------|-------|
| | UIP | Other pattern | |
| UIP pattern on HRCT | 5 | 0 | 5 |
| non-UIP pattern on HRCT | 7 | 9 | 16 |
| Total | 12 | 9 | 21 |

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

When HRCT pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive predictive value and negative predictive value for detecting histopathological UIP was 41.7%, 100%, 100% and 56.3%, respectively.

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

| | Total N = 51 | non-AE group ⁺ N = 40 (78%) | AE group [§] N = 11 (22%) | P value |
|----------------------------------|-----------------|---|---------------------------------------|--------------------|
| Treatment, yes | 37 (73) | 27(68) | 10 (91) | 0.12 |
| Corticosteroid | 29 (57) | 22 (55) | 7 (64) | 0.61 |
| Immunosuppressant except for MTX | 17 (33) | 14 (35) | 3 (27) | 0.63 |
| MTX | 10 (20) | 4 (10) | 6 (55) | 0.001 [*] |
| Other drugs | 17 (33) | 13 (33) | 4 (36) | 0.81 |

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cyclophosphamide (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

⁺ Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

^{*} $p < 0.05$

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 1.03 | 0.97-1.10 | 0.35 |
| Age at ILD diagnosis | 1.11 | 1.02-1.21 | 0.01 ⁺ |
| Sex, male | 0.90 | 0.49-1.69 | 0.73 |
| Smoking habit, yes | 1.60 | 0.81-4.10 | 0.19 |
| UIP pattern on HRCT, yes | 1.95 | 1.07-3.63 | 0.03 ⁺ |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.12 | 0.14 |
| %FVC at ILD diagnosis | 1.02 | 0.99-1.06 | 0.24 |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 0.97 | 0.53-1.92 | 0.94 |
| Immunosuppressant except for MTX | 0.76 | 0.35-1.41 | 0.39 |
| MTX | 3.04 | 1.62-6.02 | 0.001 ⁺ |
| Other drugs | 0.98 | 0.50-1.80 | 0.96 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 0.98 | 0.93-1.04 | 0.48 |
| Age at ILD diagnosis | 1.08 | 0.99-1.17 | 0.057 |
| Sex, male | 1.14 | 0.63-2.22 | 0.67 |
| Smoking habit, yes | 1.70 | 0.87-4.35 | 0.13 |
| UIP pattern on HRCT, yes | 1.74 | 0.97-3.12 | 0.06 |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.11 | 0.15 |
| %FVC at ILD diagnosis | 1.01 | 0.98-1.04 | 0.55 |
| AE during observation period, yes | 2.47 | 1.39-4.56 | 0.003 ⁺ |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 1.23 | 0.67-2.65 | 0.52 |
| Immunosuppressant except for MTX | 0.69 | 0.32-1.27 | 0.25 |
| MTX | 1.44 | 0.67-2.68 | 0.31 |
| Other drugs | 0.76 | 0.36-1.41 | 0.40 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Figure legends

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were excluded, and 51 patients with chronic course of RA-ILD were included. During observation period, 11 patients developed AE.

RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank $p=0.018$).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 23. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank $p=0.04$).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

1
2
3
4
5
6 Figure 34. Survival of AE group and non-AE group.
7
8

9 Patients who developed AE during observation periods (AE group) had a significantly
10
11 worse survival compared with those who did not (non-AE group) (log-rank $p=0.001$).
12
13

14 AE, acute exacerbation.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




FIGURE 2.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank $p=0.018$).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
80x80mm (300 x 300 DPI)




FIGURE 3.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank $p=0.04$).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
80x80mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




FIGURE 4.

Figure 4. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly worse survival compared with those who did not (non-AE group) (log-rank $p=0.001$).

AE, acute exacerbation.
80x80mm (300 x 300 DPI)

1
2
3
4
5
6 **Title:** Acute exacerbation in rheumatoid arthritis associated interstitial lung disease
7
8
9

10
11
12 **Authors:**

13
14 Hironao Hozumi, M.D., Ph.D.¹

15
16 Yutaro Nakamura, M.D., Ph.D.¹

17
18 Takeshi Johkoh, M.D., Ph.D.²

19
20 Hiromitsu Sumikawa, M.D., Ph.D.³

21
22 Thomas V. Colby, M.D.⁴

23
24 Masato Kono, M.D, Ph.D.¹

25
26 Dai Hashimoto, M.D., Ph.D.¹

27
28 Noriyuki Enomoto, M.D., Ph.D.¹

29
30 Tomoyuki Fujisawa, M.D., Ph.D.¹

31
32 Naoki Inui, M.D., Ph.D.¹

33
34 Takafumi Suda, M.D., Ph.D.¹

35
36 Kingo Chida, M.D., Ph.D.¹

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 **Affiliations:**

53
54
55 ¹Second division, Department of Internal Medicine, Hamamatsu University School of
56
57
58

1
2
3
4
5
6 Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan
7

8
9 ²Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public
10
11 School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan
12
13

14 ³Diagnostic and Interventional Radiology, Osaka University Graduate School of
15
16
17
18 Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
19

20 ⁴Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East
21
22
23 Shea Boulevard Scottsdale, AZ 85259, USA
24
25
26
27
28

29 **Corresponding author:**
30

31
32 Yutaro Nakamura, M.D., Ph.D.
33

34
35 Second division, Department of Internal Medicine, Hamamatsu University School of
36
37
38 Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan
39

40
41 Tel: 81-53-435-2263, Fax: 81-53-435-2354
42

43
44 E-mail address: nakayuta@hama-med.ac.jp
45
46
47
48

49 **Keywords:** Acute exacerbation, interstitial lung disease, risk factor, prognostic factor,
50
51
52
53
54
55
56
57
58
59
60
rheumatoid arthritis.

1
2
3
4
5
6 **Word count paper: 3382**
7
8

9 **Word count abstract: 280**
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Background Acute exacerbation (AE) in idiopathic pulmonary fibrosis is characterised by acute deterioration of respiratory status and the mortality is high.

Recently, AE was reported in patients with other interstitial lung diseases, especially rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives To investigate the risk factors and prognosis associated with AE in patients with RA-ILD.

Design A retrospective case-control study.

Setting A single academic hospital.

Participants 51 consecutive patients diagnosed with RA-ILD between 1995 and 2012.

All patients fulfilled the diagnostic criteria of the American College of Rheumatology for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures Overall survival and cumulative AE incidence were analysed using Kaplan–Meier method. Cox hazards analysis was used to determine significant variables associated with AE occurrence and survival status.

Results A total of 11 patients (22%) developed AE, with an overall 1-year incidence of 2.8%. Univariate analysis revealed that higher age at ILD diagnosis [hazard ratio

1
2
3
4
5
6 (HR), 1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], usual interstitial
7
8
9 pneumonia (UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and
10
11
12 treatment with methotrexate (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were risk factors
13
14
15 for AE. Of 11 patients who developed AE during observation period, seven (64%) died
16
17
18 of initial AE. In survival, AE was a prognostic factor for poor outcome (HR, 2.47; 95%
19
20
21 CI, 1.39–4.56; $P = 0.003$).

22
23 **Conclusions** In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on
24
25
26 HRCT and treatment with methotrexate are risk factors for AE. Furthermore, AE has a
27
28
29 serious impact on their survival.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis (IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with RA-ILD?

Key messages;

In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on HRCT, and treatment with methotrexate are risk factors for AE occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE has a serious impact on the survival of patients with RA-ILD.

Given its retrospective study design, it is subject to several possible biases. Therefore, prospective studies are necessary to confirm our results.

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterised by acute deterioration in respiratory status, with newly developed bilateral ground-glass opacities and/or consolidations on chest radiographs or computed tomography scans. It should be in the absence of other alternative causes such as infection, left heart failure, pulmonary embolism, and an identifiable cause of acute lung injury. AE reportedly occurs not only in patients with IPF but also in patients with other interstitial lung diseases (ILDs), including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital mortality associated with AE in patients with CVD-ILD was demonstrated to be as high as that in patients with IPF,[1-4] suggesting that AE may be associated with poor prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown etiology that primarily involves joints.[5] ILD is one of common extra-articular manifestations.[6, 7] The reported prevalence is variable (1–58%) and depends on the detection and diagnostic method, or the selected population.[8-13] We and Park *et al* previously reported that RA-associated ILD (RA-ILD) was the most common

1
2
3
4
5
6 CVD-ILD associated with AE.[3, 4] However the risk factors and prognosis associated
7
8
9 with AE in patients with RA-ILD are not clarified.

10
11 In the present study, we attempted to elucidate the cumulative incidence of AE, its
12
13 risk factors, and prognostic factors in patients with RA-ILD.
14
15
16
17
18
19

20 MATERIALS AND METHODS

21 Subjects

22
23
24
25 Institutional review board in Hamamatsu University School of Medicine approved
26
27 this study (approval number 24-191) and waived patient approval or informed consent
28
29 because the study involved a retrospective review of patient records and images. We
30
31 retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995
32
33 and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the
34
35 diagnostic criteria of the American College of Rheumatology for RA.[14] Patients with
36
37 other coexisting CVD were excluded. In addition, because our aim was to investigate
38
39 the features of AE among patients with a chronic course of RA-ILD, patients with no
40
41 evidence of chronic ILD were also excluded.
42
43
44
45
46
47
48
49
50
51

52
53 ILD was diagnosed on the basis of clinical presentation, pulmonary function tests,
54
55 high resolution computed tomography (HRCT) findings, and lung biopsy findings.
56
57
58
59
60

1
2
3
4
5
6 HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities
7
8
9 and honeycomb patterns were interpreted and defined as ILD by a consensus between
10
11 radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and
12
13 bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to
14
15 definitively diagnose ILD or rule out other diseases. The patients with environmental
16
17 exposures, suspected of drug induced pneumonia (ILD developed within 1 year after
18
19 initiation of new drug), or with other known causes of ILD were excluded after
20
21 considering exposure history and the findings of appropriate tests and histopathological
22
23 examinations.
24
25
26
27
28
29
30
31
32
33
34

35 **Acute exacerbation (AE)**

36
37
38 AE was defined using recently proposed criteria[1] that were slightly modified for
39
40 adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or
41
42 development of dyspnea within 30 days of onset, new bilateral ground-glass
43
44 abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern
45
46 on HRCT, no evidence of pulmonary infection on negative respiratory culture,
47
48 including endotracheal aspirate or bronchoalveolar lavage, and serological test results
49
50 for respiratory pathogens, and exclusion of alternative causes such as left heart failure,
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 pulmonary embolism, and an identifiable cause of acute lung injury. Patients with AE
7
8
9 were required to meet all five criteria. In our institution, cultures of sputum, blood, urine,
10
11 and bronchoalveolar lavage fluid, and serological tests examined for mycobacteria,
12
13 fungi, bacteria, and some viruses were routinely performed. Echocardiography and, if
14
15 necessary, CT scanning with intravenous contrast were performed to rule out left heart
16
17 failure or pulmonary thromboembolism. The patients who developed acute pneumonitis
18
19 within 1 year after initiation of drug for RA were excluded because drug-induced
20
21 pneumonitis was not completely ruled out. Patients who did or did not develop AE
22
23 during the observation period were classified into the AE and non-AE groups,
24
25 respectively.
26
27
28
29
30
31
32
33
34
35
36
37

38 **Data collection**

39
40 All clinical and laboratory data were collected from medical records. The observation
41
42 period was calculated from the date of diagnosis of RA-ILD to the last visit. The
43
44 AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis
45
46 and the first AE occurrence (AE group) or the last visit (non-AE group).
47
48
49
50
51
52
53
54

55 **Review of radiographic findings**

56
57
58
59
60

1
2
3
4
5
6 HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images
7
8
9 comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were
10
11
12 reconstructed by a high spatial frequency algorithm, and were displayed at window
13
14
15 settings appropriate for viewing the lung parenchyma (window level, -600 to -800
16
17 Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were
18
19
20 randomised and reviewed independently by two expert chest radiologists (with 23 and
21
22
23 12 years of experience) who were unaware of the related clinical information.
24
25
26 Interobserver agreement was classified as follows: poor ($\kappa = 0-0.20$), fair ($\kappa =$
27
28
29 $0.21-0.40$), moderate ($\kappa = 0.41-0.60$), good ($\kappa = 0.61-0.80$) and excellent ($\kappa =$
30
31
32 $0.81-1.00$).

33
34
35 RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a
36
37
38 non-UIP pattern according to recent guideline with slight modification.[15] Briefly, a
39
40
41 UIP pattern on HRCT was characterised by subpleural and basal predominance,
42
43
44 reticular abnormalities, honeycombing with or without traction bronchiectasis and the
45
46
47 absence of features listed as inconsistent with a UIP pattern, including upper or
48
49
50 mid-lung predominance, peribronchovascular predominance, extensive ground glass
51
52
53 abnormalities, profuse micronodules, discrete cysts, diffuse mosaic
54
55
56 attenuation/air-trapping and consolidation in bronchopulmonary segment(s)/lobe(s). If
57
58
59
60

1
2
3
4
5
6 the HRCT pattern did not meet the criteria, it was interpreted as a non-UIP pattern.
7

8
9 Disagreements regarding HRCT interpretation were resolved by a consensus between
10
11 both radiologists.
12

13 14 15 16 17 18 **Review of histopathological findings** 19

20
21 SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was
22
23 originally made in all cases on the basis of histological features evaluated by a lung
24
25 pathologist at our hospital, correlated with the clinical and radiological findings. All
26
27 SLB specimens were also reviewed by a second lung pathologist with 36 years of
28
29 experience. The histological classification of interstitial pneumonia was based on the
30
31 consensus statement criteria for idiopathic interstitial pneumonias,[16] and histological
32
33 patterns that could not be classified according to the criteria were categorised as
34
35 unclassified interstitial pneumonia.
36
37
38
39
40
41
42
43
44
45
46

47 **Statistical analysis** 48

49
50 All values are expressed as median (range) or number (%). The Mann-Whitney U test
51
52 was used for nonparametric comparisons involving continuous data, whereas Fisher's
53
54 exact test was used for comparing categorical data. Interobserver agreement on HRCT
55
56
57
58
59
60

1
2
3
4
5
6 pattern was analyzed using the κ statistic test. Survival was evaluated using the
7
8
9 Kaplan–Meier method and the log-rank test according to observation period. The
10
11
12 cumulative AE incidence was obtained from a Kaplan–Meier survival curve by treating
13
14
15 AE as the death variable according to AE free period. The 1-year AE incidence was
16
17
18 based on person year method and calculated by dividing the number of patients who
19
20
21 developed AE by the total of AE-free period (year) of all the patients. Cox hazards
22
23
24 analysis was used to determine significant variables associated with survival and AE
25
26
27 occurrence. In all analyses, $P < 0.05$ was considered statistically significant. All data
28
29
30 were analysed using commercially available software (JMP version 9.0.3a, SAS
31
32
33 Institute Inc, Cary, NC, USA).

34 35 36 37 38 **RESULTS**

39 40 41 **Patient characteristics (Table 1)**

42
43
44 A total of 82 patients with RA-ILD were identified from medical records at
45
46
47 Hamamatsu University Hospital. From these, 11 patients with other coexisting CVDs, 8
48
49
50 with no evidence of chronic ILD and an initial acute/subacute course of ILD, and 3
51
52
53 suspected of drug-induced pneumonitis were excluded. In addition, 9 patients for whom
54
55
56 no initial HRCT images were available for review were also excluded. The remaining
57
58
59
60

1
2
3
4
5
6 51 patients with RA-ILD were included in this study.(Figure 1)
7

8
9 The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82)
10
11 years and 62 (range, 31–83) years, respectively. The median observation period and
12
13 AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.
14
15

16
17 During the observation period, 11 patients (22%) developed AE. The median age at
18
19 the onset of AE was 72 (range, 60–86) years. There were no statistically significant
20
21 differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period,
22
23 AE-free period, smoking habits, predicted forced vital capacity (%FVC) at diagnosis of
24
25 RA-ILD, and arterial oxygen pressure (PaO₂) at diagnosis of RA-ILD between the AE
26
27 and non-AE groups. Also there were no statistically significant differences in articular
28
29 disease activities (RF and DAS28-CRP) at the last visit (non-AE group) or the first AE
30
31 occurrence (AE group).
32
33
34
35
36
37
38
39

40
41 In the AE group, seven of 11 patients (64%) died of initial AE during the observation
42
43 period. In the non-AE group, 2 of 40 patients (5%) died of respiratory failure. There was
44
45 a statistically significant difference in the mortality rate between the AE and non-AE
46
47 groups.
48
49

50
51 Extra-articular manifestations except for ILD had been observed in 8 (16%) of 51
52
53 patients (pericarditis in 2 patients, pleuritis in 1, neuropathy in 2, cutaneous vasculitis in
54
55
56
57
58
59
60

1
2
3
4
5
6 2, glomerulonephritis in 1, rheumatoid nodule in 2). There was no significant difference
7
8
9 in the incidence between AE group and non-AE group (27% vs. 13%, $P=0.26$).
10

11 12 13 14 15 **HRCT pattern (Table 1)** 16

17 Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT.
18
19
20 HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%)
21
22 patients in the AE group demonstrated a UIP pattern. Interobserver agreement between
23
24 both radiologists was moderate (κ statistic test, $\kappa = 0.44$). The number of patients who
25
26 exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the
27
28 non-AE group.
29
30
31
32
33
34

35 When HRCT pattern was identified as a UIP pattern, the positive predictive value and
36
37 negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.
38
39
40
41
42
43

44 **Diagnostic accuracy of HRCT pattern for histopathological pattern (Table 2)** 45

46 Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis
47
48 revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and
49
50 an unclassified interstitial pneumonia in 1. The diagnostic accuracy of HRCT pattern for
51
52 histopathological pattern was evaluated in 21 histopathologically confirmed patients.
53
54
55
56
57
58
59
60

1
2
3
4
5
6 When the pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity,
7
8 positive predictive value and negative predictive value for detecting histopathological
9
10
11
12 UIP was 41.7%, 100%, 100% and 56.3%, respectively.
13

14 15 16 17 18 **Treatment for RA (Table 3)** 19

20
21 Of the 51 patients, 37 (73%) had received treatment for RA at their final visit
22
23 (non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) had
24
25 received corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10
26
27 (20%) received MTX and 17 (33%) received other drugs. There were 6 (55%) patients
28
29 who had received MTX in AE group while 4 (10%) patients in non-AE group and
30
31 statistically significant difference was observed between the groups ($P = 0.001$).
32
33
34
35
36
37

38 No patients had received MTX before in AE group while 2 in non-AE group. Thus,
39
40 there were 6 (55%) patients who had experienced MTX treatment during observation
41
42 period in AE group while 6 (15%) patients in non-AE group. Median cumulative MTX
43
44 dose were 1952mg (384-3872) in 6 patients who had experienced MTX among AE
45
46 group and 802mg (32-2496) in 6 patients among non-AE group. No statistically
47
48 significant difference was observed between two groups in cumulative MTX dose
49
50
51
52
53
54
55
56
57
58
59
60 ($P=0.20$).

1
2
3
4
5
6 Articular disease activities (RF and DAS28-CRP) were compared between patients
7
8
9 who had received MTX at the last visit or at the first AE occurrence, and those who had
10
11
12 not. Median RF (range) were 112 IU/mL (16-334) and 284 IU/mL (6-2666) ($P=0.25$),
13
14
15 Median DAS28-CRP (range) were 1.94 (1.02-3.87) and 1.97 (1.02-5.13) ($P=0.78$),
16
17
18 respectively. There were no statistically significant differences in articular disease
19
20
21 activities.

22 23 24 25 26 **AE incidence**

27
28
29 The cumulative AE incidence in patients with RA-ILD is shown in Figure 2. The
30
31
32 5-year AE incidence was 11% [95% confidence interval (CI), 2–21%] in all patients,
33
34
35 33% (95% CI, 7–60%) in patients with a UIP pattern on HRCT (UIP pattern group) and
36
37
38 3% (95% CI, 0–9%) in patients with a non-UIP pattern on HRCT (non-UIP pattern
39
40
41 group). The AE incidence was significantly higher in UIP pattern group than in
42
43
44 non-UIP pattern group (log-rank test, $P = 0.018$). The overall 1-year AE incidence was
45
46
47 2.8%. The 1-year AE incidence was 6.5% in the UIP pattern group and 1.7 % in the
48
49
50 non-UIP pattern group.

51
52
53 Univariate analysis (Table 4) revealed that higher age at ILD diagnosis [hazard ratio
54
55
56 (HR), 1.11; 95% CI, 1.02–1.21; $P = 0.01$], UIP pattern on HRCT (HR, 1.95; 95% CI,

1
2
3
4
5
6 1.07–3.63; $P = 0.03$) and treatment with MTX (HR, 3.04; 95% CI, 1.62–6.02; $P =$
7
8
9 0.001) were significant risk factors for AE occurrence.

10 11 12 13 14 15 **Survival**

16
17 The overall survival of patients with RA-ILD is shown in Figure 3.

18
19
20 The 5-year survival was 90% (95% CI, 81–98%) in all patients, 70% (95% CI, 44–94%)
21
22 in the UIP pattern group and 97% (95% CI, 92–100%) in the non-UIP pattern group.

23
24
25 Survival was significantly poorer in the UIP pattern group than in the non-UIP pattern
26
27 group (log-rank test, $P = 0.04$). In addition, significantly worse survival was
28
29 demonstrated in the AE group compared with the non-AE group (Figure 4, log-rank test,
30
31
32
33
34
35
36
37 $P = 0.001$).

38
39 Univariate analysis (Table 5) revealed that higher age at ILD diagnosis (HR, 1.08;
40
41 95% CI, 0.99–1.17; $P = 0.057$) and UIP pattern on HRCT (HR, 1.74; 95% CI,
42
43 0.97–3.12; $P = 0.06$) showed a trend toward poor outcome, while AE (HR, 2.47; 95%
44
45 CI, 1.39–4.56; $P = 0.003$) was significantly associated with poor survival.
46
47
48
49
50
51

52 **DISCUSSION**

53
54
55 To our knowledge, the present study is the first one focusing on the risk factors and
56
57
58
59
60

1
2
3
4
5
6 prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence
7
8
9 was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern
10
11
12 on HRCT, MTX treatment and higher age at ILD diagnosis were significant risk factors
13
14
15 for AE. Furthermore, AE was a prognostic factor for poor survival.

16
17
18 The 1-year AE incidence among patients with IPF has been reported to be 5-19%,[17,
19
20
21 18] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP, 3.3 %
22
23
24 for CVD-ILD and 5.6 % for CVD-UIP.[4] In the present study, the 1-year AE incidence
25
26
27 among patients with a UIP pattern on HRCT was 6.5% and cumulative incidence was
28
29
30 significantly higher in UIP pattern group than in non-UIP pattern group. Furthermore, a
31
32
33 UIP pattern on HRCT was a risk factor for AE. In a previous report of small number of
34
35
36 biopsy-proven cases, AE incidence among patients with RA-UIP was reported to be
37
38
39 11.1%, similar to that among patients with IPF.[4] The correlation between pathological
40
41
42 and radiological UIP patterns has been established in IPF, but not in RA-ILD.[19] In the
43
44
45 present study, determination of a UIP pattern on HRCT exhibited high specificity and
46
47
48 positive predictive values for the detection of pathological UIP pattern. Therefore, a
49
50
51 typical UIP pattern on HRCT was assumed to be highly suggestive of pathological UIP
52
53
54 pattern in patients with RA-ILD as well as IPF.[15, 19] Collectively, these results
55
56
57 suggest that AE incidence in a subgroup with pathological UIP pattern or a UIP pattern
58
59
60

1
2
3
4
5
6 on HRCT may be higher than that in other patterns..
7

8
9 The present study also identified MTX treatment as a risk factor for AE. MTX is
10 widely used to treat RA, while its toxicity affects the pulmonary system. Diagnostic
11 criteria for MTX-associated pneumonitis (MTX-pneumonitis) have been proposed
12 previously.[20] However, the specificity of the criteria has not been fully examined yet.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MTX-pneumonitis typically occurs with acute/subacute onset early in the course of
MTX treatment,[20-23] in particular, mostly within the first year[24] and often presents
a hypersensitive pneumonitis pattern. Patients with MTX-pneumonitis generally
respond to discontinuation of MTX or corticosteroid treatment and have a favorable
prognosis.[20-23] In the present study, 6 of 11 patients with AE had received MTX, and
5 of the 6 patients had been treated for 3 or more years. The remaining patient had been
treated for 1 year. In all 6 patients, their respiratory conditions progressively
deteriorated despite discontinuation of MTX, and they poorly responded to high-dose
corticosteroid. Consequently, on the basis of inconsistency in terms of MTX treatment
duration and clinical features, we diagnosed these patients with AE of RA-ILD.

Similar to AE in patients with IPF, the etiology of AE in RA-ILD is unknown;
however, several reports have suggested that AE may be a distinct manifestation of the
primary disease process, a distinct condition associated with undiagnosed infection, or a

1
2
3
4
5
6 subsequent acceleration of a fibroproliferative process caused by acute direct stress to
7
8
9 the lung.[1] In the present study, DAS28-CRP in all patients with AE showed low
10
11
12 disease activity or remission at the time of AE occurrence, and no significant difference
13
14
15 in articular disease activities was observed between AE group and non-AE group or
16
17
18 regardless of MTX treatment; therefore, RA activity may not be related to AE
19
20
21 occurrence, a finding similar to that of a previous study.[4] MTX possibly accelerates
22
23
24 the fibroproliferative process of RA-ILD. It was reported that MTX treatment was a risk
25
26
27 factor for RA-ILD progression.[12] For RA-ILD, MTX may be associated not only with
28
29
30 newly developing drug-induced pneumonitis but also with deterioration of pre-existing
31
32
33 ILD, including AE.

34
35 The present study found that patients with a UIP pattern on HRCT had significantly
36
37
38 poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic
39
40
41 factor for poor outcome. AE has a serious impact on the survival of patients with
42
43
44 IPF,[18] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with these
45
46
47 reports, the present study revealed that seven (64%) of 11 patients with AE died of
48
49
50 respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE
51
52
53 group was significantly poorer than that in the non-AE group. Therefore, AE is
54
55
56 suggested to be a predictor of poor prognosis in patients with RA-ILD as well as
57
58
59
60

1
2
3
4
5
6 patients with IPF.
7

8
9 Other prognostic factors in RA-ILD have been reported, including pathological
10
11 UIP,[25-29] UIP pattern on HRCT,[30] and age at RA-ILD onset.[31] In the present
12
13 study, pathological UIP could not be identified as prognostic factors because the number
14
15 of biopsy-proven cases were small. However, we observed similar results regarding UIP
16
17 pattern on HRCT and age at RA-ILD onset.
18
19
20
21

22
23 In our study, the average time between age at onset of RA and that of RA-ILD was
24
25 relatively shorter than some previous reports.[7, 8] However, Gabbay et al [11] reported
26
27 that nearly 60 % of the patients have interstitial lung disease in recent onset RA. In
28
29 another point of view, since the current authors' institution is regional referral center for
30
31 interstitial lung disease, referral bias might have increased the proportion of patients
32
33 with early-stage ILD, leading above results.
34
35
36
37
38
39

40 This study had several limitations. First, given its retrospective study design, it is
41
42 subject to several possible biases. For instance, selection and recall bias may exist.
43
44 Second, because of the relatively small sample size, it may be difficult to determine the
45
46 precise incidence of AE and the number of event (AE occurrence or death) was too
47
48 small to perform multivariate analysis. Therefore, larger studies are necessary to
49
50 confirm our results. Third, because the presence of a UIP pattern on HRCT had low
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 sensitivity and negative predictive value for the detection of pathologic UIP, it was
7
8 likely that some patients with a non-UIP pattern on HRCT may have had pathological
9
10 UIP. HRCT criteria used in our study do not aim to detect pathological UIP but to
11
12 clinically diagnose IPF and to exclude alternative diagnosis.[15] The frequency of
13
14 honeycombing on HRCT differs between RA-ILD and IPF, and some ILDs by other
15
16 causes including RA-ILD have some of findings inconsistent with UIP. Therefore,
17
18 HRCT pattern in RA-ILD may be more frequently interpreted as non-UIP pattern than
19
20 that in IPF. In our study, 2 of 5 patients with histopathological UIP in the absence of a
21
22 UIP pattern on HRCT develop AE. Thus, SLB may have to be considered for these
23
24 patients to make pathological diagnosis and to predict AE. Finally, RA includes a
25
26 variety of manifestations. Therefore, other comorbidities may have affected the results.
27
28
29
30
31
32
33
34
35
36
37

38 In conclusion, higher age at ILD diagnosis, UIP pattern on HRCT and treatment with
39
40 MTX are risk factors for AE occurrence in patients with RA-ILD. Furthermore, the
41
42 mortality associated with AE is high and AE is prognostic factor for poor outcome.
43
44 Larger prospective studies investigating acute exacerbations in RA-ILD are indicated.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENT

We appreciate the help of Dr. T. Tsuchiya in the statistical advice.

This study was partly supported by the Diffuse Lung Diseases Research Group from the ministry of Health, Labour and Welfare, Japan.

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S., and K.C. revised the paper.

All authors approved the paper.

Competing interest:

All authors do not have any personal or financial support or involvement with organization(s) that have financial interest in the subject matter, or any competing interest.

Funding:

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this study (approval number 24-191) and waived patient approval or informed consent because the study involved a retrospective review of patient records and images.

Copyright:

I [*Yutaro Nakamura*] the Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs, other illustrative material, video, film or any other material howsoever submitted by the Contributor(s) at

1
2
3
4
5
6 any time and related to the Contribution (“the Contribution”) have the right to grant on
7
8
9 behalf of all authors and do grant on behalf of all authors, a licence to the BMJ
10
11 Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be
12
13 published in BMJ Open and any other BMJ Group products and to exploit all subsidiary
14
15
16
17 rights, as set out in the licence
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.
2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. *Histopathology.* 2011;58:525-30.
3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.
4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.
5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.
6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.* 1998;19:667-85.
7. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis.* 2003;62:722-7.
8. Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and

- 1
2
3
4
5
6 their impact on outcome. *Rheumatology (Oxford)*. 2013;52:99-110.
7
8
9 9. Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain:
10
11 occurrence of extra-articular manifestations and estimates of disease severity. *Ann*
12
13 *Rheum Dis*. 2003;62:897–900.
14
15
16
17 10. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with
18
19 rheumatoid arthritis as assessed by high resolution computed tomography, chest
20
21 radiography, and pulmonary function tests. *Thorax*. 2001;56:622–7.
22
23
24
25
26 11. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset
27
28 rheumatoid arthritis. *Am J Respir Crit Care Med*. 1997;156:528–35.
29
30
31
32 12. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung
33
34 disease in rheumatoid arthritis. *Arch Intern Med*. 2008;168:159–66.
35
36
37
38 13. Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on
39
40 high-resolution computed tomography in patients with early versus longstanding
41
42 rheumatoid arthritis. *J Rheumatol*. 2008;35:1513–21.
43
44
45
46 14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association
47
48 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*.
49
50 1988;31:315-24.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 15. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on
7
8 Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:
9
10 idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and
11
12 management. *Am J Respir Crit Care Med*. 2011;183:788-824.
13
14
15
16
17 16. American Thoracic Society/European Respiratory Society International
18
19 Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
20
21 *Am J Respir Crit Care Med*. 2002;165:277-304.
22
23
24
25
26 17. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary
27
28 fibrosis. *Chest*. 2007;132:1652-8.
29
30
31
32 18. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary
33
34 fibrosis: incidence, risk factors and outcome. *Eur Respir J*. 2011;37:356-63.
35
36
37
38 19. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung
39
40 disease: the relevance of histopathologic and radiographic pattern. *Chest*.
41
42 2009;136:1397-405.
43
44
45
46 20. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic,
47
48 and histopathologic features of methotrexate-associated lung injury in patients with
49
50 rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum*.
51
52 1997;40:1829-37.
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 21. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced
7
8 lung injury in patients with rheumatoid arthritis. A multicenter, case-control study.
9
10 Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.
11
12
13
14 22. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in
15
16 patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.*
17
18 2009;68:1100-4.
19
20
21
22 23. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the
23
24 literature and histopathological findings in nine patients. *Eur Respir J.*
25
26 2000;15:373-81.
27
28
29
30 24. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in
31
32 rheumatoid arthritis. *Rheumatology (Oxford).* 2004;43:143-7.
33
34
35
36 25. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis
37
38 of 54 biopsy-proven cases. *Respir Med.* 2012;106:1164-9.
39
40
41
42 26. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am*
43
44 *Rev Respir Dis.* 1985;131:770-7.
45
46
47
48 27. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of
49
50 rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2005;127:2019-27.
51
52
53
54 28. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern
55
56
57
58
59
60

- 1
2
3
4
5
6 as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int.* 2005;26:121-5.
7
8
9 29. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia:
10
11 idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care*
12
13 *Med.* 2007;175:705-11.
14
15
16
17 30. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in
18
19 rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.*
20
21 2010;35:1322-8.
22
23
24
25
26 31. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study).
27
28
29 Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an
30
31 inception cohort. *Rheumatology (Oxford).* 2010;49:1483-9.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Clinical characteristics

| Characteristics | Total N = 51 (100) | Non-AE group [#] N = 40 (78) | AE group [¶] N = 11 (22) | P value ⁺ |
|---|-----------------------|--|--------------------------------------|----------------------|
| Median age, years (range) | | | | |
| at RA diagnosis | 61 (28-82) | 60 (28-81) | 65 (42-82) | 0.15 |
| at ILD diagnosis | 62 (31-83) | 62 (31-83) | 69 (58-83) | 0.15 |
| at AE onset | | | 72 (60-86) | |
| Sex Male, n (%) | 29 (57) | 23 (58) | 6 (55) | 0.86 |
| Observation period, years (range) | 8.5 (1-17) | 9 (1-17) | 6.4 (2-14) | 0.45 |
| AE-free period, years (range) | 7(1-17) | 9 (1-17) | 6 (2-14) | 0.19 |
| Smoking habit, n (%) | | | | |
| Never | 20 (39) | 18 (45) | 2 (18) | |
| Former | 24 (47) | 16 (40) | 8 (73) | 0.15 |
| Current | 7 (14) | 6 (15) | 1 (9) | |
| RF, IU/mL (range)* | 197 (6-2666) | 189 (6-2666) | 205 (39-2530) | 0.47 |
| DAS28-CRP, score (range)* | 1.95(1.02-5.13) | 2.53(1.02-5.13) | 1.82(1.47-2.3) | 0.62 |
| PaO ₂ , torr (range) | 82.4 (67-109) | 81 (67-102) | 85.8 (74-109) | 0.19 |
| %FVC, % (range) | 91.1 (50.6-130) | 87.5 (51-130) | 95 (60-125) | 0.38 |
| HRCT pattern, n (%) | | | | |
| UIP pattern | 14 (27) | 8 (20) | 6 (55) | |
| non-UIP pattern | 37 (73) | 32 (80) | 5 (45) | 0.02 [§] |
| Death during observation period, n (%) | | | | |
| caused by respiratory failure | 8 (16) | 2 (5) | 7 (64) | |
| caused by other diseases | 4 (8) | 3 (8) | 0 (0) | 0.02 [§] |

Data are presented as n (%), median (range). AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; RF, rheumatoid factor; DAS28-CRP, disease activity score 28 CRP; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶]AE group, patients who developed AE during observation period.

⁺Non-AE group vs AE group

[§] $p < 0.05$

* at the first AE occurrence (AE group) or the last visit (non-AE group).

When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

1
2
3
4
5 In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of
6 respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding
7 and 2 of unknown causes.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 2 Diagnostic accuracy of HRCT pattern for histopathological pattern in 21 histopathologically confirmed patients.

| | Histopathological pattern | | Total |
|-------------------------|---------------------------|---------------|-------|
| | UIP | Other pattern | |
| UIP pattern on HRCT | 5 | 0 | 5 |
| non-UIP pattern on HRCT | 7 | 9 | 16 |
| Total | 12 | 9 | 21 |

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

When HRCT pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive predictive value and negative predictive value for detecting histopathological UIP was 41.7%, 100%, 100% and 56.3%, respectively.

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

| | Total N = 51 | non-AE group ⁺ N = 40 (78%) | AE group [§] N = 11 (22%) | P value |
|----------------------------------|-----------------|---|---------------------------------------|--------------------|
| Treatment, yes | 37 (73) | 27(68) | 10 (91) | 0.12 |
| Corticosteroid | 29 (57) | 22 (55) | 7 (64) | 0.61 |
| Immunosuppressant except for MTX | 17 (33) | 14 (35) | 3 (27) | 0.63 |
| MTX | 10 (20) | 4 (10) | 6 (55) | 0.001 [*] |
| Other drugs | 17 (33) | 13 (33) | 4 (36) | 0.81 |

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cyclophosphamide (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

⁺ Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

^{*} $p < 0.05$

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 1.03 | 0.97-1.10 | 0.35 |
| Age at ILD diagnosis | 1.11 | 1.02-1.21 | 0.01 ⁺ |
| Sex, male | 0.90 | 0.49-1.69 | 0.73 |
| Smoking habit, yes | 1.60 | 0.81-4.10 | 0.19 |
| UIP pattern on HRCT, yes | 1.95 | 1.07-3.63 | 0.03 ⁺ |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.12 | 0.14 |
| %FVC at ILD diagnosis | 1.02 | 0.99-1.06 | 0.24 |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 0.97 | 0.53-1.92 | 0.94 |
| Immunosuppressant except for MTX | 0.76 | 0.35-1.41 | 0.39 |
| MTX | 3.04 | 1.62-6.02 | 0.001 ⁺ |
| Other drugs | 0.98 | 0.50-1.80 | 0.96 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 0.98 | 0.93-1.04 | 0.48 |
| Age at ILD diagnosis | 1.08 | 0.99-1.17 | 0.057 |
| Sex, male | 1.14 | 0.63-2.22 | 0.67 |
| Smoking habit, yes | 1.70 | 0.87-4.35 | 0.13 |
| UIP pattern on HRCT, yes | 1.74 | 0.97-3.12 | 0.06 |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.11 | 0.15 |
| %FVC at ILD diagnosis | 1.01 | 0.98-1.04 | 0.55 |
| AE during observation period, yes | 2.47 | 1.39-4.56 | 0.003 ⁺ |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 1.23 | 0.67-2.65 | 0.52 |
| Immunosuppressant except for MTX | 0.69 | 0.32-1.27 | 0.25 |
| MTX | 1.44 | 0.67-2.68 | 0.31 |
| Other drugs | 0.76 | 0.36-1.41 | 0.40 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Figure legends

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were excluded, and 51 patients with chronic course of RA-ILD were included. During observation period, 11 patients developed AE.

RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank $p=0.018$).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank $p=0.04$).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

1
2
3
4
5
6 Figure 4. Survival of AE group and non-AE group.
7

8
9 Patients who developed AE during observation periods (AE group) had a significantly
10
11 worse survival compared with those who did not (non-AE group) (log-rank $p=0.001$).
12
13

14
15 AE, acute exacerbation.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID: | bmjopen-2013-003132.R2 |
| Article Type: | Research |
| Date Submitted by the Author: | 02-Aug-2013 |
| Complete List of Authors: | Hozumi, Hironao; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Nakamura, Yutaro; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Johkoh, Takeshi; Kinki Central Hospital of Mutual Aid Association of Public Teachers, Department of Radiology Sumikawa, Hiromitsu; Osaka University Graduate School of Medicine, Diagnostic and Interventional Radiology Colby, Thomas; Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology kono, Masato; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Hashimoto, Dai; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Enomoto, Noriyuki; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Fujisawa, Tomoyuki; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Inui, Naoki; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Suda, Takafumi; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine Chida, Kingo; Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine |
| Primary Subject Heading: | Respiratory medicine |
| Secondary Subject Heading: | Rheumatology |
| Keywords: | Interstitial lung disease < THORACIC MEDICINE, RHEUMATOLOGY, Adult thoracic medicine < THORACIC MEDICINE |
| | |

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **Title:** Acute exacerbation in rheumatoid arthritis associated interstitial lung disease
7
8
9

10
11
12 **Authors:**

13
14 Hironao Hozumi, M.D., Ph.D.¹

15
16 Yutaro Nakamura, M.D., Ph.D.¹

17
18 Takeshi Johkoh, M.D., Ph.D.²

19
20 Hiromitsu Sumikawa, M.D., Ph.D.³

21
22 Thomas V. Colby, M.D.⁴

23
24 Masato Kono, M.D, Ph.D.¹

25
26 Dai Hashimoto, M.D., Ph.D.¹

27
28 Noriyuki Enomoto, M.D., Ph.D.¹

29
30 Tomoyuki Fujisawa, M.D., Ph.D.¹

31
32 Naoki Inui, M.D., Ph.D.¹

33
34 Takafumi Suda, M.D., Ph.D.¹

35
36 Kingo Chida, M.D., Ph.D.¹

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 **Affiliations:**

53
54
55 ¹Second division, Department of Internal Medicine, Hamamatsu University School of
56
57
58

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

²Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public
School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan

³Diagnostic and Interventional Radiology, Osaka University Graduate School of
Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

⁴Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East
Shea Boulevard Scottsdale, AZ 85259, USA

Corresponding author:

Yutaro Nakamura, M.D., Ph.D.

Second division, Department of Internal Medicine, Hamamatsu University School of
Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

Tel: 81-53-435-2263, Fax: 81-53-435-2354

E-mail address: nakayuta@hama-med.ac.jp

Keywords: Acute exacerbation, interstitial lung disease, risk factor, prognostic factor,
rheumatoid arthritis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word count paper: 3494

Word count abstract: 279

For peer review only

ABSTRACT

Background Acute exacerbation (AE) in idiopathic pulmonary fibrosis is characterised by acute deterioration of respiratory status and the mortality is high.

Recently, AE was reported in patients with other interstitial lung diseases, especially rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives To investigate the risk factors and prognosis associated with AE in patients with RA-ILD.

Design A retrospective case-control study.

Setting A single academic hospital.

Participants 51 consecutive patients diagnosed with RA-ILD between 1995 and 2012.

All patients fulfilled the diagnostic criteria of the American College of Rheumatology for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures Overall survival and cumulative AE incidence were analysed using Kaplan–Meier method. Cox hazards analysis was used to determine significant variables associated with AE occurrence and survival status.

Results A total of 11 patients (22%) developed AE, with an overall 1-year incidence of 2.8%. Univariate analysis revealed that older age at ILD diagnosis [hazard ratio (HR),

1
2
3
4
5
6 1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], usual interstitial pneumonia
7
8
9 (UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and methotrexate
10
11
12 usage (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were associated with AE. Of 11
13
14
15 patients who developed AE during observation period, seven (64%) died of initial AE.
16
17
18 In survival, AE was a prognostic factor for poor outcome (HR, 2.47; 95% CI,
19
20
21 1.39–4.56; $P = 0.003$).
22

23 **Conclusions** In patients with RA-ILD, older age at ILD diagnosis, UIP pattern on
24
25
26 HRCT and methotrexate usage are associated with the development of AE. Furthermore,
27
28
29 AE has a serious impact on their survival.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis (IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with RA-ILD?

Key messages;

In patients with RA-ILD, older age at ILD diagnosis, UIP pattern on HRCT and methotrexate usage are associated with AE occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE has a serious impact on the survival of patients with RA-ILD.

Given its retrospective study design, it is subject to several possible biases. Therefore, prospective studies are necessary to confirm our results.

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterised by acute deterioration in respiratory status, with newly developed bilateral ground-glass opacities and/or consolidations on chest radiographs or computed tomography scans. It should be in the absence of other alternative causes such as infection, left heart failure, pulmonary embolism, or an identifiable cause of lung injury. AE reportedly occurs not only in patients with IPF but also in patients with other interstitial lung diseases (ILDs), including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital mortality associated with AE in patients with CVD-ILD was demonstrated to be as high as that in patients with IPF,[1-4] suggesting that AE may be associated with poor prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown etiology that primarily involves joints.[5] ILD is one of common extra-articular manifestations.[6, 7] The reported prevalence is variable (1–58%) and depends on the detection and diagnostic method, or the selected population.[8-13] We and Park *et al* previously reported that RA-associated ILD (RA-ILD) was the most common

1
2
3
4
5
6 CVD-ILD associated with AE.[3, 4] However the risk factors and prognosis associated
7
8
9 with AE in patients with RA-ILD are not clarified.

10
11 In the present study, we attempted to elucidate the cumulative incidence of AE, its
12
13 risk factors, and prognostic factors in patients with RA-ILD.
14
15
16
17
18
19

20 MATERIALS AND METHODS

21 Subjects

22
23
24
25 Institutional review board in Hamamatsu University School of Medicine approved
26
27 this study (approval number 24-191) and waived patient approval or informed consent
28
29 because the study involved a retrospective review of patient records and images. We
30
31 retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995
32
33 and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the
34
35 diagnostic criteria of the American College of Rheumatology for RA.[14] Patients with
36
37 other coexisting CVD were excluded. In addition, because our aim was to investigate
38
39 the features of AE among patients with a chronic course of RA-ILD, patients with no
40
41 evidence of chronic ILD were also excluded. Chronic ILD was defined as the ILD
42
43 which had been stable for over 3 months.
44
45
46
47
48
49
50
51
52
53

54
55 ILD was diagnosed on the basis of clinical presentation, pulmonary function tests,
56
57
58
59
60

1
2
3
4
5
6 high resolution computed tomography (HRCT) findings, and lung biopsy findings.
7
8
9 HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities
10
11 and honeycomb patterns were interpreted and defined as ILD by a consensus between
12
13 radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and
14
15 bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to
16
17 definitively diagnose ILD or rule out other diseases. The patients with environmental
18
19 exposures, suspected of drug induced pneumonia (ILD developed within 1 year after
20
21 initiation of new drug), or with other known causes of ILD were excluded after
22
23 considering exposure history and the findings of appropriate tests and histopathological
24
25 examinations.
26
27
28
29
30
31
32
33
34
35
36
37

38 **Acute exacerbation (AE)**

39
40 AE was defined using recently proposed criteria[1] that were slightly modified for
41
42 adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or
43
44 development of dyspnea within 30 days of onset, new bilateral ground-glass
45
46 abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern
47
48 on HRCT, no evidence of pulmonary infection on negative respiratory culture,
49
50 including endotracheal aspirate or bronchoalveolar lavage, and serological test results
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 for respiratory pathogens, and exclusion of alternative causes such as left heart failure,
7
8
9 pulmonary embolism, or an identifiable cause of lung injury. Patients with AE were
10
11
12 required to meet all five criteria. In our institution, cultures of sputum, blood, urine, and
13
14 bronchoalveolar lavage fluid, and serological tests examined for mycobacteria, fungi,
15
16 bacteria, and some viruses were routinely performed. Echocardiography and, if
17
18 necessary, CT scanning with intravenous contrast were performed to rule out left heart
19
20 failure or pulmonary thromboembolism. The patients who developed acute pneumonitis
21
22 within 1 year after initiation of drug for RA were excluded because drug-induced
23
24 pneumonitis was not completely ruled out. Patients who did or did not develop AE
25
26 during the observation period were classified into the AE and non-AE groups,
27
28 respectively.
29
30
31
32
33
34
35
36
37
38
39
40

41 **Data collection**

42
43 All clinical and laboratory data were collected from medical records. The observation
44
45 period was calculated from the date of diagnosis of RA-ILD to the last visit. The
46
47 AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis
48
49 and the first AE occurrence (AE group) or the last visit (non-AE group).
50
51
52
53
54
55
56
57
58
59
60

Review of radiographic findings

HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were reconstructed by a high spatial frequency algorithm, and were displayed at window settings appropriate for viewing the lung parenchyma (window level, -600 to -800 Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were randomised and reviewed independently by two expert chest radiologists (with 23 and 12 years of experience) who were unaware of the related clinical information. Interobserver agreement was classified as follows: poor ($\kappa = 0-0.20$), fair ($\kappa = 0.21-0.40$), moderate ($\kappa = 0.41-0.60$), good ($\kappa = 0.61-0.80$) and excellent ($\kappa = 0.81-1.00$).

RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a non-UIP pattern according to recent guideline with slight modification.[15] Briefly, a UIP pattern on HRCT was characterised by subpleural and basal predominance, reticular abnormalities, honeycombing with or without traction bronchiectasis and the absence of features listed as inconsistent with a UIP pattern, including upper or mid-lung predominance, peribronchovascular predominance, extensive ground glass abnormalities, profuse micronodules, discrete cysts, diffuse mosaic

1
2
3
4
5
6 attenuation/air-trapping and consolidation in bronchopulmonary segment(s)/lobe(s). If
7
8
9 the HRCT pattern did not meet the criteria, it was interpreted as a non-UIP pattern.
10
11
12 Disagreements regarding HRCT interpretation were resolved by a consensus between
13
14
15 both radiologists.
16
17
18
19

20 **Review of histopathological findings**

21
22
23 SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was
24
25
26 originally made in all cases on the basis of histological features evaluated by a lung
27
28
29 pathologist at our hospital, correlated with the clinical and radiological findings. All
30
31
32 SLB specimens were also reviewed by a second lung pathologist with 36 years of
33
34
35 experience. The histological classification of interstitial pneumonia was based on the
36
37
38 consensus statement criteria for idiopathic interstitial pneumonias,[16] and histological
39
40
41 patterns that could not be classified according to the criteria were categorised as
42
43
44 unclassified interstitial pneumonia.
45
46
47
48

49 **Statistical analysis**

50
51
52 All values are expressed as median (range) or number (%). The Mann-Whitney U test
53
54
55 was used for nonparametric comparisons involving continuous data, whereas Fisher's
56
57
58

1
2
3
4
5
6 exact test was used for comparing categorical data. Interobserver agreement on HRCT
7
8
9 pattern was analyzed using the κ statistic test. Survival was evaluated using the
10
11 Kaplan–Meier method and the log-rank test according to observation period. The
12
13 cumulative AE incidence was obtained from a Kaplan–Meier survival curve by treating
14
15 AE as the death variable according to AE free period. The 1-year AE incidence was
16
17 based on person year method and calculated by dividing the number of patients who
18
19 developed AE by the total of AE-free period (year) of all the patients. Cox hazards
20
21 analysis was used to determine significant variables associated with survival and AE
22
23 occurrence. In all analyses, $P < 0.05$ was considered statistically significant. All data
24
25 were analysed using commercially available software (JMP version 9.0.3a, SAS
26
27 Institute Inc, Cary, NC, USA).
28
29
30
31
32
33
34
35
36
37
38
39
40

41 RESULTS

42 Patient characteristics (Table 1)

43
44
45 A total of 82 patients with RA-ILD were identified from medical records at
46
47 Hamamatsu University Hospital. From these, 11 patients with other coexisting CVDs, 8
48
49 with no evidence of chronic ILD and an initial acute/subacute course of ILD, and 3
50
51 suspected of drug-induced pneumonitis were excluded. In addition, 9 patients for whom
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 no initial HRCT images were available for review were also excluded. The remaining
7
8
9 51 patients with RA-ILD were included in this study.(Figure 1)
10

11 The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82)
12
13 years and 62 (range, 31–83) years, respectively. The median observation period and
14
15 AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.
16
17

18
19 During the observation period, 11 patients (22%) developed AE. The median age at
20
21 the onset of AE was 72 (range, 60–86) years. There were no statistically significant
22
23 differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period,
24
25 AE-free period, smoking habits, predicted forced vital capacity (%FVC) at diagnosis of
26
27 RA-ILD, and arterial oxygen pressure (PaO₂) at diagnosis of RA-ILD between the AE
28
29 and non-AE groups. Also there were no statistically significant differences in articular
30
31 disease activities (RF and DAS28-CRP) at the last visit (non-AE group) or the first AE
32
33 occurrence (AE group).
34
35
36
37
38
39
40
41
42

43 In the AE group, seven of 11 patients (64%) died of respiratory failure caused by
44
45 initial AE during the observation period. In the non-AE group, two of 40 patients (5%)
46
47 died of respiratory failure. Regarding death caused by respiratory failure, there was a
48
49 statistically significant difference in the mortality rate between the AE and non-AE
50
51 groups ($P=0.02$).
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Extra-articular manifestations except for ILD had been observed in 8 (16%) of 51
7
8
9 patients (pericarditis in 2 patients, pleuritis in 1, neuropathy in 2, cutaneous vasculitis in
10
11
12 2, glomerulonephritis in 1, rheumatoid nodule in 2). There were 3 (27%) patients with
13
14 extra-articular manifestations beyond ILD in AE group while 5 (13%) in non-AE group.
15
16
17 No significant difference in the incidence was observed between AE group and non-AE
18
19
20 group ($P=0.26$).
21
22
23
24
25

26 **HRCT pattern (Table 1)**

27
28
29 Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT.
30
31
32 HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%)
33
34 patients in the AE group demonstrated a UIP pattern. Interobserver agreement between
35
36 both radiologists was moderate (κ statistic test, $\kappa = 0.44$). The number of patients who
37
38 exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the
39
40
41 non-AE group.
42
43
44
45

46
47 When HRCT pattern was identified as a UIP pattern, the positive predictive value and
48
49 negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.
50
51
52
53
54

55 **Diagnostic accuracy of HRCT pattern for histopathological pattern (Table 2)**

1
2
3
4
5
6 Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis
7
8
9 revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and
10
11 an unclassified interstitial pneumonia in 1. The diagnostic accuracy of HRCT pattern for
12
13 histopathological pattern was evaluated in 21 histopathologically confirmed patients.
14
15 The sensitivity, specificity, positive predictive value, and negative predictive value of
16
17 HRCT for histopathological evidence of UIP is 41.7%, 100%, 100% and 56.3%,
18
19
20
21
22
23
24
25
26
27
28
29
20 respectively.

30 **Treatment for RA (Table 3)**

31
32 Of the 51 patients, 37 (73%) had received treatment for RA at their final visit
33
34 (non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) had
35
36 received corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10
37
38 (20%) received MTX and 17 (33%) received other drugs. There were 6 (55%) patients
39
40
41
42
43
44
45
46
47
48 who had received MTX in AE group while 4 (10%) patients in non-AE group and
49
50 statistically significant difference was observed between the groups ($P = 0.001$).

51
52 No patients had received MTX before in AE group while 2 in non-AE group had
53
54 received MTX during observation period but discontinued prior to final visit. Thus,
55
56
57
58
59
60 there were 6 (55%) patients who had experienced MTX treatment during observation

1
2
3
4
5
6 period in AE group while 6 (15%) patients in non-AE group. Median cumulative MTX
7
8
9 dose were 1952mg (384-3872) in 6 patients who had experienced MTX among AE
10
11 group and 802mg (32-2496) in 6 patients among non-AE group. No statistically
12
13 significant difference was observed between two groups in cumulative MTX dose
14
15
16
17
18 ($P=0.20$).
19

20
21 Articular disease activities (RF and DAS28-CRP) were compared between patients
22
23 who had received MTX at the last visit or at the first AE occurrence, and those who had
24
25 not. Median RF (range) were 112 IU/mL (16-334) and 284 IU/mL (6-2666) ($P=0.25$),
26
27
28 Median DAS28-CRP (range) were 1.94 (1.02-3.87) and 1.97 (1.02-5.13) ($P=0.78$),
29
30
31 respectively. There were no statistically significant differences in articular disease
32
33
34
35 activities.
36
37
38
39
40

41 **AE incidence**

42
43 The cumulative AE incidence in patients with RA-ILD is shown in Figure 2. The
44
45 5-year AE incidence was 11% [95% confidence interval (CI), 2–21%] in all patients,
46
47
48 33% (95% CI, 7–60%) in patients with a UIP pattern on HRCT (UIP pattern group) and
49
50
51 3% (95% CI, 0–9%) in patients with a non-UIP pattern on HRCT (non-UIP pattern
52
53
54
55 group). The AE incidence was significantly higher in UIP pattern group than in
56
57
58
59
60

1
2
3
4
5
6 non-UIP pattern group (log-rank test, $P = 0.018$). The overall 1-year AE incidence was
7
8
9 2.8%. The 1-year AE incidence was 6.5% in the UIP pattern group and 1.7 % in the
10
11
12 non-UIP pattern group.

13
14
15 Univariate analysis (Table 4) revealed that older age at ILD diagnosis [hazard ratio
16
17 (HR), 1.11; 95% CI, 1.02–1.21; $P = 0.01$], UIP pattern on HRCT (HR, 1.95; 95% CI,
18
19 1.07–3.63; $P = 0.03$), and MTX usage (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were
20
21
22 associated with the development of AE.
23
24

25 26 27 28 29 **Survival**

30
31
32 The overall survival of patients with RA-ILD and the survival according to HRCT
33
34 pattern subgroup are shown in Figure 3. The 5-year survival was 90% (95% CI,
35
36 81–98%) in all patients, 70% (95% CI, 44–94%) in the UIP pattern group and 97%
37
38 (95% CI, 92–100%) in the non-UIP pattern group. Survival was significantly poorer in
39
40
41 the UIP pattern group than in the non-UIP pattern group (log-rank test, $P = 0.04$).
42
43
44

45
46 The survival of AE group and non-AE group are shown in Figure 4., Significantly
47
48 worse survival was demonstrated in the AE group compared with the non-AE group
49
50 (log-rank test, $P = 0.001$).
51
52
53

54
55 Univariate analysis (Table 5) revealed that older age at ILD diagnosis (HR, 1.08;
56
57
58
59
60

1
2
3
4
5
6 95% CI, 0.99–1.17; $P = 0.057$) and UIP pattern on HRCT (HR, 1.74; 95% CI,
7
8
9 0.97–3.12; $P = 0.06$) showed a trend toward poor outcome, while AE (HR, 2.47; 95%
10
11
12 CI, 1.39–4.56; $P = 0.003$) was significantly associated with poor survival.
13

14 15 16 17 18 **DISCUSSION**

19
20 To our knowledge, the present study is the first one focusing on the risk factors and
21
22 prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence
23
24 was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern
25
26 was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern
27
28 on HRCT, MTX usage, and older age at ILD diagnosis were associated with the
29
30 development of AE. Furthermore, AE was a prognostic factor for poor survival.
31
32

33
34
35 The 1-year AE incidence among patients with IPF has been reported to be 5-19%,[17,
36
37 18] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP, 3.3 %
38
39 for CVD-ILD and 5.6 % for CVD-UIP.[4] In the present study, the 1-year AE incidence
40
41 among patients with a UIP pattern on HRCT was 6.5% and cumulative incidence was
42
43 significantly higher in UIP pattern group than in non-UIP pattern group. Therefore, a
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
UIP pattern on HRCT was associated with the development of AE. In a previous report
of small number of biopsy-proven cases, AE incidence among patients with RA-UIP
was reported to be 11.1%, similar to that among patients with IPF.[4] The correlation

1
2
3
4
5
6 between pathological and radiological UIP patterns has been established in IPF, but not
7
8
9 in RA-ILD.[19] In the present study, determination of a UIP pattern on HRCT exhibited
10
11
12 high specificity and positive predictive values for the detection of pathological UIP
13
14
15 pattern. Therefore, a typical UIP pattern on HRCT was assumed to be highly suggestive
16
17
18 of pathological UIP pattern in patients with RA-ILD as well as IPF.[15, 19] Collectively,
19
20
21 these results suggest that AE incidence in a subgroup with pathological UIP pattern or a
22
23
24 UIP pattern on HRCT may be higher than that in other patterns..

25
26 The present study also identified MTX usage was associated with the development of
27
28
29 AE. MTX is widely used to treat RA, while its toxicity affects the pulmonary system.
30
31
32 Diagnostic criteria for MTX-associated pneumonitis (MTX-pneumonitis) have been
33
34
35 proposed previously.[20] However, the specificity of the criteria has not been fully
36
37
38 examined yet. MTX-pneumonitis typically occurs with acute/subacute onset early in the
39
40
41 course of MTX treatment,[20-23] in particular, mostly within the first year[24] and
42
43
44 often presents a hypersensitive pneumonitis pattern. Patients with MTX-pneumonitis
45
46
47 generally respond to discontinuation of MTX or corticosteroid treatment and have a
48
49
50 favorable prognosis.[20-23] In the present study, 6 of 11 patients with AE had received
51
52
53 MTX, and 5 of the 6 patients had been treated for 3 or more years. The remaining
54
55
56 patient had been treated for 1 year. In all 6 patients, their respiratory conditions
57
58
59
60

1
2
3
4
5
6 progressively deteriorated despite discontinuation of MTX, and they poorly responded
7
8
9 to high-dose corticosteroid. Consequently, on the basis of inconsistency in terms of
10
11
12 MTX treatment duration and clinical features, we diagnosed these patients with AE of
13
14
15 RA-ILD.

16
17
18 Similar to AE in patients with IPF, the etiology of AE in RA-ILD is unknown;
19
20
21 however, several reports have suggested that AE may be a distinct manifestation of the
22
23
24 primary disease process, a distinct condition associated with undiagnosed infection, or a
25
26
27 subsequent acceleration of a fibroproliferative process caused by acute direct stress to
28
29
30 the lung.[1] In the present study, DAS28-CRP in all patients with AE showed low
31
32
33 disease activity or remission at the time of AE occurrence, and no significant difference
34
35
36 in articular disease activities was observed between AE group and non-AE group or
37
38
39 regardless of MTX treatment; therefore, RA activity may not be related to AE
40
41
42 occurrence, a finding similar to that of a previous study.[4] MTX possibly accelerates
43
44
45 the fibroproliferative process of RA-ILD. It was reported that MTX treatment was a risk
46
47
48 factor for RA-ILD progression.[12] For RA-ILD, MTX may be associated not only with
49
50
51 newly developing drug-induced pneumonitis but also with deterioration of pre-existing
52
53
54 ILD, including AE.

55
56 The present study found that patients with a UIP pattern on HRCT had significantly
57
58
59

1
2
3
4
5
6 poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic
7
8
9 factor for poor outcome. AE has a serious impact on the survival of patients with
10
11
12 IPF,[18] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with these
13
14
15 reports, the present study revealed that seven (64%) of 11 patients with AE died of
16
17
18 respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE
19
20
21 group was significantly poorer than that in the non-AE group. Therefore, AE is
22
23
24 suggested to be a predictor of poor prognosis in patients with RA-ILD as well as
25
26
27 patients with IPF.

28
29 Other prognostic factors in RA-ILD have been reported, including pathological
30
31
32 UIP,[25-29] UIP pattern on HRCT,[30] and age at RA-ILD onset.[31] In the present
33
34
35 study, pathological UIP could not be identified as prognostic factors because the number
36
37
38 of biopsy-proven cases were small. However, we observed similar results regarding UIP
39
40
41 pattern on HRCT and age at RA-ILD onset.

42
43
44 In our study, the average time between age at onset of RA and that of RA-ILD was
45
46
47 relatively shorter than some previous reports.[7, 8] However, Gabbay et al [11] reported
48
49
50 that nearly 60 % of the patients have interstitial lung disease in recent onset RA. In
51
52
53 another point of view, since the current authors' institution is regional referral center for
54
55
56 interstitial lung disease, referral bias might have increased the proportion of patients
57
58
59
60

1
2
3
4
5
6 with early-stage ILD, leading above results.
7

8
9 This study had several limitations. First, given its retrospective study design, it is
10
11 subject to several possible biases. For instance, selection and recall bias may exist.
12
13
14 Second, because of the relatively small sample size, it may be difficult to determine the
15
16 precise incidence of AE and the number of event (AE occurrence or death) was too
17
18 small to perform multivariate analysis. In this analysis, the incidence of extra-articular
19
20 manifestations beyond ILD and the proportion of current/former smokers in AE group
21
22 were higher than those in non-AE group (27% vs. 13% and 82% vs. 55%, respectively),
23
24
25 with no statistically significant differences. Such differences might be statistically
26
27 significant in a larger study. Therefore, larger studies are necessary to confirm our
28
29 results. Third, because the presence of a UIP pattern on HRCT had low sensitivity and
30
31 negative predictive value for the detection of pathologic UIP, it was likely that some
32
33 patients with a non-UIP pattern on HRCT may have had pathological UIP. HRCT
34
35 criteria used in our study do not aim to detect pathological UIP but to clinically
36
37 diagnose IPF and to exclude alternative diagnosis.[15] The frequency of honeycombing
38
39 on HRCT differs between RA-ILD and IPF, and some ILDs by other causes including
40
41 RA-ILD have some of findings inconsistent with UIP. Therefore, HRCT pattern in
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
RA-ILD may be more frequently interpreted as non-UIP pattern than that in IPF. In our

1
2
3
4
5
6 study, 2 of 5 patients with histopathological UIP in the absence of a UIP pattern on
7
8
9 HRCT develop AE. Thus, SLB may have to be considered for these patients to make
10
11 pathological diagnosis and to predict AE. Finally, RA includes a variety of
12
13 manifestations. Therefore, other comorbidities may have affected the results.
14
15

16
17 In conclusion, older age at ILD diagnosis, UIP pattern on HRCT and MTX usage are
18
19 associated with the development of AE in patients with RA-ILD. Furthermore, the
20
21 mortality associated with AE is high and AE is prognostic factor for poor outcome.
22
23
24
25
26 Larger prospective studies investigating acute exacerbations in RA-ILD are indicated.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENT

We appreciate the help of Dr. T. Tsuchiya in the statistical advice.

This study was partly supported by the Diffuse Lung Diseases Research Group from the ministry of Health, Labour and Welfare, Japan.

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S., and K.C. revised the paper.

All authors approved the paper.

Competing interest:

All authors do not have any personal or financial support or involvement with organization(s) that have financial interest in the subject matter, or any competing interest.

Funding:

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this study (approval number 24-191) and waived patient approval or informed consent because the study involved a retrospective review of patient records and images.

Copyright:

I [*Yutaro Nakamura*] the Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs, other illustrative material, video, film or any other material howsoever submitted by the Contributor(s) at

1
2
3
4
5
6 any time and related to the Contribution (“the Contribution”) have the right to grant on
7
8
9 behalf of all authors and do grant on behalf of all authors, a licence to the BMJ
10
11
12 Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be
13
14 published in BMJ Open and any other BMJ Group products and to exploit all subsidiary
15
16
17 rights, as set out in the licence
18
19
20
21
22

23 **Data sharing**

24
25
26 No unpublished data from the study are available.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.
2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. *Histopathology.* 2011;58:525-30.
3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.
4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.
5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.
6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.* 1998;19:667-85.
7. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis.* 2003;62:722-7.
8. Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and

- 1
2
3
4
5
6 their impact on outcome. *Rheumatology (Oxford)*. 2013;52:99-110.
7
8
9 9. Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain:
10
11 occurrence of extra-articular manifestations and estimates of disease severity. *Ann*
12
13 *Rheum Dis*. 2003;62:897–900.
14
15
16
17 10. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with
18
19 rheumatoid arthritis as assessed by high resolution computed tomography, chest
20
21 radiography, and pulmonary function tests. *Thorax*. 2001;56:622–7.
22
23
24
25
26 11. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset
27
28 rheumatoid arthritis. *Am J Respir Crit Care Med*. 1997;156:528–35.
29
30
31
32 12. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung
33
34 disease in rheumatoid arthritis. *Arch Intern Med*. 2008;168:159–66.
35
36
37
38 13. Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on
39
40 high-resolution computed tomography in patients with early versus longstanding
41
42 rheumatoid arthritis. *J Rheumatol*. 2008;35:1513–21.
43
44
45
46 14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association
47
48 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*.
49
50 1988;31:315-24.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 15. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on
7
8 Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:
9
10 idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and
11
12 management. *Am J Respir Crit Care Med.* 2011;183:788-824.
13
14
15
16
17 16. American Thoracic Society/European Respiratory Society International
18
19 Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
20
21 *Am J Respir Crit Care Med.* 2002;165:277-304.
22
23
24
25
26 17. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary
27
28 fibrosis. *Chest.* 2007;132:1652-8.
29
30
31
32 18. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary
33
34 fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356-63.
35
36
37
38 19. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung
39
40 disease: the relevance of histopathologic and radiographic pattern. *Chest.*
41
42 2009;136:1397-405.
43
44
45
46 20. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic,
47
48 and histopathologic features of methotrexate-associated lung injury in patients with
49
50 rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum.*
51
52 1997;40:1829-37.
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 21. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced
7
8 lung injury in patients with rheumatoid arthritis. A multicenter, case-control study.
9
10 Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.
11
12
13
14 22. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in
15
16 patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.*
17
18 2009;68:1100-4.
19
20
21
22 23. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the
23
24 literature and histopathological findings in nine patients. *Eur Respir J.*
25
26 2000;15:373-81.
27
28
29
30 24. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in
31
32 rheumatoid arthritis. *Rheumatology (Oxford).* 2004;43:143-7.
33
34
35
36 25. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis
37
38 of 54 biopsy-proven cases. *Respir Med.* 2012;106:1164-9.
39
40
41
42 26. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am*
43
44 *Rev Respir Dis.* 1985;131:770-7.
45
46
47
48 27. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of
49
50 rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2005;127:2019-27.
51
52
53
54 28. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern
55
56
57
58
59
60

- 1
2
3
4
5
6 as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int.* 2005;26:121-5.
7
8
9 29. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia:
10
11 idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care*
12
13 *Med.* 2007;175:705-11.
14
15
16
17 30. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in
18
19 rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.*
20
21 2010;35:1322-8.
22
23
24
25
26 31. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study).
27
28
29 Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an
30
31 inception cohort. *Rheumatology (Oxford).* 2010;49:1483-9.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Clinical characteristics

| Characteristics | Total N = 51 (100) | Non-AE group [#] N = 40 (78) | AE group [¶] N = 11 (22) | P value ⁺ |
|---|-----------------------|--|--------------------------------------|----------------------|
| Median age, years (range) | | | | |
| at RA diagnosis | 61 (28-82) | 60 (28-81) | 65 (42-82) | 0.15 |
| at ILD diagnosis | 62 (31-83) | 62 (31-83) | 69 (58-83) | 0.15 |
| at AE onset | | | 72 (60-86) | |
| Sex Male, n (%) | 29 (57) | 23 (58) | 6 (55) | 0.86 |
| Observation period, years (range) | 8.5 (1-17) | 9 (1-17) | 6.4 (2-14) | 0.45 |
| AE-free period, years (range) | 7(1-17) | 9 (1-17) | 6 (2-14) | 0.19 |
| Smoking habit, n (%) | | | | |
| Never | 20 (39) | 18 (45) | 2 (18) | |
| Former | 24 (47) | 16 (40) | 8 (73) | 0.15 |
| Current | 7 (14) | 6 (15) | 1 (9) | |
| RF, IU/mL (range)* | 197 (6-2666) | 189 (6-2666) | 205 (39-2530) | 0.47 |
| DAS28-CRP, score (range)* | 1.95(1.02-5.13) | 2.53(1.02-5.13) | 1.82(1.47-2.3) | 0.62 |
| PaO ₂ , torr (range) | 82.4 (67-109) | 81 (67-102) | 85.8 (74-109) | 0.19 |
| %FVC, % (range) | 91.1 (50.6-130) | 87.5 (51-130) | 95 (60-125) | 0.38 |
| HRCT pattern, n (%) | | | | |
| UIP pattern | 14 (27) | 8 (20) | 6 (55) | |
| non-UIP pattern | 37 (73) | 32 (80) | 5 (45) | 0.02 [§] |
| Death during observation period, n (%) | | | | |
| caused by respiratory failure | 9 (18) | 2 (5) | 7 (64) | |
| caused by other diseases | 3 (6) | 3 (8) | 0 (0) | 0.02 [§] |

Data are presented as n (%), median (range). AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; RF, rheumatoid factor; DAS28-CRP, disease activity score 28 CRP; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶]AE group, patients who developed AE during observation period.

⁺Non-AE group vs AE group

[§] $p < 0.05$

* at the first AE occurrence (AE group) or the last visit (non-AE group).

When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

1
2
3
4
5 In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of
6 respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding
7 and 2 of unknown causes.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 2 Diagnostic accuracy of HRCT pattern for histopathological pattern in 21 histopathologically confirmed patients.

| | Histopathological pattern | | Total |
|-------------------------|---------------------------|---------------|-------|
| | UIP | Other pattern | |
| UIP pattern on HRCT | 5 | 0 | 5 |
| non-UIP pattern on HRCT | 7 | 9 | 16 |
| Total | 12 | 9 | 21 |

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

The sensitivity, specificity, positive predictive value, and negative predictive value of HRCT for histopathological evidence of UIP is 41.7%, 100%, 100% and 56.3%, respectively.

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

| | Total N = 51 | non-AE group ⁺ N = 40 (78%) | AE group [§] N = 11 (22%) | P value |
|----------------------------------|-----------------|---|---------------------------------------|--------------------|
| Treatment, yes | 37 (73) | 27(68) | 10 (91) | 0.12 |
| Corticosteroid | 29 (57) | 22 (55) | 7 (64) | 0.61 |
| Immunosuppressant except for MTX | 17 (33) | 14 (35) | 3 (27) | 0.63 |
| MTX | 10 (20) | 4 (10) | 6 (55) | 0.001 [*] |
| Other drugs | 17 (33) | 13 (33) | 4 (36) | 0.81 |

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cyclophosphamide (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

⁺ Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

^{*} $p < 0.05$

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 1.03 | 0.97-1.10 | 0.35 |
| Age at ILD diagnosis | 1.11 | 1.02-1.21 | 0.01 ⁺ |
| Sex, male | 0.90 | 0.49-1.69 | 0.73 |
| Smoking habit, yes | 1.60 | 0.81-4.10 | 0.19 |
| UIP pattern on HRCT, yes | 1.95 | 1.07-3.63 | 0.03 ⁺ |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.12 | 0.14 |
| %FVC at ILD diagnosis | 1.02 | 0.99-1.06 | 0.24 |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 0.97 | 0.53-1.92 | 0.94 |
| Immunosuppressant except for MTX | 0.76 | 0.35-1.41 | 0.39 |
| MTX | 3.04 | 1.62-6.02 | 0.001 ⁺ |
| Other drugs | 0.98 | 0.50-1.80 | 0.96 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 0.98 | 0.93-1.04 | 0.48 |
| Age at ILD diagnosis | 1.08 | 0.99-1.17 | 0.057 |
| Sex, male | 1.14 | 0.63-2.22 | 0.67 |
| Smoking habit, yes | 1.70 | 0.87-4.35 | 0.13 |
| UIP pattern on HRCT, yes | 1.74 | 0.97-3.12 | 0.06 |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.11 | 0.15 |
| %FVC at ILD diagnosis | 1.01 | 0.98-1.04 | 0.55 |
| AE during observation period, yes | 2.47 | 1.39-4.56 | 0.003 ⁺ |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 1.23 | 0.67-2.65 | 0.52 |
| Immunosuppressant except for MTX | 0.69 | 0.32-1.27 | 0.25 |
| MTX | 1.44 | 0.67-2.68 | 0.31 |
| Other drugs | 0.76 | 0.36-1.41 | 0.40 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Figure legends

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were excluded, and 51 patients with chronic course of RA-ILD were included. During observation period, 11 patients developed AE.

RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank $p=0.018$).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank $p=0.04$).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

1
2
3
4
5
6 Figure 4. Survival of AE group and non-AE group.
7

8
9 Patients who developed AE during observation periods (AE group) had a significantly
10
11 worse survival compared with those who did not (non-AE group) (log-rank $p=0.001$).
12
13

14
15 AE, acute exacerbation.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




FIGURE 1.

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were excluded, and 51 patients with chronic course of RA-ILD were included. During observation period, 11 patients developed AE.

RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.

80x160mm (300 x 300 DPI)




FIGURE 2.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank $p=0.018$).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
80x80mm (300 x 300 DPI)




FIGURE 3.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank $p=0.04$).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
80x80mm (300 x 300 DPI)




FIGURE 4.

Figure 4. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly worse survival compared with those who did not (non-AE group) (log-rank $p=0.001$).

AE, acute exacerbation.
80x80mm (300 x 300 DPI)

1
2
3
4
5
6 **Title:** Acute exacerbation in rheumatoid arthritis associated interstitial lung disease
7
8
9
10

11
12 **Authors:**

13
14 Hironao Hozumi, M.D., Ph.D.¹

15
16 Yutaro Nakamura, M.D., Ph.D.¹

17
18 Takeshi Johkoh, M.D., Ph.D.²

19
20 Hiromitsu Sumikawa, M.D., Ph.D.³

21
22 Thomas V. Colby, M.D.⁴

23
24 Masato Kono, M.D, Ph.D.¹

25
26 Dai Hashimoto, M.D., Ph.D.¹

27
28 Noriyuki Enomoto, M.D., Ph.D.¹

29
30 Tomoyuki Fujisawa, M.D., Ph.D.¹

31
32 Naoki Inui, M.D., Ph.D.¹

33
34 Takafumi Suda, M.D., Ph.D.¹

35
36 Kingo Chida, M.D., Ph.D.¹

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 **Affiliations:**

53
54
55 ¹Second division, Department of Internal Medicine, Hamamatsu University School of
56
57
58
59
60

1
2
3
4
5
6 Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan
7

8
9 ²Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public
10
11 School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan
12
13

14
15 ³Diagnostic and Interventional Radiology, Osaka University Graduate School of
16
17 Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
18
19

20
21 ⁴Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East
22
23 Shea Boulevard Scottsdale, AZ 85259, USA
24
25
26
27
28

29 **Corresponding author:**
30

31 Yutaro Nakamura, M.D., Ph.D.
32
33

34
35 Second division, Department of Internal Medicine, Hamamatsu University School of
36
37 Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan
38
39

40 Tel: 81-53-435-2263, Fax: 81-53-435-2354
41
42

43 E-mail address: nakayuta@hama-med.ac.jp
44
45
46
47
48

49 **Keywords:** Acute exacerbation, interstitial lung disease, risk factor, prognostic factor,
50
51
52
53
54
55
56
57
58
59
60
rheumatoid arthritis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word count paper: [3494382](#)

Word count abstract: [27980](#)

For peer review only

ABSTRACT

Background Acute exacerbation (AE) in idiopathic pulmonary fibrosis is characterised by acute deterioration of respiratory status and the mortality is high.

Recently, AE was reported in patients with other interstitial lung diseases, especially rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives To investigate the risk factors and prognosis associated with AE in patients with RA-ILD.

Design A retrospective case-control study.

Setting A single academic hospital.

Participants 51 consecutive patients diagnosed with RA-ILD between 1995 and 2012.

All patients fulfilled the diagnostic criteria of the American College of Rheumatology for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures Overall survival and cumulative AE incidence were analysed using Kaplan–Meier method. Cox hazards analysis was used to determine significant variables associated with AE occurrence and survival status.

Results A total of 11 patients (22%) developed AE, with an overall 1-year incidence of 2.8%. Univariate analysis revealed that higher-older age at ILD diagnosis [hazard

1
2
3
4
5
6 ratio (HR), 1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], usual interstitial
7
8
9 pneumonia (UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and-
10
11 ~~treatment with~~ methotrexate usage (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were ~~risk-~~
12
13 ~~factors for~~associated with AE. Of 11 patients who developed AE during observation
14
15
16
17
18 period, seven (64%) died of initial AE. In survival, AE was a prognostic factor for poor
19
20
21 outcome (HR, 2.47; 95% CI, 1.39–4.56; $P = 0.003$).
22

23 **Conclusions** In patients with RA-ILD, ~~old~~high age at ILD diagnosis, UIP pattern on
24
25
26 HRCT and ~~treatment with~~ methotrexate usage are ~~risk factors~~associated with ~~for the~~
27
28
29 development of AE. Furthermore, AE has a serious impact on their survival.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis (IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with RA-ILD?

Key messages;

In patients with RA-ILD, ~~higher older~~ age at ILD diagnosis, UIP pattern on HRCT, and ~~treatment with~~ methotrexate usage are ~~risk factors for~~ associated with AE occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE has a serious impact on the survival of patients with RA-ILD.

Given its retrospective study design, it is subject to several possible biases. Therefore, prospective studies are necessary to confirm our results.

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterised by acute deterioration in respiratory status, with newly developed bilateral ground-glass opacities and/or consolidations on chest radiographs or computed tomography scans. It should be in the absence of other alternative causes such as infection, left heart failure, pulmonary embolism, orand an identifiable cause of acute lung injury. AE reportedly occurs not only in patients with IPF but also in patients with other interstitial lung diseases (ILDs), including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital mortality associated with AE in patients with CVD-ILD was demonstrated to be as high as that in patients with IPF,[1-4] suggesting that AE may be associated with poor prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown etiology that primarily involves joints.[5] ILD is one of common extra-articular manifestations.[6, 7] The reported prevalence is variable (1–58%) and depends on the detection and diagnostic method, or the selected population.[8-13] We and Park *et al* previously reported that RA-associated ILD (RA-ILD) was the most common

1
2
3
4
5
6 CVD-ILD associated with AE.[3, 4] However the risk factors and prognosis associated
7
8
9 with AE in patients with RA-ILD are not clarified.

10
11 In the present study, we attempted to elucidate the cumulative incidence of AE, its
12
13 risk factors, and prognostic factors in patients with RA-ILD.
14
15
16
17
18
19

20 MATERIALS AND METHODS

21 Subjects

22
23
24
25
26 Institutional review board in Hamamatsu University School of Medicine approved
27
28 this study (approval number 24-191) and waived patient approval or informed consent
29
30 because the study involved a retrospective review of patient records and images. We
31
32 retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995
33
34 and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the
35
36 diagnostic criteria of the American College of Rheumatology for RA.[14] Patients with
37
38 other coexisting CVD were excluded. In addition, because our aim was to investigate
39
40 the features of AE among patients with a chronic course of RA-ILD, patients with no
41
42 evidence of chronic ILD were also excluded. [Chronic ILD was defined as the ILD](#)
43
44 [which had been stable for over 3 months.](#)
45
46
47
48
49
50
51
52
53

54
55 ILD was diagnosed on the basis of clinical presentation, pulmonary function tests,
56
57
58
59
60

1
2
3
4
5
6 high resolution computed tomography (HRCT) findings, and lung biopsy findings.
7
8
9 HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities
10
11
12 and honeycomb patterns were interpreted and defined as ILD by a consensus between
13
14 radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and
15
16 bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to
17
18 definitively diagnose ILD or rule out other diseases. The patients with environmental
19
20 exposures, suspected of drug induced pneumonia (ILD developed within 1 year after
21
22 initiation of new drug), or with other known causes of ILD were excluded after
23
24 considering exposure history and the findings of appropriate tests and histopathological
25
26 examinations.
27
28
29
30
31
32
33
34
35
36
37

38 **Acute exacerbation (AE)**

39
40 AE was defined using recently proposed criteria[1] that were slightly modified for
41
42 adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or
43
44 development of dyspnea within 30 days of onset, new bilateral ground-glass
45
46 abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern
47
48 on HRCT, no evidence of pulmonary infection on negative respiratory culture,
49
50 including endotracheal aspirate or bronchoalveolar lavage, and serological test results
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 for respiratory pathogens, and exclusion of alternative causes such as left heart failure,
7
8
9 pulmonary embolism, and-or an identifiable cause of ~~acute~~-lung injury. Patients with AE
10
11 were required to meet all five criteria. In our institution, cultures of sputum, blood, urine,
12
13 and bronchoalveolar lavage fluid, and serological tests examined for mycobacteria,
14
15 fungi, bacteria, and some viruses were routinely performed. Echocardiography and, if
16
17 necessary, CT scanning with intravenous contrast were performed to rule out left heart
18
19 failure or pulmonary thromboembolism. The patients who developed acute pneumonitis
20
21 within 1 year after initiation of drug for RA were excluded because drug-induced
22
23 pneumonitis was not completely ruled out. Patients who did or did not develop AE
24
25 during the observation period were classified into the AE and non-AE groups,
26
27 respectively.
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Data collection**

42
43 All clinical and laboratory data were collected from medical records. The observation
44
45 period was calculated from the date of diagnosis of RA-ILD to the last visit. The
46
47 AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis
48
49 and the first AE occurrence (AE group) or the last visit (non-AE group).
50
51
52
53
54
55
56
57
58
59
60

Review of radiographic findings

HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were reconstructed by a high spatial frequency algorithm, and were displayed at window settings appropriate for viewing the lung parenchyma (window level, -600 to -800 Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were randomised and reviewed independently by two expert chest radiologists (with 23 and 12 years of experience) who were unaware of the related clinical information. Interobserver agreement was classified as follows: poor ($\kappa = 0-0.20$), fair ($\kappa = 0.21-0.40$), moderate ($\kappa = 0.41-0.60$), good ($\kappa = 0.61-0.80$) and excellent ($\kappa = 0.81-1.00$).

RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a non-UIP pattern according to recent guideline with slight modification.[15] Briefly, a UIP pattern on HRCT was characterised by subpleural and basal predominance, reticular abnormalities, honeycombing with or without traction bronchiectasis and the absence of features listed as inconsistent with a UIP pattern, including upper or mid-lung predominance, peribronchovascular predominance, extensive ground glass abnormalities, profuse micronodules, discrete cysts, diffuse mosaic

1
2
3
4
5
6 attenuation/air-trapping and consolidation in bronchopulmonary segment(s)/lobe(s). If
7
8
9 the HRCT pattern did not meet the criteria, it was interpreted as a non-UIP pattern.
10
11
12 Disagreements regarding HRCT interpretation were resolved by a consensus between
13
14
15 both radiologists.
16
17
18
19

20 **Review of histopathological findings**

21
22
23 SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was
24
25
26 originally made in all cases on the basis of histological features evaluated by a lung
27
28
29 pathologist at our hospital, correlated with the clinical and radiological findings. All
30
31
32 SLB specimens were also reviewed by a second lung pathologist with 36 years of
33
34
35 experience. The histological classification of interstitial pneumonia was based on the
36
37
38 consensus statement criteria for idiopathic interstitial pneumonias,[16] and histological
39
40
41 patterns that could not be classified according to the criteria were categorised as
42
43
44 unclassified interstitial pneumonia.
45
46
47
48

49 **Statistical analysis**

50
51
52 All values are expressed as median (range) or number (%). The Mann-Whitney U test
53
54
55 was used for nonparametric comparisons involving continuous data, whereas Fisher's
56
57
58

1
2
3
4
5
6 exact test was used for comparing categorical data. Interobserver agreement on HRCT
7
8
9 pattern was analyzed using the κ statistic test. Survival was evaluated using the
10
11
12 Kaplan–Meier method and the log-rank test according to observation period. The
13
14
15 cumulative AE incidence was obtained from a Kaplan–Meier survival curve by treating
16
17
18 AE as the death variable according to AE free period. The 1-year AE incidence was
19
20
21 based on person year method and calculated by dividing the number of patients who
22
23
24 developed AE by the total of AE-free period (year) of all the patients. Cox hazards
25
26
27 analysis was used to determine significant variables associated with survival and AE
28
29
30 occurrence. In all analyses, $P < 0.05$ was considered statistically significant. All data
31
32
33 were analysed using commercially available software (JMP version 9.0.3a, SAS
34
35
36 Institute Inc, Cary, NC, USA).

40 RESULTS

43 Patient characteristics (Table 1)

44
45
46 A total of 82 patients with RA-ILD were identified from medical records at
47
48
49 Hamamatsu University Hospital. From these, 11 patients with other coexisting CVDs, 8
50
51
52 with no evidence of chronic ILD and an initial acute/subacute course of ILD, and 3
53
54
55 suspected of drug-induced pneumonitis were excluded. In addition, 9 patients for whom
56
57
58
59
60

1
2
3
4
5
6 no initial HRCT images were available for review were also excluded. The remaining
7
8
9 51 patients with RA-ILD were included in this study.(Figure 1)
10

11 The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82)
12
13 years and 62 (range, 31–83) years, respectively. The median observation period and
14
15 AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.
16
17

18
19
20 During the observation period, 11 patients (22%) developed AE. The median age at
21
22 the onset of AE was 72 (range, 60–86) years. There were no statistically significant
23
24 differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period,
25
26 AE-free period, smoking habits, predicted forced vital capacity (%FVC) at diagnosis of
27
28 RA-ILD, and arterial oxygen pressure (PaO₂) at diagnosis of RA-ILD between the AE
29
30 and non-AE groups. Also there were no statistically significant differences in articular
31
32 disease activities (RF and DAS28-CRP) at the last visit (non-AE group) or the first AE
33
34 occurrence (AE group).
35
36
37
38
39
40
41
42

43 In the AE group, seven of 11 patients (64%) died of [respiratory failure caused by](#)
44
45 initial AE during the observation period. In the non-AE group, ~~2~~[two](#) of 40 patients
46
47 (5%) died of respiratory failure. [Regarding death caused by respiratory failure, t](#)There
48
49
50 was a statistically significant difference in the mortality rate between the AE and
51
52
53 non-AE groups ([P=0.02](#)).
54
55
56
57
58
59
60

1
2
3
4
5
6 Extra-articular manifestations except for ILD had been observed in 8 (16%) of 51
7
8
9 patients (pericarditis in 2 patients, pleuritis in 1, neuropathy in 2, cutaneous vasculitis in
10
11
12 2, glomerulonephritis in 1, rheumatoid nodule in 2). There was-were 3 (27%) patients
13
14 with extra-articular manifestations beyond ILD in AE group while 5 (13%) in non-AE
15 group. No significant difference in the incidence was observed between AE group and
16
17
18 non-AE group (27% vs. 13%, P=0.26).
19
20
21
22
23
24
25

26 **HRCT pattern (Table 1)**

27
28
29 Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT.
30
31
32 HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%)
33
34
35 patients in the AE group demonstrated a UIP pattern. Interobserver agreement between
36
37
38 both radiologists was moderate (κ statistic test, $\kappa = 0.44$). The number of patients who
39
40
41 exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the
42
43
44 non-AE group.
45

46
47 When HRCT pattern was identified as a UIP pattern, the positive predictive value and
48
49
50 negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.
51
52
53
54

55 **Diagnostic accuracy of HRCT pattern for histopathological pattern (Table 2)**

1
2
3
4
5
6 Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis
7
8
9 revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and
10
11
12 an unclassified interstitial pneumonia in 1. The diagnostic accuracy of HRCT pattern for
13
14
15 histopathological pattern was evaluated in 21 histopathologically confirmed patients.
16
17
18 ~~When the pattern was identified as a UIP pattern on HRCT, the~~ The sensitivity, specificity,
19
20
21 positive predictive value, and negative predictive value ~~of HRCT for detecting~~
22
23
24 histopathological ~~evidence of~~ UIP ~~was is~~ 41.7%, 100%, 100% and 56.3%, respectively.
25
26
27
28

29 Treatment for RA (Table 3)

30
31
32 Of the 51 patients, 37 (73%) had received treatment for RA at their final visit
33
34
35 (non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) had
36
37
38 received corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10
39
40
41 (20%) received MTX and 17 (33%) received other drugs. There were 6 (55%) patients
42
43
44 who had received MTX in AE group while 4 (10%) patients in non-AE group and
45
46
47 statistically significant difference was observed between the groups ($P = 0.001$).
48

49
50 No patients had received MTX before in AE group while 2 in non-AE group had
51
52 received MTX during observation period but discontinued prior to final visit. Thus,
53
54
55 there were 6 (55%) patients who had experienced MTX treatment during observation
56
57
58
59
60

1
2
3
4
5
6 period in AE group while 6 (15%) patients in non-AE group. Median cumulative MTX
7
8
9 dose were 1952mg (384-3872) in 6 patients who had experienced MTX among AE
10
11 group and 802mg (32-2496) in 6 patients among non-AE group. No statistically
12
13 significant difference was observed between two groups in cumulative MTX dose
14
15
16
17
18 ($P=0.20$).
19

20
21 Articular disease activities (RF and DAS28-CRP) were compared between patients
22
23 who had received MTX at the last visit or at the first AE occurrence, and those who had
24
25 not. Median RF (range) were 112 IU/mL (16-334) and 284 IU/mL (6-2666) ($P=0.25$),
26
27
28 Median DAS28-CRP (range) were 1.94 (1.02-3.87) and 1.97 (1.02-5.13) ($P=0.78$),
29
30
31 respectively. There were no statistically significant differences in articular disease
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
activities.

AE incidence

61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
The cumulative AE incidence in patients with RA-ILD is shown in Figure 2. The
5-year AE incidence was 11% [95% confidence interval (CI), 2–21%] in all patients,
33% (95% CI, 7–60%) in patients with a UIP pattern on HRCT (UIP pattern group) and
3% (95% CI, 0–9%) in patients with a non-UIP pattern on HRCT (non-UIP pattern
group). The AE incidence was significantly higher in UIP pattern group than in

1
2
3
4
5
6 non-UIP pattern group (log-rank test, $P = 0.018$). The overall 1-year AE incidence was
7
8
9 2.8%. The 1-year AE incidence was 6.5% in the UIP pattern group and 1.7 % in the
10
11
12 non-UIP pattern group.

13
14 Univariate analysis (Table 4) revealed that ~~higher older~~ age at ILD diagnosis [hazard
15
16 ratio (HR), 1.11; 95% CI, 1.02–1.21; $P = 0.01$], UIP pattern on HRCT (HR, 1.95; 95%
17
18 CI, 1.07–3.63; $P = 0.03$), and ~~treatment with-MTX usage~~ (HR, 3.04; 95% CI, 1.62–6.02;
19
20 $P = 0.001$) were associated with the development of AE.~~significant risk factors for AE-~~
21
22
23
24
25
26
27 ~~occurrence.~~

32 Survival

33
34
35 The overall survival of patients with RA-ILD and the survival according to HRCT
36
37
38 pattern subgroup are shown in Figure 3.
39

40
41 The 5-year survival was 90% (95% CI, 81–98%) in all patients, 70% (95% CI, 44–94%)
42
43
44 in the UIP pattern group and 97% (95% CI, 92–100%) in the non-UIP pattern group.

45
46
47 Survival was significantly poorer in the UIP pattern group than in the non-UIP pattern
48
49
50 group (log-rank test, $P = 0.04$).

51
52 The survival of AE group and non-AE group are shown in Figure 4.~~In addition,~~
53
54
55
56 Significantly worse survival was demonstrated in the AE group compared with the
57
58
59
60

1
2
3
4
5
6 non-AE group (Figure 4, log-rank test, $P = 0.001$).

7
8
9 Univariate analysis (Table 5) revealed that higher-older age at ILD diagnosis (HR,
10
11
12 1.08; 95% CI, 0.99–1.17; $P = 0.057$) and UIP pattern on HRCT (HR, 1.74; 95% CI,
13
14
15 0.97–3.12; $P = 0.06$) showed a trend toward poor outcome, while AE (HR, 2.47; 95%
16
17
18 CI, 1.39–4.56; $P = 0.003$) was significantly associated with poor survival.

21 22 23 **DISCUSSION**

24
25
26 To our knowledge, the present study is the first one focusing on the risk factors and
27
28
29 prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence
30
31
32 was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern
33
34
35 on HRCT, MTX treatment-usage, and higher-older age at ILD diagnosis were associated
36
37
38 with the development of significant risk factors for AE. Furthermore, AE was a
39
40
41 prognostic factor for poor survival.

42
43
44 The 1-year AE incidence among patients with IPF has been reported to be 5-19%,[17,
45
46
47 18] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP, 3.3 %
48
49
50 for CVD-ILD and 5.6 % for CVD-UIP.[4] In the present study, the 1-year AE incidence
51
52
53 among patients with a UIP pattern on HRCT was 6.5% and cumulative incidence was
54
55
56 significantly higher in UIP pattern group than in non-UIP pattern group.

1
2
3
4
5
6 FurthermoreTherefore, a UIP pattern on HRCT was associated with the development of
7
8 a risk factor forAE. In a previous report of small number of biopsy-proven cases, AE
9
10 incidence among patients with RA-UIP was reported to be 11.1%, similar to that among
11
12 patients with IPF.[4] The correlation between pathological and radiological UIP patterns
13
14 has been established in IPF, but not in RA-ILD.[19] In the present study, determination
15
16 of a UIP pattern on HRCT exhibited high specificity and positive predictive values for
17
18 the detection of pathological UIP pattern. Therefore, a typical UIP pattern on HRCT was
19
20 assumed to be highly suggestive of pathological UIP pattern in patients with RA-ILD as
21
22 well as IPF.[15, 19] Collectively, these results suggest that AE incidence in a subgroup
23
24 with pathological UIP pattern or a UIP pattern on HRCT may be higher than that in
25
26 other patterns..
27
28
29
30
31
32
33
34
35
36

37
38 The present study also identified MTX treatment usage was associated with the
39
40 development of as a risk factor forAE. MTX is widely used to treat RA, while its
41
42 toxicity affects the pulmonary system. Diagnostic criteria for MTX-associated
43
44 pneumonitis (MTX-pneumonitis) have been proposed previously.[20] However, the
45
46 specificity of the criteria has not been fully examined yet. MTX-pneumonitis typically
47
48 occurs with acute/subacute onset early in the course of MTX treatment,[20-23] in
49
50 particular, mostly within the first year[24] and often presents a hypersensitive
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 pneumonitis pattern. Patients with MTX-pneumonitis generally respond to
7
8
9 discontinuation of MTX or corticosteroid treatment and have a favorable
10
11
12 prognosis.[20-23] In the present study, 6 of 11 patients with AE had received MTX, and
13
14
15 5 of the 6 patients had been treated for 3 or more years. The remaining patient had been
16
17
18 treated for 1 year. In all 6 patients, their respiratory conditions progressively
19
20
21 deteriorated despite discontinuation of MTX, and they poorly responded to high-dose
22
23
24 corticosteroid. Consequently, on the basis of inconsistency in terms of MTX treatment
25
26
27 duration and clinical features, we diagnosed these patients with AE of RA-ILD.

28
29 Similar to AE in patients with IPF, the etiology of AE in RA-ILD is unknown;
30
31
32 however, several reports have suggested that AE may be a distinct manifestation of the
33
34
35 primary disease process, a distinct condition associated with undiagnosed infection, or a
36
37
38 subsequent acceleration of a fibroproliferative process caused by acute direct stress to
39
40
41 the lung.[1] In the present study, DAS28-CRP in all patients with AE showed low
42
43
44 disease activity or remission at the time of AE occurrence, and no significant difference
45
46
47 in articular disease activities was observed between AE group and non-AE group or
48
49
50 regardless of MTX treatment; therefore, RA activity may not be related to AE
51
52
53 occurrence, a finding similar to that of a previous study.[4] MTX possibly accelerates
54
55
56 the fibroproliferative process of RA-ILD. It was reported that MTX treatment was a risk
57
58
59
60

1
2
3
4
5
6 factor for RA-ILD progression.[12] For RA-ILD, MTX may be associated not only with
7
8 newly developing drug-induced pneumonitis but also with deterioration of pre-existing
9
10
11
12 ILD, including AE.

13
14 The present study found that patients with a UIP pattern on HRCT had significantly
15
16 poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic
17
18 factor for poor outcome. AE has a serious impact on the survival of patients with
19
20
21
22
23 IPF,[18] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with these
24
25 reports, the present study revealed that seven (64%) of 11 patients with AE died of
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE
group was significantly poorer than that in the non-AE group. Therefore, AE is
suggested to be a predictor of poor prognosis in patients with RA-ILD as well as
patients with IPF.

Other prognostic factors in RA-ILD have been reported, including pathological
UIP,[25-29] UIP pattern on HRCT,[30] and age at RA-ILD onset.[31] In the present
study, pathological UIP could not be identified as prognostic factors because the number
of biopsy-proven cases were small. However, we observed similar results regarding UIP
pattern on HRCT and age at RA-ILD onset.

In our study, the average time between age at onset of RA and that of RA-ILD was

1
2
3
4
5
6 relatively shorter than some previous reports.[7, 8] However, Gabbay et al [11] reported
7
8
9 that nearly 60 % of the patients have interstitial lung disease in recent onset RA. In
10
11
12 another point of view, since the current authors' institution is regional referral center for
13
14
15 interstitial lung disease, referral bias might have increased the proportion of patients
16
17
18 with early-stage ILD, leading above results.
19

20
21 This study had several limitations. First, given its retrospective study design, it is
22
23
24 subject to several possible biases. For instance, selection and recall bias may exist.
25
26
27 Second, because of the relatively small sample size, it may be difficult to determine the
28
29
30 precise incidence of AE and the number of event (AE occurrence or death) was too
31
32 small to perform multivariate analysis. [In this analysis, the incidence of extra-articular](#)
33
34 [manifestations beyond ILD and the proportion of current/former smokers in AE group](#)
35
36 [were higher than those in non-AE group \(27% vs. 13% and 82% vs. 55%, respectively\).](#)
37
38 [with no statistically significant differences. Such differences might be statistically](#)
39
40 [significant in a larger study.](#) Therefore, larger studies are necessary to confirm our
41
42
43
44
45
46 results. Third, because the presence of a UIP pattern on HRCT had low sensitivity and
47
48
49 negative predictive value for the detection of pathologic UIP, it was likely that some
50
51
52 patients with a non-UIP pattern on HRCT may have had pathological UIP. HRCT
53
54
55
56
57
58
59
60 criteria used in our study do not aim to detect pathological UIP but to clinically

1
2
3
4
5
6 diagnose IPF and to exclude alternative diagnosis.[15] The frequency of honeycombing
7
8
9 on HRCT differs between RA-ILD and IPF, and some ILDs by other causes including
10
11
12 RA-ILD have some of findings inconsistent with UIP. Therefore, HRCT pattern in
13
14
15 RA-ILD may be more frequently interpreted as non-UIP pattern than that in IPF. In our
16
17
18 study, 2 of 5 patients with histopathological UIP in the absence of a UIP pattern on
19
20
21 HRCT develop AE. Thus, SLB may have to be considered for these patients to make
22
23
24 pathological diagnosis and to predict AE. Finally, RA includes a variety of
25
26
27 manifestations. Therefore, other comorbidities may have affected the results.

28
29 In conclusion, higher older age at ILD diagnosis, UIP pattern on HRCT and treatment
30
31 with MTX usage are associated with the development of risk factors for AE occurrence
32
33
34
35 in patients with RA-ILD. Furthermore, the mortality associated with AE is high and AE
36
37
38 is prognostic factor for poor outcome. Larger prospective studies investigating acute
39
40
41 exacerbations in RA-ILD are indicated.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENT

We appreciate the help of Dr. T. Tsuchiya in the statistical advice.

This study was partly supported by the Diffuse Lung Diseases Research Group from the ministry of Health, Labour and Welfare, Japan.

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S., and K.C. revised the paper.

All authors approved the paper.

Competing interest:

All authors do not have any personal or financial support or involvement with organization(s) that have financial interest in the subject matter, or any competing interest.

Funding:

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this study (approval number 24-191) and waived patient approval or informed consent because the study involved a retrospective review of patient records and images.

Copyright:

I [*Yutaro Nakamura*] the Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs, other illustrative material, video, film or any other material howsoever submitted by the Contributor(s) at

1
2
3
4
5
6 any time and related to the Contribution (“the Contribution”) have the right to grant on
7
8
9 behalf of all authors and do grant on behalf of all authors, a licence to the BMJ
10
11
12 Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be
13
14
15 published in BMJ Open and any other BMJ Group products and to exploit all subsidiary
16
17
18 rights, as set out in the licence
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.
2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. *Histopathology.* 2011;58:525-30.
3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.
4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.
5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.
6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.* 1998;19:667-85.
7. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis.* 2003;62:722-7.
8. Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and

- 1
2
3
4
5
6 their impact on outcome. *Rheumatology (Oxford)*. 2013;52:99-110.
7
8
9 9. Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain:
10
11 occurrence of extra-articular manifestations and estimates of disease severity. *Ann*
12
13 *Rheum Dis*. 2003;62:897–900.
14
15
16
17 10. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with
18
19 rheumatoid arthritis as assessed by high resolution computed tomography, chest
20
21 radiography, and pulmonary function tests. *Thorax*. 2001;56:622–7.
22
23
24
25
26 11. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset
27
28 rheumatoid arthritis. *Am J Respir Crit Care Med*. 1997;156:528–35.
29
30
31
32 12. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung
33
34 disease in rheumatoid arthritis. *Arch Intern Med*. 2008;168:159–66.
35
36
37
38 13. Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on
39
40 high-resolution computed tomography in patients with early versus longstanding
41
42 rheumatoid arthritis. *J Rheumatol*. 2008;35:1513–21.
43
44
45
46 14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association
47
48 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*.
49
50 1988;31:315-24.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 15. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on
7
8 Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:
9
10 idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and
11
12 management. *Am J Respir Crit Care Med.* 2011;183:788-824.
13
14
15
16
17 16. American Thoracic Society/European Respiratory Society International
18
19 Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
20
21 *Am J Respir Crit Care Med.* 2002;165:277-304.
22
23
24
25
26 17. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary
27
28 fibrosis. *Chest.* 2007;132:1652-8.
29
30
31
32 18. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary
33
34 fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356-63.
35
36
37
38 19. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung
39
40 disease: the relevance of histopathologic and radiographic pattern. *Chest.*
41
42 2009;136:1397-405.
43
44
45
46 20. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic,
47
48 and histopathologic features of methotrexate-associated lung injury in patients with
49
50 rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum.*
51
52 1997;40:1829-37.
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 21. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced
7
8 lung injury in patients with rheumatoid arthritis. A multicenter, case-control study.
9
10 Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.
11
12
13
14 22. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in
15
16 patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.*
17
18 2009;68:1100-4.
19
20
21
22
23 23. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the
24
25 literature and histopathological findings in nine patients. *Eur Respir J.*
26
27 2000;15:373-81.
28
29
30
31
32 24. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in
33
34 rheumatoid arthritis. *Rheumatology (Oxford).* 2004;43:143-7.
35
36
37
38 25. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis
39
40 of 54 biopsy-proven cases. *Respir Med.* 2012;106:1164-9.
41
42
43
44 26. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am*
45
46 *Rev Respir Dis.* 1985;131:770-7.
47
48
49 27. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of
50
51 rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2005;127:2019-27.
52
53
54
55 28. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern
56
57
58
59
60

- 1
2
3
4
5
6 as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int.* 2005;26:121-5.
7
8
9 29. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia:
10
11 idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care*
12
13 *Med.* 2007;175:705-11.
14
15
16
17 30. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in
18
19 rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.*
20
21 2010;35:1322-8.
22
23
24
25
26 31. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study).
27
28
29 Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an
30
31 inception cohort. *Rheumatology (Oxford).* 2010;49:1483-9.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Clinical characteristics

| Characteristics | Total N = 51 (100) | Non-AE group [#] N = 40 (78) | AE group [¶] N = 11 (22) | P value ⁺ |
|---|-----------------------|--|--------------------------------------|----------------------|
| Median age, years (range) | | | | |
| at RA diagnosis | 61 (28-82) | 60 (28-81) | 65 (42-82) | 0.15 |
| at ILD diagnosis | 62 (31-83) | 62 (31-83) | 69 (58-83) | 0.15 |
| at AE onset | | | 72 (60-86) | |
| Sex Male, n (%) | 29 (57) | 23 (58) | 6 (55) | 0.86 |
| Observation period, years (range) | 8.5 (1-17) | 9 (1-17) | 6.4 (2-14) | 0.45 |
| AE-free period, years (range) | 7(1-17) | 9 (1-17) | 6 (2-14) | 0.19 |
| Smoking habit, n (%) | | | | |
| Never | 20 (39) | 18 (45) | 2 (18) | |
| Former | 24 (47) | 16 (40) | 8 (73) | 0.15 |
| Current | 7 (14) | 6 (15) | 1 (9) | |
| RF, IU/mL (range)* | 197 (6-2666) | 189 (6-2666) | 205 (39-2530) | 0.47 |
| DAS28-CRP, score (range)* | 1.95(1.02-5.13) | 2.53(1.02-5.13) | 1.82(1.47-2.3) | 0.62 |
| PaO ₂ , torr (range) | 82.4 (67-109) | 81 (67-102) | 85.8 (74-109) | 0.19 |
| %FVC, % (range) | 91.1 (50.6-130) | 87.5 (51-130) | 95 (60-125) | 0.38 |
| HRCT pattern, n (%) | | | | |
| UIP pattern | 14 (27) | 8 (20) | 6 (55) | 0.02 [§] |
| non-UIP pattern | 37 (73) | 32 (80) | 5 (45) | |
| Death during observation period, n (%) | | | | |
| caused by respiratory failure | <u>98</u> (1816) | 2 (5) | 7 (64) | 0.02 [§] |
| caused by other diseases | <u>34</u> (68) | 3 (8) | 0 (0) | |

Data are presented as n (%), median (range). AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; RF, rheumatoid factor; DAS28-CRP, disease activity score 28 CRP; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶]AE group, patients who developed AE during observation period.

⁺Non-AE group vs AE group

[§] $p < 0.05$

* at the first AE occurrence (AE group) or the last visit (non-AE group).

When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

1
2
3
4
5 In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of
6 respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding
7 and 2 of unknown causes.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 2 Diagnostic accuracy of HRCT pattern for histopathological pattern in 21 histopathologically confirmed patients.

| | Histopathological pattern | | Total |
|-------------------------|---------------------------|---------------|-------|
| | UIP | Other pattern | |
| UIP pattern on HRCT | 5 | 0 | 5 |
| non-UIP pattern on HRCT | 7 | 9 | 16 |
| Total | 12 | 9 | 21 |

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

When HRCT pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive predictive value, and negative predictive value of HRCT for detecting histopathological evidence of UIP was 41.7%, 100%, 100% and 56.3%, respectively.

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

| | Total N = 51 | non-AE group ⁺ N = 40 (78%) | AE group [§] N = 11 (22%) | P value |
|----------------------------------|-----------------|---|---------------------------------------|--------------------|
| Treatment, yes | 37 (73) | 27(68) | 10 (91) | 0.12 |
| Corticosteroid | 29 (57) | 22 (55) | 7 (64) | 0.61 |
| Immunosuppressant except for MTX | 17 (33) | 14 (35) | 3 (27) | 0.63 |
| MTX | 10 (20) | 4 (10) | 6 (55) | 0.001 [*] |
| Other drugs | 17 (33) | 13 (33) | 4 (36) | 0.81 |

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cyclophosphamide (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

⁺ Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

^{*} $p < 0.05$

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 1.03 | 0.97-1.10 | 0.35 |
| Age at ILD diagnosis | 1.11 | 1.02-1.21 | 0.01 ⁺ |
| Sex, male | 0.90 | 0.49-1.69 | 0.73 |
| Smoking habit, yes | 1.60 | 0.81-4.10 | 0.19 |
| UIP pattern on HRCT, yes | 1.95 | 1.07-3.63 | 0.03 ⁺ |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.12 | 0.14 |
| %FVC at ILD diagnosis | 1.02 | 0.99-1.06 | 0.24 |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 0.97 | 0.53-1.92 | 0.94 |
| Immunosuppressant except for MTX | 0.76 | 0.35-1.41 | 0.39 |
| MTX | 3.04 | 1.62-6.02 | 0.001 ⁺ |
| Other drugs | 0.98 | 0.50-1.80 | 0.96 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

| | HR | 95%CI | P value |
|---|------|-----------|--------------------|
| Age at RA diagnosis | 0.98 | 0.93-1.04 | 0.48 |
| Age at ILD diagnosis | 1.08 | 0.99-1.17 | 0.057 |
| Sex, male | 1.14 | 0.63-2.22 | 0.67 |
| Smoking habit, yes | 1.70 | 0.87-4.35 | 0.13 |
| UIP pattern on HRCT, yes | 1.74 | 0.97-3.12 | 0.06 |
| PaO ₂ at ILD diagnosis | 1.05 | 0.98-1.11 | 0.15 |
| %FVC at ILD diagnosis | 1.01 | 0.98-1.04 | 0.55 |
| AE during observation period, yes | 2.47 | 1.39-4.56 | 0.003 ⁺ |
| Treatment for RA at final visit [#] or AE onset [¶] | | | |
| Corticosteroids | 1.23 | 0.67-2.65 | 0.52 |
| Immunosuppressant except for MTX | 0.69 | 0.32-1.27 | 0.25 |
| MTX | 1.44 | 0.67-2.68 | 0.31 |
| Other drugs | 0.76 | 0.36-1.41 | 0.40 |

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO₂, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

⁺ $p < 0.05$

Figure legends

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were excluded, and 51 patients with chronic course of RA-ILD were included. During observation period, 11 patients developed AE.

RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank $p=0.018$).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank $p=0.04$).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

1
2
3
4
5
6 Figure 4. Survival of AE group and non-AE group.
7

8
9 Patients who developed AE during observation periods (AE group) had a significantly
10
11 worse survival compared with those who did not (non-AE group) (log-rank $p=0.001$).
12
13

14
15 AE, acute exacerbation.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60